AME MARK STEVEN FREEDMAN - ECTRIMS Congress · Mark Steven FREEDMAN 3 PROFESSIONAL TRAINING:...

Revised 31.08.2015

CURRICULUM VITAE

[Abbreviated Version]

NAME: MARK STEVEN FREEDMAN CURRENT RANK & POSITION: Professor of Medicine (Neurology) University of Ottawa Director, Multiple Sclerosis Research Unit The Ottawa Hospital-General Campus DEGREES: Undergraduate B.Sc. in Science (1976) (University of Toronto) Hon. B.Sc. in Zoology (1977) (University of Toronto) M.Sc. in Molecular Neurochemistry (1980) (University of Toronto) M.D. (1983) (University of Toronto) PostGraduate Neurology Specialist Training (Queen Square, London, England University of Toronto; Montréal Neurological Institute) Specialist Certification: Canada F.R.C.P.(C) (1987) & Quebec C.S.P.Q. (1988) Fellow, American Academy of Neurology (FAAN) (2004)

RESEARCH EXPERIENCE:

4 years of Molecular Biochemistry and Neurochemistry (M.Sc.), 3 years Clinical

Biochemistry and 17 years in Immunology basic research (Toronto, Israel, Montréal, and

Ottawa).

Currently holding peer reviewed and industry related funding for investigating immune

mechanisms of multiple sclerosis and exploring new potential MS therapies, including the

role of stem cell transplantation.

Over 200 published articles, book chapters and abstracts.

Given 100’s of invited lectures, talks or presentations, nationally and internationally.

Membership in several international societies for basic research.

CLINICAL EXPERIENCE:

Nearly 27 years experience in the management of patients with multiple sclerosis.

Principal investigator on numerous clinical trials with new agents in multiple sclerosis.

OTHER IMPORTANT EXPERIENCE:

Director of the multiple sclerosis research clinic at Ottawa Hospital-General Campus.

Director of the Neuroimmunology diagnostic laboratory at Ottawa General Hospital

Member, medical advisory for the clinical trials group of the National (U.S.) Multiple

Sclerosis Society.

Previous member of the scientific grants review committee and medical advisory for the MS

Society of Canada.

Immediate past president of the Canadian Network of MS Clinics

Secretary, Consortium of Multiple Sclerosis Centers.

Editorial board member for several journals

Mark Steven FREEDMAN 2

CURRICULUM VITAE

NAME: MARK STEVEN FREEDMAN RANK: Professor of Medicine (Neurology) University of Ottawa Senior Scientist, OHRI OFFICE ADDRESS: 501 Smyth Road, The Ottawa Hospital, General Site Ottawa, Ontario K1H 8L6 TELEPHONE (office): (613)737-8917 TELEFAX: (613)737-8857 e-mail: [email protected] (hospital) HOME ADDRESS: 26 Saddlebrook St. Ottawa, Ontario

K2G 5N7

HOME TELEPHONE: (613) 226-6440 CITIZENSHIP: Canadian LANGUAGES SPOKEN: English, French, Hebrew DATE AND PLACE OF BIRTH: May 3,1955 Toronto, Ontario MARITAL STATUS: Married with 3 children

DEGREES: B.Sc. (1976) University of Toronto (Science) Hon. B.Sc. (1977) University of Toronto (Zoology) M.Sc. (1980) University of Toronto (Molecular neurochemistry) M.D. (1983) University of Toronto PROFESSIONAL CERTIFICATION: F.R.C.P.(C) (1987) (Neurology) #373306 C.S.P.Q. (1988) (Neurology) #12046 LICENSURE: Ontario (CPSO) #52527 Québec (CPMQ) #90009


PROFESSIONAL TRAINING: Clinical Sept 1980 - May 1982: Sunnybrook Medical Centre: Undergraduate Medical

Student (years II & III). Sept 1980 - May 1982: Mount Sinai Hospital: 1 day per week for the entire year

plus the entire summer in: Clinical Neurology, (Elective). Sept 1982 - Oct 1982: Institute of Neurology, The National Hospital, Queen

Square (London, England): 2 month elective in Clinical Neurology.

June 1982 - June 1983: Mount Sinai Hospital: Clinical Clerkship. June 1983 - June 1984: Sunnybrook Medical Centre: Straight internship in Internal

Medicine. July 1984 - Sept 1984: Toronto General Hospital: Resident in Neurology. Oct 1984 - Dec 1984: Hospital for Sick Children: Resident in Pediatric

Neurology. Jan 1985 - June 1985: Wellesley Hospital: Senior Resident in Neurology. July 1985 - Dec 1985: St. Michael's Hospital: Senior Resident in Neurology. Jan 1986 - June 1986: St. Michael's Hospital: 1 day per week in: Multiple

sclerosis assessment Clinic. Jan 1986 - June 1986: Toronto Western Hospital: Resident in Neuropathology. July 1986 - Dec 1986: Toronto General Hospital: Resident in Neurophysiology

(EEG & evoked potentials); Resident in Chief, Dept. Neurology.

Jan 1986 - June 1987: Toronto Western Hospital: Senior Resident and Resident in Chief, Dept. Neurology.

Research 1977-1980: University of Toronto: Standard Biochemistry: Molecular Biochemistry, Neurochemistry: Electron Microscopy. 1980: Weizmann Institute of Science (Rehovot, Israel): Molecular Biology. 1981-82: Mount Sinai Hospital, Dept. Clinical Biochemistry: Enzyme Kinetics and Assays. 1982-83: Mount Sinai Hospital, Dept. Clinical Biochemistry, Surgical Oncology 1987-93: Montréal Neurological Institute, McGill University, Dept. Neuro-

immunology: The cellular mechanisms of immune-mediated demyelination as related to multiple sclerosis.

1993-: The Ottawa Hospital, General Site, Division of Neurology, University of Ottawa: Cellular mechanisms of immune-mediated damage in multiple sclerosis; the role of heat shock protein T cell interactions.

2015: Collaborative Institutional Training Initiative (CITI) Canada Good Clinical Practice (GCP).

2013: Ottawa Hospital Research Institute, Health Canada Division 5-Drugs for Clinical Trials Involving Human Subjects.

ACADEMIC APPOINTMENTS: July 1990- June 1993: Assistant Professor, Department of Neurology and Neurosurgery,

McGill University July 1992-June 1993: Cross appointment to Department of Microbiology and

Immunology McGill University


July 1993-April 1995: Assistant Professor, Department of Medicine (Neurology), University of Ottawa

May 1995-April 2000: Associate Professor, Department of Medicine (Neurology),

University of Ottawa, Ottawa, Ontario CURRENT POSITION: May 2000- : Professor, Department of Medicine (Neurology), University of

Ottawa Nov. 1993- : Cross appointment to Department of Microbiology, Immunology

and Biochemistry, University of Ottawa Aug. 1998- : Director, Multiple Sclerosis Research Clinic, The Ottawa Hospital,

General Campus June 2003-present: Senior Scientist, Ottawa Hospital Research Institute HONOURS AND AWARDS: 1978: University of Toronto Open Master’s Fellowship. Pure & Applied Science

Research Grant. Dept. Zoology, University of Toronto 1979: Pure & Applied Science Research Grant Ontario Graduate Fellowship* NSERC Post-Graduate Fellowship* Addiction Research Foundation Research Scholarship* 1980: Walter F. Watkins Scholarship (U of T for honour standing in year I

medicine) 1981: MRC Summer Research Scholarship 1986: St. Michael's Hospital, Toronto Clinical Research Prize 1987: MRC Research Fellowship Multiple Sclerosis Society of Canada Research Fellowship. (Declined in favour of the MRC award) 1998: Recognition Award from the International Society for Neuroimmunology

for contribution to the field 2002: Recipient of the McEwan Lectureship, University of Toronto 2009-2013: Department of Medicine Mid-Career Salary Award 2012-2013: Department of Medicine Research Salary Award 2013: Herndon Award for Outstanding International Journal of MS Care Article *These awards were regretfully declined in order to accept entrance into the Faculty of Medicine at the University of

Toronto in the Fall of 1979.

HOSPITAL APPOINTMENTS: Jan. 1988-Dec. 1994: St. Vincent de Paul and Brockville General Hospital, Brockville

Ontario, Consultant Neurologist Oct. 1988-present: Brockville Psychiatric Hospital, Brockville, Ontario: Staff

Neurology Consultant; Head, EEG Department Mar. 1990-June 1993: Montréal Neurological Hospital and Institute: Staff Neurologist. Mar. 1990-June 1993: Queen Elizabeth Hospital, Montréal: Staff Consultant Neurologist


Jan. 1991-June 1993: Director Clinical Neuroimmunology Laboratory, Montréal Neurological Hospital

July 1993-present: Staff Consultant Neurologist with cross appointment in Pathology and Laboratory Medicine, The Ottawa Hospital, General Site

April 1994-present: Royal Ottawa Hospital, Rehabilitation Centre, Consultant Neurologist

March 1995-present: Pembroke General Hospital, Consultant Neurologist June 2003-present: Senior Scientist, Ottawa Hospital Research Institute July 2009-present: Perth & Smith Falls Hospital, Consultant Neurologist SCHOLARLY AND PROFESSIONAL ACTIVITIES: Committees 1990-93: Member, Special Laboratories Committee, Montréal Neurological Hospital 1992-93: Member, Clinical Research Committee, Montréal Neurological Hospital 1993-99: Examiner, Medical Council of Canada 1995-: Member, OSAC Committee, Multiple Sclerosis Society of Canada 1995-: Member, Multiple Sclerosis Society of Canada, Research Grants Review

Committee 1995-: Member, University of Ottawa Research Subcommittee 1997-: Member, Neurology Selection Committee 1999: Member of International Scientific Committee for 15

th Congress of The European

Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the 4

th Annual Meeting of the America’s Committee for Treatment and Research in

Multiple Sclerosis (ACTRIMS) 2000: Member of International Consensus Group for developing Treatment Guidelines

for Multiple Sclerosis. 2000: Member Scientific Advisory for the Canadian Congress of Neurological Sciences 2001-: Member Medical Advisory Committee for the Canadian Multiple Sclerosis

Society 2001-: Member of the America’s Committee for Treatment and Research in Multiple

Sclerosis (ACTRIMS) Programming Committee 2001: Member of the America’s (ACTRIMS) and European (ECTRIMS) Committees

for Treatment and Research in Multiple Sclerosis Programming Committee for joint meeting in 2002

2001: Member of Organizing Committee for the Guidelines for Diagnosis of Multiple Sclerosis Forum (http://www.mscare.org/professional)

2002: Head of Steering Committee on the Standardization of Spinal Fluid Analysis for the Diagnosis of Multiple Sclerosis for the Consortium of MS Clinics (CMSC)

2003: Member of Joint CBS/Bayer Grant Competition Committee; Canadian IVIG Research Committee

2004: Member, National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trial of New Drugs in MS

2004: Member, Executive Committee, Consortium of Multiple Sclerosis Clinics 2006: Member, New York Academy of Science 2007-: Secretary, Consortium of Multiple Sclerosis Centers 2007-: President, Canadian Network of Multiple Sclerosis Clinics 2009: Member, Editorial Board, The European Neurological Journal 2009: Member, Editorial Board, Multiple Sclerosis International

2010: Member, Québec-Ottawa endMS Regional Research and Training Centre 2010: Member, Editorial Advisory Board, Clinical Investigation

http://www.mscare.org/professional


2011: Member, National Institute of Neurological Disorders and Stroke (NINDS)

Working Group to Develop Common Data Elements (CDE's) for MS (Short Title:

NINDS MS Common Data Elements)

2012: Secretary, Americas Committee for Treatment and Research in Multiple Sclerosis

(ACTRIMS)

2012: President, Ottawa Chapter for the Canadian Society for the Weizmann Institute of

Science

2012: Secretary / Treasurer, ACTRIMS

2013: CPD Committee for Consortium of Multiple Sclerosis Centers (CMSC)

2014: Relapse Adjudication Committee for NMO Study for Tocilizumab, run by Chugai

2015: Member of IMSGC PMSA Round 2 phase 1 grant application

Memberships Fellow, Royal College of Physicians and Surgeons of Canada Member, Federation of Medical Specialists of Québec Member, Ontario Medical Association Member, Canadian Neurological Society Associate Member, American Academy of Neurology Member, American Society for Neurological Investigation Member, Clinical Immunology Society Member, International Society for Neuroimmunology Fellow Member, American Academy of Neurology Member, Executive Committee, Consortium of Multiple Sclerosis Clinics Member, New York Academy of Science President, Canadian Weizmann Institute of Science, Ottawa Chapter Fellow, American Neurological Assocation Data Safety Monitoring Boards:

2004-2006: Member, Data Safety Monitoring Board, Bayhill Therapeutics, Palo Alto, CA.

Study Name: Phase I trial of immunotherapy with BHT-3009 alone or combined

with atorvastatin in patients with multiple sclerosis (Protocol BHT-3009-01.

2004-2007: Phase IV, rater-blinded, randomized study, comparing the effects of 250 μg of

Betaseron with 20 mg of Copaxone in patients with the relapsing-remitting or

clinically isolated forms of multiple sclerosis using 3 Tesla MRI with triple-dose

Gadolinium, (the BECOME study), Berlex Laboratories, USA.

2004-2007: A Phase II Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study

of Subcutaneous Daclizumab in Patients with Active, Relapsing Forms of

Multiple Sclerosis, Protein Design Labs, USA.

2008- : Member DSMB NIH/NIAID monitoring several clinical trials. NIH Bethesda,

MD. Steering Committee Memberships: 2003- : Member of BENEFIT Study (Schering AG) Steering Committee

Study Name: Double-blind, placebo controlled, randomized, parallel group, multicenter, phase III study in patients with a first clinical demyelinaing event suggestive of multiple sclerosis to evaluate the safety, tolerability, and efficacy of


8 MIU (250 mcg) interferon beta-1b (Betaseron) given subcutaneously every other day over a period of up to 24 months.

2003-05: Member of Steering Committee for the Study of NBI-5788 (Neurocrine) Study Name: A randomized, double-blind, placebo-controlled study to evaluate

the safety, tolerability and efficacy of NBI-5788 in patients with relapsing multiple sclerosis. Neurocrine BioSciences.

2004: Member and principal investigator of IMPLEMENT Study Steering Committee (Pfizer).

Study Name: Implementation study of treatment optimization recommendations comparing subjects continuing treatment with IFN qw IM (Avonex) or glatiramer acetate 20mg qd SC (Copaxone) to those randomized to IFN-1a 44mcg tiw SC (Rebif), in a multicenter study of subjects with RRMS currently on disease-modifying therapy.

2004-: Member of NIH Combi Study Steering Committee

Study Name: A multicenter, double-blind, randomized study comparing the

combined use of Interferon Beta-1a and glatiramer acetate to either agent alone in

patients with relapsing remitting multiple sclerosis (CombiRx-Phase III).

2004- : A double-blind, placebo controlled multicenter study to evaluate the efficacy and

safety of MBP8298 in subjects with secondary progressive multiple sclerosis.

BioMS (Eli-Lilly), Canada. (MAESTRO #1); An open-label follow-on study to

assess the ongoing safety of MBP8298 in subjects with secondary progressive

multiple sclerosis. BioMS (Eli Lilly) (MAESTRO #2). 2007-: HMR1726D/ 2003 Randomized, multinational, double-blinded, placebo-

controlled, pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with Interferon-ß in subjects with multiple sclerosis. Sanofi-Aventis (PDY 6045). Global principal investigator.

2007-: HMR1726D/ 2003 Randomized, multinational, double-blinded, placebo-controlled, pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with glatiramer acetate in subjects with multiple sclerosis. Sanofi-Aventis (PDY 6046). Global principal investigator.

2007-10: A phase III, randomized, double-blind, placebo-controlled, multicentre clinical

trial of Rebif new formulation

(44 mcg tiw and 44 mcg ow) in subjects at high

risk of converting to multiple sclerosis. Merck Serono, Switzerland (REFLEX

study). Merck Serono. (REFLEX trial).

2008-09: ATAMS Trial Steering Committee. A four-arm, randomized, double-blind,

placebo-controlled, multicenter Phase II study to evaluate the safety, tolerability

and efficacy as assessed by frequent MRI measures of three doses of Atacicept

monotherapy in subjects with relapsing multiple sclerosis (RMS) over a 36 week

treatment course. (Atacicept in RMS). Merck Serono Inc., Germany.

2008- : ORACLE Study (Merck Serono). A phase III, randomized, double-blind,

placebo-controlled, multi-center clinical trial of oral cladribine in subjects with a

first clinical event at high risk of converting to MS. 2008: A double-blind, randomized, multicenter, placebo-controlled, parallel-group study

comparing the efficacy and safety of 1.25mg FTY 720 administered orally once daily VS placebo in patients with primary progressive multiple sclerosis, Novartis Pharmaceuticals, Switzerland.

2008-09: Long-term extension of PDY 6045 and PDY 6046 of Teriflunomide when added with Interferon or glatiramer acetate in MS. Sanofi-Aventis Inc.


2009: Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy, safety and tolerability of three doses of ACT-128800, an oral S1P1 receptor agonist, administered for twenty-four weeks in patients with relapsing remitting multiple sclerosis. Actelion.

2009: Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of converting to MS, treated with Rebif

® New

Formulation (REFLEXION). 2011: Phase 1B, randomized, placebo-controlled dose study of IV infusion of human

placenta-derived cells (PDA001). Celgene 2011: Efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis.

TERACLES with Sanofi. 2013: Steering Committee OPEXA 2013: Steering Committee SANOFI 2013: Steering Committee GENZYME 2013: Steering Committee BIOGEN IDEC 2013: Steering Committee BAYER 2013: Steering Committee NOVARTIS

Task Forces:

2002-04: CMSC Task Force on CSF guidelines for the diagnosis of MS

2008- : AAN Task Force: Group leader for Prognosis – development of a treatment

guideline Organized Symposia:

Montréal Neurological Institute Symposium on The matter of neurological disease: Idiopathic

Parkinson’s disease: the role of surgical transplantation, March 1993, Montréal, QC.

Organizing and Scientific Advisory Committee member for the 1998 International Society for

Neuroimmunology Conference, Montréal, QC.

Organizing Committee for the Annual Meeting of the Canadian Congress of Neurological

Sciences Conference, Ottawa, ON. 2000.

Organized Multiple Sclerosis Satellite Symposium for the Canadian Congress of Neurological

Sciences Conference, Ottawa, ON. 2000.

Organized Industry course for the Canadian Congress of Neurological Sciences Conference,

Ottawa, ON. 2000.

Annual Conference of the Consortium of MS Clinics (CMSC): Organized and moderated the following symposia: Grey Matter Disease in MS: The Untold Story Standardizing CSF Analysis Sheraton Hotel & Marina, San Diego CA. May 30, 2003.


Annual Conference of the Consortium of MS Clinics (CMSC): Organized and moderated the following symposia: Defining Sub-Optimal Response to MS Treatment De-diagnosing MS Toronto, ON. June 2004. Annual Conference of the Consortium of MS Clinics (CMSC): Organized and moderated the following symposia: Diagnosing MS in 2005: Focus on Accuracy The Use of Serological or Cerebrospinal Fluid Diagnostic Tests Orlando, FL. June 2005. Annual Conference of the Consortium of MS Clinics (CMSC): Organized and moderated the following symposia: Contemporary Issues in Multiple Sclerosis Ottawa, ON. June 2005. Schering MS Fireplace Talks. Responsible for the following Scientific Program: MS Treatment in Practice (Chair) Berlin, Germany. March 24, 2006. American Academy of Neurology Annual Conference 2006: Responsible for the following program: Multiple Sclerosis Therapy: Demyelinating Disorders San Diego, CA. April 7, 2006. American Academy of Neurology Annual Conference 2006: Responsible for the following program: Multiple Sclerosis Therapy: Demyelinating Disorders San Diego, CA. April 7, 2006. Mesenchymal Stem Cells in the Treatment of Multiple Sclerosis Chairperson Paris, France. March 11-12, 2009. Stem Cell in Neurology, Symposium, 50

th Anniversary Academic Conference, Northern

Neuroscience Center, Chiang Mai University, Thailand: November 2, 2009. Annual Conference of the Consortium of MS Clinics (CMSC): Organized and moderated the following symposia:

Making an Accurate Diagnosis of MS Mesenchymal Stem Cell

San Antonio, Texas, June 2-5, 2010 CONy – The 4

th World Congress on Controversies in Neurology

Chairperson: Multiple Sclerosis

Barcelona, Spain, October 30, 2010 SSIF CME Annual Meeting Workshop: How to Treat Early MS St. Petersburg Russia, May 6 2011


DIME - Discovery Institute of Medication Education in conjunction with Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting Faculty: Critical Issues in the Long-Term Management of Multiple Sclerosis Montréal QC, June 2 2011 CONy Co-Chair:

Multiple Sclerosis Scientific Program Debate Host:

To tap or not to tap: Is there still a role for lumbar puncture and CSF analysis in MS diagnosis?

Vienna, Austria, March 2012 Bone Marrow Transplant in MS Transplants for MS: Moving Forward CMSC Annual Meeting June 2 2012 An early start for treatment success. ENS Prague Czech Republic, June 10 2012 Treatment options for Fingolimod in clinical practice Novartis Symposia Prague, Czech Republic, June 11 2012

Get on track, stay on track: patient journeys in MS

Merck Serono Symposia

ECTRIMS, Lyon France, Oct 10 2012.

Chair, Satellite Symposium: Evolving the management of MS: new insights and new directions.

ECTRIMS. Copenhagen Denmark. Oct 3 2013.

Chair: Parallel Session 12: Looking into the future: experimental studies of new therapies.

ECTRIMS. Copenhagen Denmark. October 4 2013.

Chair: Parallel Session: Myasthenia Gravis and Multiple Sclerosis.

9th

International Congress on Autoimmunity. Nice, France. March 28, 2014.

Chair: Parallel Session: Cell-based Therapies (PS1.1-PS1.6)

A/ECTRIMS. Boston MA Sept 2014

Innovation and Optimization: Engaging Today’s Patients: Treating to target

Merck Serono Symposia

A/ECTRIMS. Boston MA. Sept 2014

Latest advances towards changing the course of MS

Novartis Symposia



Treating to target and beyond: is improvement in functioning a realistic treatment goal in

multiple sclerosis?: Are We Changing the Natural History of MS with Current Therapies?

Abbvie Symposia


CSF in MS: Current Assays and Significance oligoclonal IgG and IgM bands, IgG index, MBP,

cells/protein)

Conference of the Consortium of MS Clinics (CMSC). Indianapolis, IA May 2015

Status of Stem Cell Therapy 2015

Conference of the Consortium of MS Clinics (CMSC). Indianapolis, IA May 2015

Preceptorships:

Organizer and lead contributor to the bi-annual one week MS Conference for visiting Italian

Neurologists; Symposia held May 1999; November 1999; April 2000, November 2000, May

2001, November 2001, November 2003 at the Ottawa Hospital General Campus, Ottawa, ON.

Organizer and lead contributor to the bi-annual one week MS Conference for visiting German

Neurologists; Symposia held February 2001, June 2001, February 2002 at the Ottawa Hospital

General Campus, Ottawa, ON.

Organized first Canadian Preceptorship Program for Canadian Neurologists, on behalf of the

Canadian Network of MS Clinics, Ottawa, ON. November, 2000.

Organizer and lead contributor to a one week MS Conference for visiting European Neurologists;

Symposia held November 2005, November 2006, February and April 2007 at the Ottawa

Hospital General Campus, Ottawa, ON.

Organizer and lead contributor to a one week MS Conference for visiting Korean Neurologists; Symposia held October 2008 at the Ottawa Hospital General Campus. October 22 2008 ½ day preceptorship: Ellen Dempsey, Biogen November 4 2008 ½ day preceptorship: Luc Renaud, Teva Neuroscience February 24 2009 ½ day preceptorship: Annick Laplante, Novartis April 14 2009 ½ day preceptorship: Marc Massé, EMD Serono April 14 2009 ½ day preceptorship: Waseem Kalair, EMD Serono April 21 2009: ½ day preceptorship: Dr. H. Gonzalez, EMD Serono


June 21 2010 ½ day preceptorship: Susan Stone, NOVARTIS July 27 2010 ½ day preceptorship: Jim Hunt, EMD Serono August 18 2010 ½ day preceptorship: Nital Patel, EMD Canada Inc. November 17 2010 ½ day preceptorship: Guylaine Vigneault, BIOGEN IDEC November 24 2010 ½ day preceptorship: Vincent Renaud, BIOGEN IDEC April 19 2011 Full day preceptorship: Daniel Bonhomme, NOVARTIS April 26 2011 Full day preceptorship: Orchid Jahanshahi, NOVARTIS June 6 2012 Full day preceptorship: Julie Kruse, NOVARTIS June 19 2012 Full day preceptorship: Karen Chow, NOVARTIS October 24 2012 Full day preceptorship: M. Pierre Bourdage, NOVARTIS August 7 2013 Full day preceptorship: Amirault-Laing, EMD Serono November 6 2013 Full day preceptorship: Paola Haddad January 7 2014 Full day preceptorship: Raffi Toniklan, Medical Science Liasons August 27 2014 Full day preceptorship: Pinay Kainth, NOVARTIS December 16 2014 Full day preceptorship: Jovna Kapur, Medical Dir, EMD Serono

Courses: Symposium for American Academy of Neurology 50

th Annual Meeting

Therapeutic Poisoning: Immunosuppressive Therapy for Non-neoplastic Neurologic Disease

Case Presentations: Demyelinating Disease Chicago IL. May 2008 SSIF MS Academia – Multiple Sclerosis Advanced Course for ECTRIMS MS Treatment in Practice Montréal QC. September 2008 Hot Topics in MS Course – American Academy of Neurology 51

st Annual Meeting

Immunosepression: Haematopoietic stem cell transplantation and intense immunosuppression – Should they have a role in the treatment of multiple sclerosis? Seattle WA. April 2009 Hot Topics Review – American Academy of Neurology 52

nd Annual Meeting

Toronto ON. April 2010 SSIF MS Academia – Multiple Sclerosis Advanced Course for ECTRIMS Current Disease Modifying Drugs: Evaluating the Evidence Gothenburg Sweden October 2010


Multiple Sclerosis Advanced Course for ECTRIMS - 12

th MS Nurse Workshop

Nurses: Key Interface between Patients and Physicians Gothenburg Sweden October 2010. Multiple Sclerosis Advanced Course for ECTRIMS - 13

th MS Nurse Workshop

Improving Organization and Optimize Treatment: MS Centers Organization Amsterdam Netherlands October 2011 Debate: Clinical issues in multiple sclerosis – American Academy of Neurology 53

rd Annual

Meeting AFFIRMATIVE: Resolved: Fingolimod and Cladribine should both be donsidered first-line oral treatments for MS with comparable efficacy and safety profiles? Chronic Cerebrospinal Venous Insufficiency (CCSVI): Do the initial claims hold up? How much more study is necessary?

Honolulu HI. April 2011 SSIF MS Academia - Multiple Sclerosis Advanced Course for ECTRIMS Current Disease Modifying Drugs: Evaluating the Evidence Amsterdam Netherlands October 2011 Teaching Course: ECTRIMS Stem Cell Therapy Amsterdam Netherlands October 2011 Teaching Course: MS Overview II: Clinical Advances – American Academy of Neurology 54

th

Annual Meeting Emerging MS therapies New Orleans LA. April 2012 Teaching Course Chair: MS Course CNSF June 8 2012. Teaching Course: MS Advanced Course. ECTRIMS Current disease modifying drugs: Evaluating the evidence Lyon France. October 2012 Teaching Course: Multiple Sclerosis Overview: Clinical Advances Demyelinating Disorders San Diego CA. March 22 2013 Teaching Course: Present and emerging therapies for multiple sclerosis San Diego CA. AAN March 2013 Teaching Course: CNSF 2014 New and emerging therapies in multiple sclerosis Banff AB. June 5 2014 Teaching Course: CNSF 2015 Emerging Therapies in Multiple Sclerosis Totonto, ON June 10 2015


Invited Lectures, Talks and Presentations: 1. Corporation Des Physiothérapeutes du Québec lecture series. Management of head

injury. November 1988.

2. Hôpital Notre Dame, Université de Montréal. Interleukins. May 1989.

3. Corporation des Physiothérapeutes du Québec Lecture series. Neurological approach to

back injuries. November 1989.

4. Montréal Neurological Institute, McGill University, Grand Rounds. Immunological

circuits in multiple sclerosis. December 1989. 5. Royal Victoria Hospital, McGill University, Resident Rounds. An assessment of lower

back pain. May 1990. 6. Corporation des Physiothérapeutes du Québec Lecture series. Management of head

injury, November 1990. 7. Montréal Neurological Institute, McGill University, Neuroscience Conference. The role

of heat shock proteins and T cells in multiple sclerosis. February 1991.

8. Queen Elizabeth Hospital, McGill University, Medical Grand Rounds. Multiple

Sclerosis. February 1991.

9. St. Michael's Hospital, University of Toronto, Medical Grand Rounds. Role of T cells

and heat shock proteins in multiple sclerosis. May 1991.

10. Health Sciences Centre, University of Manitoba, Immunology Seminar. Role of T

cells and heat shock proteins in multiple sclerosis. August 1991.

11. Leeds-Grenville Medical Community, Brockville, ON. New concepts in the management

of Parkinson's Disease. October 1991.

12. Queen Elizabeth Hospital, McGill University, Medical Grand Rounds. Approach to the

management of the first seizure. September 1991.

13. Guest Expert on Visa Santé, a Québec television health program on Multiple Sclerosis.

October 1991.

14. Queen Elizabeth Hospital, McGill University, Medical Grand Rounds. Anti-

phospholipid antibodies and neurological disease. December 1991.

15. Queen Elizabeth Hospital, McGill University, Medical Grand Rounds. Diagnosis and

management of Parkinson's Disease. February 1992.


16. Queen Elizabeth Hospital, Department of Medicine, Special Lecture. Au Vieux St. Gabriel, Montréal, QC. New advances in stroke management. February 1992.

17. Ste. Anne de Bellevue VA Hospital, Medical Grand Rounds. New concepts of stroke

management. March 1992.

18. Leeds-Grenville Medical Community, Brockville, ON. New advances in stroke

management. April 1992.

19. Hôpital Notre Dame, Université de Montréal. New strategies in the management of

multiple sclerosis: Potential role of TNF. May 1992.

20. St. John Medical Society, St. John, NB. New approaches to the management of

Parkinson's Disease. May, 1992.

21. Calgary General Hospital, University of Calgary, City-Wide Neurology Rounds.

Immunopathogenesis of multiple sclerosis. June 1992.

22. Department of Immunology Seminar, University of Calgary. Immunopathogenesis of

multiple sclerosis. June 1992.

23. Queen Elizabeth Hospital, McGill University, Medical Grand Rounds. Neurological

Emergencies. August 1992.

24. University Hospital, University of Colorado School of Medicine, Neurology-

Neurosurgery Grand Rounds, New concepts in the immunopathogenesis of MS. September 1992.

25. Ottawa General Hospital, University of Ottawa, Neuroradiology/Neurology/Neurosurgery

Rounds. New concepts in the immunopathogenesis of MS. September 1992.

26. Queen Elizabeth Hospital, McGill University, Montréal, QC. Medical Grand Rounds.

Diagnosis and management of headache. October 1992.

27. Lakeshore General Hospital. Pointe-Claire, QC. The role of DHE in the treatment of

migraine. November 1992.

28. Royal Victoria Hospital and Jewish General Hospital Combined Resident Special

Lecture. New advances in stroke management. November 1992.

29. Guest expert on Medically Speaking, a PBS television health program on Multiple

Sclerosis. November 1992.

30. Queen Elizabeth Hospital, McGill University, Montréal, QC, Medical Grand Rounds.

Neurosarcoidosis. March 1993.

31. Workshop participant on heat shock/stress proteins in multiple sclerosis and other

disorders, sponsored by the National (US) MS Society. MHC unrestricted killing of oligodendrocytes by T- cells, La Toja, Galicia Spain. April 2-6 1993.


32. Course Lecturer, The immunology of multiple sclerosis, Canadian Congress of

Neurological Sciences. Toronto ON. June 1993.

33. MS Society Local Chapter, Pembroke, ON. Interferon- and the treatment of multiple

sclerosis. September 1993.

34. MS Society, Ottawa/Carleton Chapter, Annual General Meeting, Ottawa ON. Treatment

of multiple sclerosis. October 1993. 35. Ottawa Civic Hospital, University of Ottawa, Neurology and Rehabilitation Medicine for

Family Practitioners. Multiple sclerosis - new theories, new therapies. November 1993. 36. Ottawa General Hospital, Neurology Grand Rounds. MS.: Interfering with interferons

and other new strategies. January 1994. 37. Health & Welfare Canada, Tunney’s Pasture. Disability due to demyelinating disorders

(MS). February, 1994. 38. Leeds Grenville Medical Society, Brigadoon Restaurant. Multiple Headache Disorder.

February 1994. 39. Neurology Update 1994, Ottawa Congress Centre. New hope for MS patients. April

1994. 40. Ottawa General Hospital Annual Research Day. Cerebral spinal fluid analysis in multiple

sclerosis. April1994. 41. Westin Hotel. New trials using -interferon in the treatment of MS. April 1994. 42. Ottawa General Hospital. Educational evening for newly diagnosed MS patients. April

1994. 43. Grand Rounds, Brockville General Hospital. Update on stroke prevention. May 1994. 44. The Rehabilitation Centre, Royal Ottawa Hospital. Physiotherapy Departmental Rounds,

The use of cyclophosphamide in the management of multiple sclerosis. August 1994. 45. Ottawa General Hospital. Guest Speaker for the Canadian Association of Neuroscience

Nurses, Innovations in neurosciences: Use of cyclophosphamide in the treatment of multiple sclerosis. October 1994.

46. Chelsea Inn, Toronto, ON. Main speaker for the medical update session, Multiple

Sclerosis Society of Canada, annual general meeting, New strategies in the treatment of multiple sclerosis. November 1994.

47. Ottawa General Hospital, Grand Rounds, Department of Medicine, When the heat is on,

007 cells may not come to the rescue. A story in the cold war against MS. May, 1995. 48. Best Western Heritage Inn, Pembroke, ON, Medication induced headache: Strategies for

diagnosis and management. May 1995.


49. Ottawa Congress Centre, Cerebrospinal fluid analysis: What can we learn from the brain’s soup? Canadian Society of Laboratory Technologists Congress. June 1995.

50. Victoria Congress Centre, Immunologic manipulation in multiple sclerosis, Neurobiology

Review Course, XXXth

Canadian Congress of Neurological Sciences. June 1995. 51. Ottawa General Hospital, Neurology Grand Rounds, MRI in the diagnosis and

management of MS. September 1995. 52. Holiday Inn, Sudbury, ON, Northern Education Conference, Immune directed therapies in

the treatment of multiple sclerosis. October 1995. 53. Tom Brown Arena, Ottawa, ON. Annual General Meeting of local MS Chapter, New and

upcoming treatments for multiple sclerosis. October 1995. 54. Royal Ottawa Hospital, Rehabilitation Centre. Pathophysiology of multiple sclerosis.

December 1995. 55. Ottawa Civic Hospital, Neurology Grand Rounds, Role of -interferon in the

management of MS. December 1995. 56. Ottawa General Hospital, Nursing and Paramedical Care In Service, -Interferon: First of

a new kind of therapy. December 1995. 57. Royal Ottawa Rehabilitation Centre, Advances in the understanding and treatment of MS.

May 1996. 58. The Canadian Society for The Weizmann Institute of Science, Ottawa Chapter, Promising

new treatments for multiple sclerosis. May 1996. 59. Jewish General Hospital, Montréal, QC. Grand Rounds on Advances in the treatment of

MS. September 1996. 60. Mississauga General Hospital, Mississauga, ON. Neuroscience Rounds on Rationale for

new treatments in MS. October 1996. 61. Royal Brock Hotel, Brockville, ON, Health Professional Education Day, MS Society of

Canada, Ontario Division, Eastern Region. Keynote speaker on (MS) Symptom management and research update. October 1996.

62. Health Sciences Centre, Winnipeg, MB. Neuroscience Rounds, Rationale for new

therapies in MS. October 1996. 63. Eldorado Hotel, Kelowna, BC. Neurology Review on Advances in the treatment of MS.

November 1996. 64. Maison de Gouverneurs, Montréal, QC. Special evening lecture on Immunological basis

for treatment of MS. November 1996. 65. Ottawa Civic Hospital, Neurology Grand Rounds on MRI and MS. December 1996. 66. Ottawa General Hospital, Neurology Grand Rounds on: Magnetic resonance imaging:

What’s the attraction to MS? January 1997.


67. Ottawa Congress Centre, Ottawa Valley Drug Information Service Update on: Advances in multiple sclerosis. March 1997.

68. Michelangelo’s, Québec City, QC, Neurology update on Rationale for rational therapy in

MS. March 1997. 69. Ottawa General Hospital, Neurology Grand Rounds on: Blasting away at MS: Is it time

for the big guns? April 1997. 70. Ottawa Civic Hospital, 46th Annual Refresher Course for Family Practitioners, What’s

new in multiple sclerosis? April 1997. 71. Hotel Lac Carling, Pine Hill, QC. MS: Clinical issues and decisions,

Immunopathogenesis of MS. June 1997. 72. Canadian Congress of Neurological Sciences, Sheraton Hotel, Saskatoon, SK. MS

satellite symposium, MRI as an outcome measure. June 1997. 73. Canadian Congress of Neurological Sciences, Sheraton Hotel, Saskatoon, SK. MS

satellite symposium, Immune mechanisms of treatment. June 1997. 74. Waterfront Centre Hotel, Vancouver, BC. Special symposium on Multiple Sclerosis:

Clinical Issues & Decisions, Immunopathogenesis of MS. October 1997. 75. Sheraton Harbor Hotel & Marina, San Diego, CA. Annual Meeting of the International

Society for Interferon and Cytokine Research, Guest speaker for a symposium on Interferon and Multiple Sclerosis, -interferon-1a treatment of multiple sclerosis: results of a clinical trial using Rebif in relapsing-remitting disease. October 1997.

76. Camberley Club Hotel, Toronto, ON, Meeting of TEVA Advisory Board. Mechanism of

copolymer-1 in multiple sclerosis. November 1997. 77. Treatment Advances in Immunology Symposium, Tampa, FL. Immunological

mechanism of copaxone. February 1998. 78. Multiple Sclerosis - an update: What’s wrong with the myelin in multiple sclerosis?

Sheraton Gateway Hotel, Toronto, ON. Guest speaker for the Association of Community Neurologists. February 1998.

79. Immunological rationale for MS therapy: What, how, who and when? Community

Neurologists, Le Latini Restaurant, Montréal QC. March 1998. 80. Charles-Lemoyne Hospital, Greenfield Park, QC. Neurology Grand Rounds

Immunological rationale for MS therapy: What, how, who and when? March 1998. 81. Corel Centre, Kanata, ON, Teva-Marion Partners Symposium. Lecture on Copaxone:

Mechanism of action in MS. March 1998. 82. Place Bonaventure, Montréal, QC. Canadian Congress of Neurological Sciences,

Neurobiology Review Course: The immunology of MS sesion generation. June 1998. 83. Marriott Chateau Champlain, Montréal, QC, Continuing Medical Education Seminar,

Multiple Sclerosis, An Update for Nurses: The immunology of MS: From chaos to clarity. June 1998.


84. Universidad Internacional Menéndez Pelayo, Santander, Spain, La destruccion de la

mielina y su reparacion: nuevas terapéuticas. Interferones: Interferon beta-1a (Rebif

). June 1998.

85. El Dorado Hotel, Santa Fe, NM, Southwest Teva Advisory Board Meeting, Mechanism

of action of copaxone. July 1998. 86. Aronsborg Conference Centre, Balsta, Sweden, Proposed mechanism of action of

copaxone to international roundtable conference. September 1998. 87. ECTRIMS Satellite Symposium, Stockholm Conference Centre, Stockholm, Sweden,

Mechanism of action of copaxone in multiple sclerosis. September 1998. 88. Drug Information Association International Workshop on Bioequivalence or

Biocomparability of Complex Molecules, Sheraton Centre Hotel, Toronto, ON. Interferon beta therapy in multiple sclerosis: A clinician’s perspective. September 1998.

89. Royal University Hospital, University of Saskatoon, Saskatoon, SK, Immunologic

perspectives, Pathology, diagnosis and prevalence of MS in symposium on Management of MS in the Era of Immunotherapy. October 1998.

90. Sheraton Halifax Hotel, Halifax, NS. Current thoughts on treatment of MS. October

1998. 91. Dalhousie University Neuroscience Rounds, Halifax, NS. Mechanism of action of

copaxone. October 1998. 92. Hotel Intercontinental, Montréal QC. Nurses Forum on Management of MS in the era of

immunotherapy: New options in the management of MS and Advances in the treatment of secondary progressive MS. October 1998.

93. Therapeutics Program, Health Canada, Banting Building, Ottawa, ON. A physician’s

perspective of what to look for in an interferon- product for multiple sclerosis. November 1998.

94. The Living Arts Centre, Bank of Montréal Room, Mississauga, ON, The current role of

Rebif in the management of MS: Results of the PRISMS Study and beyond. November 1998.

95. Sault Ste. Marie Annual Clinical Day, Water Tower Inn, Sault Ste. Marie, ON. Plenary

session: 1998 update on multiple sclerosis. November 1998. 96. Second Annual Montréal Neurology Symposium, Hôpital Notre-Dame, Montréal, QC.

Multiple Sclerosis Symposium: Immunopathogenesis and Disease modifying therapies, special role in transitional MS. November 1998.

97. Neurology Rounds at Jewish General Hospital, Montréal, QC, Advances in the treatment

of secondary progressive multiple sclerosis. January 1999. 98. Hotel Sofitel, Paris, France. Multiple Sclerosis (MS) Frontiers: Symposium on

Copaxone-new developments. Mechanism of action of copaxone. January 1999.


99. American Academy of Neurology, Toronto, ON. Guest faculty for course No. 7AC.008 on Immunosuppressive Treatment for Neurologists: Multiple sclerosis: further therapies. May 1999.

100. Dubrovnik Restaurant, Winnipeg, MB. Multiple sclerosis-The basics. May 1999. 101. Health Sciences Centre, University of Manitoba, Winnipeg, MB. Multiple sclerosis-

What, why, who & when. May 1999. 102. The Deerhurst, Huntsville, ON. Lecture on Mechanism of Action of Copaxone in MS &

The newer therapies. Part of a symposium on MS: Now a treatable disease. June 1999. 103. The Provincial Museum of Alberta, Edmonton AB. Special lecture in conjunction with

the CCNS. Results of the Rebif secondary progressive study. June 1999. 104. Janet Lynn’s Bistro, Waterloo ON. Multiple sclerosis-what, why, who & when. June

1999. 105. Lights and Lesions aboard the Mariposa Belle in Toronto Harbour, a discussion of

pertinent management points in the use of Copaxone in treating MS patients. June 1999. 106. Chateau Mt. Tremblant, Mt. Tremblant, QC. MS: Newer therapies and their

immunological rationale. Part of a symposium on Prise en charge de la SEP au temps de l’immunothérapie. June 1999.

107. Courtyard Restaurant, Ottawa, ON. , The current role of Rebif in the management of MS:

The results of PRISMS, OWIMS & SPECTRIMS Trials. August 1999. 108. Muskoka Sands Resort, Gravenhurst, ON. MS: Newer therapies and their immunological

rationale, part of a symposium on Management of MS in the era of immunotherapy. August 1999.

109. Maverick’s Restaurant, Moncton NB. Rationale for immunotherapy in multiple sclerosis-

what, why, who & when. August 1999. 110. Hilton Hotel, St. John NB. Rationale for immunotherapy in multiple sclerosis-what, why,

who & when. August 1999. 111. Guest speaker of the Polish Neurological Society Meeting, Lublin Poland. The role of

Interferon -1a (Rebif) in the management of MS. August 1999. 112. Newfoundland Education Day, Memorial University of Newfoundland, St. John’s, NF. 3

Lectures: Diagnosis and differential, use of MRI. Rationale for immunotherapy, pathogenesis, MOA’s and Current therapy choices. October 1999.

113. X

th Pan American Congress of Neurology, Cartagena Columbia. Immune mechanisms in

multiple sclerosis, and Overview of -interferon-1a (Rebif) in the treatment of multiple sclerosis. October 1999.

114. The Victoria Conference Centre, Victoria BC. Immunological basis for the treatment of

MS as part of a symposium of the on Management of MS in the Era of Immunotherapy. October 1999.


115. Delta Chelsea Hotel, Toronto ON. Address to the Ontario Division of the Multiple Sclerosis Society of Canada at their Annual General Meeting entitled MS: A Millennium of Research. November 1999.

116. Park Hyatt Hotel, Toronto ON. Neuroimmunological rationale for interferon therapy as

part of a symposium entitled MS: Inside and Out, in which I was also the Chairman. November 1999.

117. Corel Centre, Kanata ON. The new MS drugs at the Collaborative Educational Session

of the Ottawa-Carleton MS Chapter and the MS Clinic of the Ottawa Hospital-General Campus. November1999.

118. Holiday Inn, Minneapolis, MN. The role of glatiramer acetate in the treatment of

relapsing-remitting MS. December 1999. 119. Inselspital, Hopital de L’Ile, Berne Switzerland. Dose and timing of interferon therapy, in

the Second Annual ‘State of the Art Symposium’ on the Diagnosis and Therapy of Multiple Sclerosis. January 2000.

120. Chateau Laurier Hotel, Ottawa ON. New approach to secondary progressive MS in a

Conference and Workshop in Multiple Sclerosis. February 2000. 121. Associacao Nacional de Jovens Empresarios, Porto Portugal. Dose and timing of

interferon therapy, In Simposio Novos Avancos Na Esclerose Multipla. February 2000. 122. Presenter: Results of the 4 year PRISMS Study at the 2000 Meeting of the Charcot

Foundation, Hotel Beau Rivage, Lausanne Switzerland. March 2000. 123. Presentation at the lecture series in Relapsing MS and the disease continuum: Addressing

early treatment and therapeutic options: the disease modifying drugs. Maclean Estates, Toronto ON. April, 2000.

124. Lecture at the Ostsee-Symposium, Klinische Neuroimmunologie, Universitat Rostock,

Experiences with long-term immunomodulatory therapy of multiple sclerosis. Rostock-Warnemünde. May 2000.

125. American Academy of Neurology, San Diego CA. Guest Faculty for course No.

7AC.008 on Immunosuppressive Treatment for Neurologists: Lecture entitled Multiple sclerosis: Current therapy. May 2000.

126. Immunology update at Symposium Treating MS-An update for clinical practitioners,

Rocky Crest Golf Resort, Mactier ON. June 2000. 127. PRISMS 4 year results at the Serono Symposium, European Neurological Society

Meeting, Jerusalem Convention Centre, Jerusalem Israel. June 2000. 128. Presentation at Physician Educational Program of Multiple Sclerosis: Recent advances &

current opinion, The American Club, Kohler WI. July 2000. 129. Lecture in Symposium entitled Multiple Sclerosis: Relapsing MS, Managing the

Continuum. The 2000 Lecture Series. Relapsing MS and the disease continuum: addressing early and aggressive treatment and therapeutic options: the disease modifying drugs, The Royal Canadian Lodge, Banff AB. August 2000.


130. Guest lecturer: Sally Letson Foundation Series in Neuro-Ophthalmology, Treatment update in MS, The Westin Ottawa, Ottawa ON. September 2000.

131. Guest Speaker: Ottawa-Carleton Chapter of the MS Society of Canada’s Annual General

Meeting on Research update in MS. October 2000. 132. Guest Speaker: Immunological rationale for BMT in MS, ACTRIMS (Americas

Committee for Treatment and Research in MS) Meeting, Boston MA. October 2000. 133. Presentation of the PRISMS 4 year results and the role for immunomodulatory agents at

LACTRIMS, Buenos Aires. November 2000. 134. Presentation of the PRISMS 4 year results at the Mexican Neurological Society Meeting,

Acapulco Mexico. November 2000. 135. Grand Rounds, University of Calgary, Foothills Hospital on The Rationale for bone

marrow transplantation in MS. December 2000. 136. Presenter: Lecture series: SP rémittente: Gestion du continuum, Mont Tremblant, QC,

Canada. Review of Immunomodulator Therapy. January 19-21 2001. 137. Guest Presentation of the International statement on the use of disease modifying agents

at the 3rd

Annual Multiple Sclerosis Meeting for Italian Neurologists, Grand Hotel Plaza, Rome Italy. February 2001.

138. Presenter: Targeting MS: Time Matters, Bermuda. Debate: Which cells are implicated in

MS? February 2001. 139. Presenter: The Canadian MS Clinics Network: Multiple Sclerosis Preceptorship.

Progressive MS. Calgary AB. March 1-4 2001. 140. Presenter: Managing multiple sclerosis and clinical decision-making and Diagnostic

dilemmas, The Boulders, Carefree AZ. March 31 2001. 141. Guest Lecturer: Dose and frequency of interferon-1a therapy in MS, European

Neurological Society, Paris France. April 2001. 142. MS Links: Multidisciplinary advances in patient care, Co-chair, organizer and speaker.

Scottsdale AZ. May 31-June 3 2001. 143. RRMS and Treatment options in clinically isolated syndromes, Adelaide Australia. May

2001. 144. Toronto Public Forum, MS treatment: Review, rethink, respond, Serono Canada and

National Pharma Com, Crowne Plaze, Toronto ON. June 2001. 145. Lecturer: Multiple Sclerosis Course of the Canadian Congress of Neurological Sciences:

Beyond modifying treatments: what to do if they are not effective, including the selection of innovative approaches. Halifax NS. June 2002.

146. Special Lecturer: Leeds and Grenville MS Chapter Research update in MS. Brockville,

ON. June 2001.


147. Guest Presenter: Bone marrow transplantation in MS: Rationale for the Canadian study, ECTRIMS (European committee for treatment and research in MS). Dublin Ireland. September 2001.

148. Keynote Speaker: Annual General Meeting, Multiple Sclerosis Society of Canada,

Ontario Division, Delta Chelsea Hotel. Update on research and treatment of MS. November 2001.

149. Guest speaker: Multiple Sclerosis Society of Canada, Toronto Chapter. Update on

symptomatic treatment. November 2001. 150. Special Guest Speaker: Comparison of different dose and application regimen of

interferon b-1a. Hotel Adlon, Kaminzimmer, Berlin Germany. November 2001. 151. Special Guest Speaker at symposium Multiple Sklerose, on Comparison of different dose

and application regimen of interferon b-1a. Cologne Germany. November 2001. 152. Lecturer at special conference of the Consortium of MS Clinics on Long term benefits of

interferon- therapy and the usefulness of CSF studies in the diagnosis of MS. Dallas, TX. December 2001.

153. Guest presenter at conference on the use of IGIV Is multiple sclerosis a target for IGIV

therapy? Case Western Reserve University, Pinehurst NC. March 2002. 154. Medical Grand Rounds, University of Ottawa, Ottawa Hospital-General Campus: New

concepts in the pathogenesis of MS. March 2002. 155. Consortium of Multiple Sclerosis Clinics Meeting, Special Symposium on ‘Do we have

enough evidence today to optimize MS Treatment’: Clinical parameters and their role in monitoring therapy. Chicago Hyatt Hotel. June 2002.

156. Consortium of Multiple Sclerosis Clinics Meeting, Symposium on Surrogate Markers in

MS:Diagnostic Criteria revisited: Role of CSF in MS diagnosis. Chicago Hyatt Hotel. June 2002.

157. 3rd Annual Comprehensive Spring Neurology Update, Updated diagnostic considerations

in MS: Use of the new ‘McDonald’ criteria and value of early treatment. White Oaks Conference Resort & Spa, Niagara-on-the-Lake ON. June 2002.

158. Toronto CME program, Using interferons to treat RRMS: Dosing and long term

considerations. Toronto Park Hyatt Hotel. June 2002. 159. Comprehensive Spring Neurology Update, EVIDENCE-48 week data, Hockley Valley

Resort ON. June 2002. 160. Educational Forum, Newport RI, Review of the AAN guidelines for treatment of MS.

June 2002. 161. Canadian Congress of Neurological Sciences Annual MS Course, Canadian consensus on

the use of disease modifying agents for the treatment of MS. Vancouver BC. June 2002. 162. Serono Regional Advisory Board Meeting, Mt. Tremblant QC. A look at the

EVIDENCE. July 2002.


163. MAMSI Health Plans Continuing Medical Education Seminar, Tysons Corner VA. Multiple Sclerosis: Clinical update and treatment strategy. July 2002.

164. Southeast Medical Center, CME program, The importance of dose and frequency in MS

interferon therapy, Dothan AL. August 2002. 165. University of Utah, Neurology Grand Rounds, Exploring bone marrow transplantation as

a treatment for aggressive MS, Utah Medical Center. September 2002. 166. Presentation of New advances in the treatment of MS to the Board of the Toronto MS

Chapter, Park Hyatt Hotel. October 2002. 167. Keynote Speaker: Annual General Meeting of the Toronto MS Chapter, Emerging issues

in MS Today. York Reception Centre. Toronto ON. October 2002. 168. Faculty presenter: CSF Considerations at a Roundtable on Primary Progressive Multiple

Sclerosis. Warwick Hotel, Houston TX. November 2002. 169. Annual University of Toronto McEwan Lectureship, Immunological perturbations in MS.

Toronto Western Hospital. November 2002. 170. Guest Lecturer: Neurology Faculty Research Day, University of Toronto, Intensive

immunotherapy of MS: Role for bone marrow transplantation. Park Hyatt Hotel. November 2002.

171. Guest CME Lecturer: Optimizing the benefits of immunomodulating therapy. Sheraton

Hotel, Montréal QC. November 2002. 172. Medical College of Georgia School of Medicine, Grand Rounds on Interferons in

multiple sclerosis: Importance of dose and frequency. Augusta GA. December 2002. 173. Guest Speaker: Analyzing the evidence for the treatments of MS. Waterford Marriott

Hotel, Oklahoma City OK. February 2003. 174. Guest Speaker: An update on diagnosis and treatment of MS? Tulsa Neuro-Sciences

Society. Summit Club, Tulsa OK. February 2003. 175. Moderator and Co-Chair: Serono Expert Panel Workshop. Treatment optimization in

MS. Bermuda. March 2003. 176. Special Guest Lecturer: University of Texas Medical School. Early treatment of multiple

sclerosis. Houston TX. March 2003. 177. Special Guest Lecturer: Pappas Bros Steak House, Houston TX. Early treatment of

multiple sclerosis. March 2003. 178. Special Guest Lecturer: A review of treatment in multiple sclerosis. Eddie V’s

Edgewater Grille, Austin TX. March 2003. 179. Special Guest Lecturer: Early treatment of multiple sclerosis. Aldo’s Ristorante Italiano,

San Antonio TX. March 2003. 180. Special Guest Lecturer: Early treatment of multiple sclerosis. Ruth’s Chris Steakhouse,

San Antonio TX. March 2003.


181. Guest Lecturer: A titration approach to the treatment of MS. Marriott Hotel Vanderbilte,

Nashville TN. March 2003. 182. Guest Lecturer: MS treatment options: Real world experience. La Piazza Restaurant,

Dallas/Fort Worth TX. April 2003. 183. Guest Lecturer: MS research trends and current research regarding ASCT. Annual

meeting of the National MS Society, Long Island Chapter, Melville NY. April 2003. 184. Guest Lecturer: NAbs in clinical trials with more frequent administration of IFNB-1a.

NABS Workshop - The relevance of antibodies to interferon-beta in MS therapy, Vienna May 2003.

185. Special Guest Speaker: Optimizing therapy in multiple sclerosis, Clio’s, Boston MA.

May 20 2003. 186. Guest Speaker: Leadership in MS: Putting current issues in MS treatment in perspective.

Toronto ON. May 2003. 187. Symposia organizer and lecturer: Grey matter disease in MS: The untold story. CMSC

2003 Annual Conference, Sheraton Hotel & Marina San Diego CA. May 2003. 188. Symposia Organizer and Lecturer: Standardizing CSF analysis. CMSC 2003 Annual

Conference, Sheraton Hotel & Marina. May 2003. 189. Special Guest Speaker: Medical Grand Rounds, Griffin Hospital, Westchester NY.

Advances in understanding the pathogenesis of multiple sclerosis. June 2003. 190. Special Guest Speaker: Medical Grand Rounds. St. Francis Hospital, Hartford CT,

Advances in understanding the pathogenesis of multiple sclerosis. June 2003. 191. Guest Speaker: MS Research Update: Current research projects and treatments. MS

Society Educational Event, Toronto ON. June 2003. 192. Guest Speaker: Clinical efficacy driving choice of therapy. Schering Satellite

Symposium at The European Neurological Society, Challenges of Choosing the Optimal MS Therapy. Istanbul Turkey. June 2003.

193. Lecturer: MS Immunobiology Course, When and why the CSF study is still useful.

Canadian Congress of Neurological Sciences Annual Meeting. Québec City QC. June 2003.

194. Guest Speaker: MRI and its link to clinical outcomes, in Workshop on MRI

Standardization and Use in Management of MS. Millennium Hotel, Minneapolis MN. August 2003.

195. Chair and Speaker: Symposium entitled: From bench to bedside: Theory and practice of

MS care, The history of copaxone as a therapy for MS and How can the immune system offer neuroprotection? The Deerhurst Inn, Huntsville ON. August 2003.

196. Co-Chair and Speaker: Immunology Workshop: Neuroprotection: The Good - Atelier en

Immunologie La neuroprotection: Le bon. 2nd

Annual Northern MS Workshop: The


good, the bad and the ugly: A focus on immunology. Finger Lake Kuujjuak. August 2003.

197. Special Grand Rounds Invited Speaker: Does aggressive MS warrant aggressive

treatment? Role of intensive immunosuppression and ASCT. Mayo Clinic, Scottsdale AZ. Sept 2003

198. Special Guest Lecturer: Early treatment of MS. University of Arizona, Tucson AZ. Sept

2003. 199. Special Evening Lecture: New treatment strategies in the management of multiple

sclerosis. Phoenix AZ. Sept 2003. 200. Faculty Lecturer of 1

st International MS Nurse Network Workshop: Update on current

MS treatment and research, ECTRIMS Meeting. Milan Italy. Sept 17-20 2003. 201. Guest Lecturer: Clinical efficacy driving choice of therapy. Schering International MS

Symposium. Amsterdam. Oct 25 2003. 202. Guest Lecturer: MS: Learning, leading living – Keeping up with MS. MS research

updates: Highlighting stem cell research, MS Society of Canada, Manitoba Division. Nov 2003.

203. Special Grand Rounds Invited Speaker: Multiple Sclerosis: An aggressive disease

warranting aggressive treatment, Royal University Hospital. Saskatoon SK. Nov 7 2003. 204. Guest Lecturer: Teva Nurses Retreat, Toronto ON. The mode of action of DMD’s in the

treatment of RRMS. Nov 23 2003. 205. Guest Lecturer: Teva Nurses Retreat Toronto ON, Nabs to DMD’s: Issue of non-issue.

Nov 23 2003. 206. Guest Lecturer: Fireplace Talks on Multiple Sclerosis, Early treatment in MS. Berlin.

Nov. 29 2003. 207. Guest Lecturer: MS: A disease lacking in good inflammation. An interactive educational

evening. Ottawa ON. Dec. 1 2003. 208. Guest Lecturer: Clinical efficacy driving choice of therapy in Multiple Sclerosis. Dublin

Ireland. Dec 5 2003. 209. Guest Lecturer: Paraclinical tests for diagnostic and follow-up of MS patients. Trois

Rivières QC. Dec 11 2003. 210. Morning Rounds Guest Speaker: Paraclinical tests for diagnostic and follow-up of MS

patients. Charles Lemoyne Hospital, Sherbrooke QC. Dec 12 2003. 211. Guest Speaker: Treating multiple sclerosis, General CME Symposium. Grove Park Inn,

Asheville NC. January 10 2004. 212. Chairman and Guest Speaker: Defining the standards of multiple sclerosis research.

International Schering Symposium, Copenhagen. March 2004.


213. Guest Speaker: Dose-efficacy relationship in MS treatment / Importance of high dose-high frequency therapies. International Schering Conference, Treatment of MS: Improving Quality of Life. Istanbul. March 20 2004.

214. Guest Speaker: Early treatment of MS, International Schering Conference, Treatment of

MS: Improving Quality of Life, Istanbul. March 20 2004. 215. Guest Speaker: Addressing early treatment and therapeutic options in MS. the disease

modifying drugs. Sioux Falls SD. March 2004. 216. Guest Speaker: Get the most out of MS therapies today. Nebraska Chapter of National

Multiple Sclerosis Society and University of Nebraska Medical Centre at Embassy Suites, Omaha NE. March 24 2004.

217. Guest Speaker: Dose and timing of interferon therapy in MS, Omaha NE. March 2004. 218. Guest Speaker: Current treatment strategies for multiple sclerosis. Sal & Curvaos,

Downers Grove IL. March 2004. 219. Guest Speaker: New Rebif slide data. Harvey IL. March 2004. 220. Guest Speaker: Treatment advances in multiple sclerosis: Treat early? Treat with high

dose? Nabs? Chicago IL. March 2004. 221. Guest Speaker: Rebif Consultant Forum Treatment Optimization. Evidence-based review

of clinical data. New York NY. April 2004. 222. Guest Speaker: Rebif Consultant Forum Treatment Optimization. Antibodies in

perspective. New York NY. April 2004. 223. Guest Speaker: Rebif Consultant Forum Treatment Optimization. MS patient

management: The analog model. New York NY. April 2004. 224. Guest Lecturer: Baltic Symposium Clinical Neuroimmunology. Stem cell transplantation

in multiple sclerosis. Berlin. May 8 2004. 225. Guest Lecturer: Multiple Sclerosis and Neuroinflammation. CIHR Training. The role of

autologous stem cell transplantation & immunoablation as a treatment for aggressive MS. Montréal QC. May 15 2004.

226. Guest Speaker: The development of IFN1a as a treatment for RRMS. Pfizer, Roanoke

VA. May 25 2004. 227. Guest Speaker: The development of IFN1a as a treatment for RRMS. Pfizer,

Fishersville VA. May 26 2004. 228. Guest Speaker: The development of IFN1a as a treatment for RRMS. University of

Virginia, Charlottesville VA. May 26 2004. 229. Guest Speaker: The development of IFN1a as a treatment for RRMS. Neurological

Associates of Richmond, Richmond VA. May 27 2004.


230. Keynote Speaker: Neurology 2004: 2nd

Annual Meeting – New & Emerging Ideas in Clinical Care: MS & Parkinson’s Disease. Optimizing therapy with disease modifying agents in MS. La Malbaie QC. May 2004.

231. Chair: CNS Fireplace Talks Scientific Program. Early MS. June 12 2004. 232. Guest Speaker: Making the most out of DMD’s for RRMS. Ruth’s Chris Steak House.

Parsippany NJ. June 16 2004. 233. Guest Speaker: Treatment optimization in RRMS. Stony Hill Inn, Hackensack NJ. June

17 2004. 234. Guest Speaker: The importance of dose and frequency in Interferon therapy. Cardwell’s

Restaurant, Clayton MI. July 2004. 235. Keynote Speaker: The changing paradigm of inflammation and neuroprotection. MS

2004: Bridging Neurology Research & Clinical Practice, PEI. July 1 2004. 236. Guest Speaker: When is an effect not an effect? MS 2004: Bridging Neurology Research

& Clinical Practice, PEI. July 17 2004 237. Guest Speaker: Interactive case discussion: What is the optimal approach to

management? MS 2004: Bridging Neurology Research & Clinical Practice, PEI. July 17 2004.

238. Neurology Grand Rounds: Optimization of treatment of MS patients. William Beaumont

Hospital, Royal Oak MI. July 21 2004. 239. Workshop: Immunosuppression vs Immunomodulation. Teva Copaxone Advisory Board,

Sonora Resort BC. August 22 2004. 240. Workshop: Treatment optimization. Teva Copaxone Advisory Board, Sonora Resort, BC.

August 22 2004. 241. Guest Speaker: Optimization recommendations in the treatment of RRMS. March

Restaurant, NY. September 21 2004. 242. Guest Speaker Optimization in the treatment of relapsing remitting multiple sclerosis,

35th

Congresso Societa Itialian di Neurologia. September 28 2004. 243. Guest Speaker: Tomorrow – Benefit right from the start. Schering Satellite Symposium:

Treating MS – Today, Tomorrow and in the Future, ECTRIMS Meeting 2004. October 8, 2004.

244. Invited Lecturer: Diagnosis and management of multiple sclerosis, 11

th Asian Oceanic

Congress of Neurology, Singapore. November 26 2004. 245. Invited Lecturer: Update on the immunological diagnosis of MS, 11

th Asian Oceanic

Congress of Neurology, Singapore. November 26 2004. 246. Guest Speaker: Therapeutic update – Developments in 2003/2004, MS Forum Pan-Asian

Congress, Ho Chi Minh City Vietnam. November 20 2004.


247. Guest Speaker: Treatment optimization in MS, Nordic Serono Symposia in MS. Oslo Norway. December 10 2004.

248. Guest Speaker: Treatment optimization in MS, Nordic Serono Symposia in MS, Oslo

Norway. December 10 2004. 249. Guest Speaker: The importance of early diagnosis and treatment of multiple sclerosis, La

Cote d’Or, Arlington VA. December 16 2004. 250. Guest Speaker: Benefit to risk: A fine balance, Toronto ON. January 19 2005. 251. Guest Speaker: Recent data in treatment of MS, Tyson’s Corner VA. January 25 2005. 252. Round Table Discussion: Recent data in treatment of MS, Bethesda MD. January 25

2005. 253. Guest Speaker: Rebif, PRISMS LTFU, MS research, Taylor Medical Group, Towson

MD. January 26 2005. 254. Guest Speaker: Rebif, PRISMS LTFU, MS research, Johns Hopkins Outpatient Clinic,

Baltimore MD. January 26 2005. 255. Guest Speaker: Current treatment options for MS: What’s new in your physician’s bag,

Phoenix AZ. February 16 2005. 256. Co-Chair & Speaker: Emerging therapies: Future look, practicum in neurology 2005,

Carefree AZ. February 19 2005. 257. Guest Speaker: Optimizing the treatment of RRMS: What’s new in your physician’s bag,

Starkers Restaurant, Kansas City MI. February 22 2005. 258. Guest Speaker: Treatment algorithms: Maximizing the impact of treatment optimization,

at Conference: Treatment Optimization – Taking Science into Practice, Madrid Spain. March 5-6 2005.

259. Guest Speaker: Long term Rebif, Mistral Restaurant, Boston MA. March 8 2005. 260. Guest Speaker: Long term Rebif, MS Centre, Cambridge MA. March 9 2005. 261. Guest Speaker: Long term Rebif, Brigham Womens’ Centre, Cambridge MA. March 9

2005. 262. Guest Speaker: MS and neuropathic pain, Toronto ON. March 22 2005. 263. Guest Speaker: Treatment options in RRMS: Maximizing the benefit, Chance Restaurant,

Edmonton AB. March 22 2005. 264. Guest Speaker: Treatment options in RRMS: Maximizing the benefit, Health Sciences

Centre, Calgary AB. March 23 2005. 265. Guest Speaker: Maximizing the benefit of treatment of RRMS, Cleveland OH. April 25

2005.


266. Guest Speaker: Maximizing the benefit of treatment for RRMS – Importance of early initiation, Japan. May 2005.

267. Special Rounds Guest Speaker: Effective treatment of RRMS – Maximizing the benefit,

University of Chiba, Tokyo Japan. May 2005. 268. Guest Speaker Rounds: Rediscovering the role of CSF in the diagnosis of MS, Tohuku

University, Sendai Japan. May 2005. 269. Japanese Neurology Society. Maximizing the benefit of treatment for RRMS –

Importance of early initiation, Kogoshima Japan. May 2005. 270. Guest Speaker: Neuropathic Pain in MS, Chateau Laurier, Ottawa ON. May 30 2005. 271. Symposia: Diagnosing MS in 2005: Focus on accuracy, The use of serological or

cerebrospinal fluid diagnostic tests, Consortium of Multiple Sclerosis Clinics, Orlando, FL. June 1 2005

272. Workshop: Bone marrow transplants, Consortium of Multiple Sclerosis Clinics, Orlando

FL. June 1 2005. 273. Guest Speaker: Sunday Housecalls – MS: Living with it, incidence, latest treatments and

research, CFRA, Ottawa ON. June 5 2005. 274. Guest Speaker: Cannabinoids: an exciting new treatment option for neuropathic pain,

Beckta Dining & Wine, Ottawa ON. June 6 2005. 275. Guest Speaker: The use of serological or cerebrospinal fluid diagnostic tests.

Presentation to Community Neurologists, Harrisburg PA. June 9 2005. 276. Guest Speaker: The bone marrow stem cell transplantation study. MS Society of Canada

North York Chapter, Glenway Country Club, Newmarket ON. June 13 2005. 277. Guest Speaker: Multiple Sclerosis: A disease of white and gray matter, CAET/NETO

Educational Seminars and AGM 2005, Ottawa ON. June 17 2005. 278. Chair: Diagnosing MS in 2005: Standards for CSF analysis, CME Teleconference hosted

by Consortium of Multiple Sclerosis Centers. June 29 2005. 279. Guest Speaker: New therapy concepts for early MS, Fireplace Talks Scientific Program.

Mykonos Greece. July 9 2005. 280. Grand Rounds: Immunoablative therapy & autologous stem cell transplant for aggressive

MS, Johns Hopkins University, Baltimore, Washington. September 13 2005. 281. Grand Rounds: Neuropathic pain in MS: The under-told story. Kingston General

Hospital, Kingston ON. September 15 2005. 282. Guest Speaker: Treatment optimization in MS. Boston MA. September 2005. 283. Guest Speaker: MS Society of Canada, Immunoprotection. Hamilton ON. October 6

2005.


284. Guest Speaker: Current concepts in neuroprotection: From bench to bedside, Interactive educational event, Restaurant Anise. Montréal QC. October 11 2005.

285. Guest Speaker: MS Forum: Benefit of early treatment of MS, Latin America Schering

Symposium. Panama. October 2005. 286. Guest Speaker: Symposium: BENEFIT Study: Clinical results, 18

th World Congress of

Neurology. Sydney Australia. November 2005. 287. Guest Speaker: Bone marrow transplantation: Does it stop MS progression?, European

Charcot Foundation. Lisbon Portugal. November 18 2005. 288. Guest Speaker: MS diagnosis, International Congress on Multiple Sclerosis, Iran

Hospital. Tehran Iran. November 2005. 289. Guest Speaker: MS treatment optimization, International Congress on Multiple Sclerosis,

Iran Hospital Tehran Iran. November 2005. 290. Guest Speaker: The BENEFIT Study: Early treatment of MS, Betaferon Symposium.

Athens Greece. November 25 2005. 291. Guest Speaker: Diagnosis and utilization of CSF markers in PPMS, Genentech / Biogen

Idec MS National Advisory Board Program. Sonoma CA. December 2 2005. 292. Neurology Grand Rounds: Optimizing MS therapy of RRMS. University of Michigan.

December 7 2005. 293. Guest Speaker: Optimizing MS therapy of RRMS, Gandi Dancer Restaurant. Ann Arbor

MI. December 7 2005. 294. Guest Speaker: Current disease-modifying drugs: Evaluating the evidence. Serono

Symposia: Unravelling the puzzle of MS: Today and tomorrow. January 14-15 2006. 295. Guest Speaker: Benefits of long-term disease-modifying agents, MS Forum Europe

Meeting MS Across Europe: Maximizing MS management. January 20 2006. 296. Pathogenesis of multiple sclerosis. Academic Program - Annual Congress of the

Neurological Association of South Africa. Durban South Africa. March 10 2006. 297. Current management of multiple sclerosis. Academic Program - Annual Congress of the

Neurological Association of South Africa. Durban South Africa. March 10 2006. 298. Chair: Schering MS Fireplace Talks: Scientific Programme: MS Treatment in Practice,

MS Treatment in Practice. Berlin. March 24 2006. 299. Chair: Schering MS Fireplace Talks: Scientific Programme: Early Signs of MS:

Predicting Late Outcome, Therapeutic options in early MS. Berlin. March 25 2006. 300. Grand Rounds: Pushing reset on the immune system: A treatment for aggressive multiple

sclerosis, Pediatric Neurology Grand Rounds, Sick Kids Hospital for Sick Children. Toronto ON. March 29 2006.


301. Panel Member: Taking a socratic approach to assessing treatment pathways in multiple sclerosis, Association of British Neurologists Spring Meeting. Brighton UK. April 19 2006.

302. Guest Speaker: Treatment optimization in multiple sclerosis, Black & Tan Grille.

Appleton WI. April 20 2006. 303. Guest Speaker: Stem cell applications in multiple sclerosis,New York Academy of

Sciences: The Neuroimmunology Discussion Group. New York NY. April 27 2006. 304. Guest Speaker: Combination therapy in MS: When, what and why? Practicum in

Neurology. Chicago IL. April 29 2006. 305. Guest Speaker: Update on treatment optimization, Multiple Sclerosis Review. St. Marc-

Sur-Richelieu QC. May 6 2006. 306. Guest Speaker: MS & neuropathic pain. Bayer, Beckta Restaurant. Ottawa ON. May 17

2006. 307. Guest Speaker: Update on the bone marrow transplant study, Ask the Experts, MS

Society of Canada and MS Society Ottawa Chapter. Ottawa ON. May 26 2006. 308. Guest Speaker: Canadian MS treatment optimization / IFN antibody update, Restaurant

Les Chèvres. Montréal QC. June 7 2006. 309. Participant: Symposium on Basic & Translational Aspects of Neuroinflammation Jeanne

Timmins Amiphitheatre. Montréal QC. June 18-19 2006. 310. Guest Speaker: Clinical Update: Canabinoids in pain management, Signatures

Restaurant. Ottawa ON. June 22 2006. 311. LACTRIMS: MRI findings in diseases that mimic MS. Isla Margarita Venezuela. June

29 2006. 312. Guest Speaker: Why high dose, high frequency Interferon therapy is important in RRMS,

No VI Chop House. Detroit MI. July 13 2006. 313. Guest Speaker: Why high dose, high frequency Interferon therapy is important in RRMS,

Novi Sheraton. Detroit MI. July 13 2006. 314. Guest Speaker: Why high dose, high frequency Interferon therapy is important in RRMS,

Southern Arizona Health Care. Tuczon AZ. July 18 2006. 315. Guest Speaker: Why high dose, high frequency Interferon therapy is important in RRMS,

Brigham & Womens’ Hospital. Boston MA. August 2 2006. 316. Guest Speaker: Patient management, therapy and treatment optimization, Garden of Eden

Restaurant. Boston MA. August 3 2006. 317. Guest Speaker: Why high dose, high frequency Interferon therapy is important in RRMS,

Carney Hospital. Boston MA. August 3 2006. 318. Guest Speaker: MS: Yesterday, today, tomorrow, Andrés Restaurant. Las Vegas NV.

August 15 2006.


319. Guest Speaker: New insights into the immunopathogenesis of MS. XXII Congresso

Brasileiro de Neurologia. August 28 2006. 320. Guest Speaker: CIS High Risk. XXII Congresso Brasileiro de Neurologia. August 28

2006. 321. Guest Speaker: Impact of available multiple sclerosis therapy. XXII Congresso Brasileiro

de Neurologia. August 28 2006. 322. Guest Speaker: Multipl skleroz tedavisi: Ne kadar erken? Klinik Kanitlar. MS

tedavisinde on yil. Turkey. September 16 2006. 323. Lecturer: Mending the Brain: Stem cells and repair in multiple sclerosis. European

Charcot Foundation Symposium 2005 – 12th

European Charcot Foundation Lecture. Taormina. Sicily Italy. November 16-18 2006.

324. Guest Speaker: BENEFIT-A view insider opinion. Fireplace Talks Betaferon. Germany.

December 1 2006. 325. Guest Speaker: Treatment in practice: Early causes of MS. Fireplace Talks Betaferon.

Germany. December 1 2006. 326. Guest Speaker: La prise en charge de la sclérose en plaques: le traitement précoce. Hotel

Place d’Armes. Montreal QC. December 5 2006. 327. Neurology Grand Rounds: Treating MS: Yesterday, today & tomorrow. Ottawa Hospital.

December 15 2006. 328. Guest Speaker: Autologous stem cell transplants for the treatment of MS. National MS

Society. San Francisco. January 16-19 2007. 329. Guest Speaker: The immunopathogenesis of multiple sclerosis: Therapeutic implications

for disease management. North American Neuro-Ophthalmology Society. Snowbird Utah. February 15 2007.

330. Guest Speaker: The evolution of multiple sclerosis therapy: yesterday, today and

tomorrow. North American Neuro-Ophthalmology Society. Snowbird Utah. February 15 2007.

331. Guest Speaker: Therapeutic gain. SSIF Conference. Barcelona. March 9-10 2007. 332. Guest Speaker: How to treat a failing patient. BAYER Inernational Scientific

Symposium. Rome. March 17 2007. 333. Guest Speaker: Why high dose, high frequency Interferon therapy is important in RRMS.

Springfield MA. April 3 2007. 334. Guest Speaker: Why high dose, high frequency Interferon therapy is important in RRMS.

Hartford CT. April 3 2007. 335. Guest Speaker: Why high dose, high frequency Interferon therapy is important in RRMS.

Hartford CT. April 4 2007.


336. Guest Speaker: Long-term follow-up of clinical trials of MS therapies: The PRISMS Study. Miami, Florida. April 14 2007.

337. Guest Speaker: Multiple sclerosis: What’s in the pipeline? OMA Annual Meeting. April

27 2007. 338. Guest Speaker: Betaferon Symposium: The benefits of early treatment for MS.

Kaohsiung, Taiwan. May 15 2007. 339. Guest Speaker: The benefits of early treatment for MS. Ching Medical University

Hospital. Taichung, Taiwan. May 16 2007. 340. Guest Speaker: Update on the 3-year BENEFIT Study. Taipei, Taiwan. May 16 2007. 341. Guest Speaker: Moving forward in MS Therapy: Benefits of early and long-term

treatment and the importance of adherence. 1st Pan Asian MS Nurses Forum. Singapore. May 20 2007.

342. Guest Speaker: Moving forward in MS Therapy: Keys to improved treatment tolerability:

Recent trial observations. 1st Pan Asian MS Nurses Forum. Singapore. May 20 2007. 343. Guest Speaker: The advantages of treating MS early: 3-year follow-up data from the

BENEFIT Study. Bayer HealthCare. Alice Springs Australia. May 21 2007. 344. Meet the Expert: Benefit of early treatment of MS: 3-year follow-up data from the

BENEFIT Study. ANZAN Meeting. Alice Springs Australia. May 22 2007. 345. Guest Speaker: Benefit of early treatment of MS: 3-year follow-up data from the

BENEFIT Study. Perth Australia. May 23 2007. 347. Guest Speaker: Treatment of MS over the next 5 years. ANZAN Meeting. Ayers Rock

Australia. May 25 2007. 348. Guest Speaker: Clinical laboratory analysis: Diagnostic and prognostic significance.

Satellite Symposium. Washington DC. CMSC. May 30 2007.

349. Lecturer: BENEFIT from timely treatment: New perspectives for treatment decisions. Satellite Symposium of ENS 2007. Rhodes Greece. June 18 2007.

350. Lecturer: Treating neurological disorders: New approaches, new therapies, new prospects.

Satellite Symposium of ENS 2007. 351. Lecturer: Optimizing MS therapy: A step further with Rebif

® new formulation. Rhodes

Greece. June 19 2007. 352. Guest Speaker: Relevance of Nabs for dose optimisation. MS preceptorship:Updating

knowledge on multiple sclerosis. Barcelona Spain. June 24 2007. 353. Guest Speaker: Betaseron in the early and long-term management of relapsing forms of

multiple sclerosis. Burlington Country Club. Burlington VT. September 19 2007. 354. Guest Speaker: Betaseron in the early and long-term management of relapsing forms of

multiple sclerosis. Norwich Inn. Norwich VT. September 20 2007.


355. Grand Rounds: Betaseron in the early and long-term management of relapsing forms of multiple sclerosis. Fletcher Allen Health Center. Burlington VT. September 20 2007.

356. Grand Rounds: Betaseron in the early and long-term management of relapsing forms of

multiple sclerosis. Hitchcock Foundation: Dartmouth-Hitchcock Medical Center. September 21 2007.

357. Guest Speaker: Betaseron in the early and long-term management of relapsing forms of

multiple sclerosis. Brigham Womens’ MS Clinic. Boston MA. October 3 2007. 358. Guest Speaker: Betaseron in the early and long-term management of relapsing forms of

multiple sclerosis. New Haven CT. October 3 2007. 359. Guest Speaker: Betaseron in the early and long-term management of relapsing forms of

multiple sclerosis. Associated Neurologists of Southern Connecticut. Fairfield CT. October 4 2007.

360. Guest Speaker: Betaseron in the early and long-term management of relapsing forms of

multiple sclerosis. Eastern Standard. October 4 2007. 361. Guest Speaker: From bench to bedside: The history of copaxone® (Copolymer-1) as a

therapy for MS. TEVA Pre-ECTRIMS Program. Vienna Austria. October 9 2007. 362. Guest Speaker: Initial MS therapy: Making the right choice. ECTRIMS Satellite

Symposium. Prague. October 12 2007. 363. Lecturer: Experimental therapies & the role of nurses in the research centre. Serono

Symposium International Foundation (SSIF) 9th

International MS Nurse Workshop on MS. Prague CZ. October 2007.

364. Lecturer: Current disease modifying drugs: Evaluating the evidence. Serono Symposium

International Foundation (SSIF). MS Academia: Multiple Sclerosis Advanced Course. Prague CZ. October 2007.

365. Lecturer: Achieving optimum results for patients MS. Bayer Schering Pharma

Symposium. Prague CZ. October 2007. 366. Lecturer: Recent experience with higher doses of Betaferon Bayer Schering Pharma

Symposium. Prague CZ. October 2007. 367. Lecturer: Rebif new formulation: Balancing efficacy & safety. Merck Serono

Symposium. Prague CZ. October 2007. 368. Lecturer: Rebif new formulation in early MS: Maximising the benefits of treatment.

Satellite Symposium. Prague CZ. October 2007. 369. Lecturer: Initial MS therapy: Making the right choice. Satellite symposium for

ECTRIMS on the window of opportunity for successful MS treatment. Prague CZ. October 2007.

370. Guest Speaker: Novel therapies for treatment of relapses (IVIg & ACTH). MS

Consensus Conference. Ft. Worth TX. October 27 2007.


371. Guest Speaker: Maximizing benefits in MS therapy. Iran MS Congress. November 22 2007.

372. Guest Speaker: Best treatment algorithm for MS patients. 4

th International Congress on

MS. Tehran Iran. November 22 2007. 373. Guest Speaker: Evidence based MS management: Evaluating benefit-to-risk. Isfahan MS

Symposium. November 24 2007. 374. Guest Speaker: Making treatment count. Shiraz MS Symposium. November 26 2007. 375. Guest Speaker: Therapeutic gain and new efficacy measures in multiple sclerosis.

Multipl Sklerozda Terapötik Kazanim ve Yeni Etkinlik Ölçutleri. Antalya Turkey. November 12 2007.

376. Guest Speaker: Early treatment and initiating MS therapy. Finnish MS Symposium.

Helsinki Finland. January 31 2008. 377. Guest Speaker: Non- and partial response to therapy. Finnish MS Symposium. Helsinki

Finland. January 31 2008. 378. Guest Speaker: Practical treatment for today’s RRMS patient. UNSOM Neurology.

Henderson NV. March 18 2008. 379. Guest Speaker: Today’s treatment of RRMS. Marriott Las Vegas Resort. Las Vegas NV.

March 18 2008. 380. Guest Speaker: A discussion surrounding treatment for today’s RRMS patient. Marriott

Las Vegas Resort. Las Vegas NV. March 18 2008. 381. Guest Speaker: A discussion surrounding a treatment for today’s RRMS patient. Reno

NV. March 19 2008. 382. Guest Speaker: Clinical considerations in managing RRMS. Reno NV. March 19 2008. 383. Guest Speaker: The RRMS spectrum: Parameters for balancing efficacy and safety. Hotel

Teatro. Denver CO. March 20 2008. 384. Guest Speaker: The RRMS spectrum: Parameters for balancing efficacy and safety.

Northwest Neurology. Wheat Ridge, CO. March 20 2008. 385. Guest Speaker: Practical treatment for today’s RRMS patient. Bistro Bella Vita. Grand

Rapids, MI. March 26 2008. 386. Guest Speaker: A discussion surrounding a treatment for today’s RRMS patient.

Wyoming MI. March 27 2008. 387. Guest Speaker: A discussion surrounding a treatment for today’s RRMS patient. Grand

Rapids MI. March 27 2008. 388. Guest Speaker: A discussion surrounding a treatment for today’s RRMS patient.

Wyoming MI. March 28 2008.


389. Guest Speaker: Evidenze cliniche. Updates in Clinical Neurology. Instituto Filosofico Asoisianum Gallarte XVII Riunione Annuale. Gallarte Italy. April 4 2008.

390. Guest Speaker: Bone marrow-derived stem cells and multiple sclerosis. National

Institutes of Health Symposium: Challenges & Promise of Cell-Based Therapies. Bethesda MD. May 6 2008.

391. Lecturer: A sea change in MS treatment: The potential of small molecules. Satellite

Symposium at The Consortium of Multiple Sclerosis Clinics 2008. Denver CO. May 30 2008.

392. Guest Speaker: Treatment for today’s RRMS patient. Cornell University. New York

NY. July 9 2008. 393. Guest Speaker: Treatment for today’s RRMS patient. Canlis. Seattle WA. August 12

2008. 394. Guest Speaker: Treatment for today’s RRMS patient Puyallup WA. August 13 2008. 395. Guest Speaker: Clinical considerations in balancing RRMS therapy. El Gaucho

Restaurant. Portland OR. August 13 2008. 396. Guest Speaker: Discussion surrounding a treatment for today’s RRMS patient. Overlake

Neurology. Bellevue WA. August 13 2008. 397. Guest Speaker: Primary progressive multiple sclerosis: What can we do? Multiple

Sclerosis Educational Seminars 2008. Athens Greece. Sept 5-7 2008. 398. Guest Speaker: Progress multiple sclerosis with severe disability (EDSS >7): treatment

decisions. Multiple Sclerosis Educational Seminars 2008. Athens Greece. Sept 5-7 2008.

399. Guest Speaker: Review of Rebif long-term data: Benefit-to-risk profile. Maximizing

Benefits, Minimizing Risks Through All Stages of MS. Geneva Switzerland. September 8 2008.

400. Lecturer: Management of experimental therapies: The compassionate use. 10

th

International MS Nurse Workshop. WCTRIMS. Montréal QC. September 16 2008. 401. Lecturer: A decade of experience with Interferons in MS. Satellite Symposium –

Improving MS Treatments. WCTRIMS. Montréal QC. September 18 2008. 402. Lecturer & Chair: Contemporary approaches to MS management. Satellite Symposium –

Montréal QC. September 17 2008. 403. Guest Speaker: Understanding disease progression in MS. MS Society Progressive Talks.

Halifax NS. October 4 2008. 404. Guest Speaker: Understanding disease progression in MS. MS Society Progressive Talks.

London ON. October 5 2008. 405. Guest Speaker: Early intervention in patients with suspected MS. University of Texas

Southwestern MS Center. Houston TX. October 29 2008.


406. Grand Rounds: Early intervention in patients with suspected MS. University of Texas Health Science Center. Houston TX. October 31 2008.

407. Guest Speaker: BENEFIT: 5-Year Results. Vermont National Country Club. So.

Burlington VT. April 15 2009. 408. Chair: La SEP débutante: actualités. Neurologies Revue Pluridisciplinaire en Neurologie.

Paris France. December 17 2008. 409. Grand Rounds: The rationale for very early treatment in MS. Baystate Medical Center.

Springfield MA. March 4 2009. 410. Guest Speaker: The rationale for very early treatment in MS. Springfield MA. March 4

2009. 411. Guest Speaker: The rationale for very early treatment in MS. Lenox MA. March 4 2009. 412. Guest Speaker: An update on MS research and clinical trials – BMT and basic stem cell

research. Foundation Neurology. Burlington VT. March 5 2009. 413. Guest Speaker: Round Table: The rationale for very early treatment in MS. New

Hampshire Multiple Sclerosis Case Presentation Dinner. Centennial Inn, Concord NH. March 5 2009.

414. Guest Speaker: The rationale for very early treatment in MS. Whidden Memorial

Hospital. Concord NH. March 6 2009. 415. Guest Speaker: Multiple sclerosis: Translating Pathophysiology into clinical practice.

Session: Treatment Individualization: Tailoring treatment to suit the individual. March 14 2009.

416. Guest Speaker: News in Early Disabilities in MS. Marseille, France. March 21 2009. 417. Guest Speaker: Therapy of MS. 5

th Dubrovnik International Conference on Multiple

Sclerosis. Dubrovnik. May 5 2009. 418. Chair: Mechanisms of Tissue Injury. 5

th Dubrovnik International Conference on

Multiple Sclerosis. Dubrovnik. May 5 2009. 419. Guest Speaker: Differential diagnosis of MS. Severance Hospital. Seoul Korea. July 10

2009. 420. Guest Speaker: Treatment optimization in multiple sclerosis. Korean Study Group for

Multiple Sclerosis. Seoul Korea. July 11 2009. 421. Guest Speaker: Rescue therapies in MS. Korean Study Group for Multiple Sclerosis.

Seoul Korea. July 11 2009. 422. Guest Speaker: Grand Rounds: Stem Cell Research in Multiple Sclerosis. Lahey Clinic

Medical Center, Lexington MA. Sep 24 2009. 423. Guest Speaker: Stem Cell Research in Multiple Sclerosis. Taboo Resort, Gravenhurst,

Muskoka ON. Oct 3 2009.


424. Guest Speaker: Use of haematopoietic stem cells for the treatment of MS. Kitchener Waterloo District MS Society. Oct 8 2009.

425. Guest Speaker: Optimizing treatment in multiple sclerosis. EMD Serono Web Event.

Windsor ON. Oct 14 2009. 426. Guest Speaker: The evolution of treatment for MS: Current & future approaches. World

Congress of Neurology. Bangkok Thailand. Oct 27 2009. 427. Guest Speaker: Molecular target therapy in demyelinating disease. World Congress of

Neurology. Bangkok Thailand. Oct 27 2009.

428. Guest Speaker: Stem cell in neurology. 50th

Anniversary Academic Conference. Northern Neuroscience Center, Chiang Mai University, Chiang Mai Thailand. Nov 2 2009.

429. Guest Speaker: Drug treatment of MS: The current situation and what the future holds.

MS Trust Annual Conference. Warwickshire UK. Nov 9 2009. 430. Guest Speaker: How to evaluate the treatment response. CHARCOT. Lisbon Portugal.

Nov 13 2009. 431. Guest Speaker: MS treatment and clinical trials update. MS Society Ottawa Chapter.

Nov 24 2009. 432. Guest Speaker: Basis of Treatment Selection: Treatment of Progressive Forms of MS New Insight in MS Management, Mexico City Mexico. Nov 27 2009. 433. Guest Speaker: Treatment Optimization in Practice: Responders and Non-Responders New Insight in MS Management, Mexico City Mexico. Nov 28 2009. 433. Guest Speaker: Liberation Treatment for MS: What is it and why is it so controversial?

Ottawa ON. Feb 9 2010. 434. Guest Speaker: Optimizing Treatment in MS. Bish Restaurant. Halifax NS. Feb 23

2010.

435. Neuroscience Rounds: BMT & Stem Cell Research in MS. QE II Hospital. Halifax NS. Feb 24 2010.

436. Guest Speaker: 9th

Annual Practicum on Neurology: Towards a New Treatment Era. Stem Cells Transplant in MS. Montréal QC. Mar 27 2010.

437. Plenary Session: 9th

Annual Practicum on Neurology: Towards a New Treatment Era. Debate in MS and Hot Topics in MS. Montréal QC. Mar 27 2010.

438. Guest Speaker: MS Nurses National Consultation Meeting. Fingolimod in MS: Clinical Trial Results. Montréal QC. Mar 27 2010.

439. Guest Speaker: Optimizing Treatment in MS. Moncton NB. Apr 1 2010.

440. Guest Speaker: Optimizing Treatment in MS. Fredericton NB. Apr 1 2010.


441. Medical Grand Rounds: Multiple Sclerosis: A treatable neurological condition. Department of Medicine, U of Ottawa. Apr 7 2010.

442. Neuroscience Rounds: The cure lies in all of us. The Ottawa Hospital Civic Campus. Apr 9 2010.

443. Guest Speaker: The use of BMT in MS: Patient selection and neurological outcomes. EndMS Research and Training and Network. Montréal QC. Apr 30 2010.

444. Guest Speaker: Mesenchymal stem cell transplantation in MS (the CMSC Lecture). BCTRIMS. Porto Alegre, Brazil. May 6 2010.

445. Guest Speaker: Bayer Symposium: Cognitive impairment in MS: Time is Brain. BCTRIMS. Porto Alegre, Brazil. May 7 2010.

446. CME Event: Bayer: Diagnosis, treatment and followup: Update in Multiple Sclerosis. Ottawa ON. May 11 2010.

447. Grand Rounds: Optimizing treatment for MS. Jewish General Hospital. Montréal QC. May 18 2010.

448. Guest Speaker: New treatments for Multiple Sclerosis with bone marrow transplants and

Teriflunomide. 5th

Annual Mini-Symposium on Multiple Sclerosis. Minneapolis MN. May 20 2010.

449. Guest Speaker: New therapeutic algorithms. Top Seminars in Multiple Sclerosis. Sorrento Italy. May 28 2010.

450. Meet the Expert: Teriflunomide. Top Seminars in Multiple Sclerosis. Sorrento Italy. May 28 2010.

451. Guest Speaker: Cladribine Tablets – Data from the Pivotal CLARITY Trial. EMD Serono MS Franchise Nurse Advisory Board. CMSC. San Antonio TX. June 2010.

452. Platform Presentation: Oral Teriflunomide added to interferon-beta in relapsing multiple sclerosis patients: 1-year safety and efficacy results. ACTRIMS. San Antonio TX. June 2010.

453. Guest Speaker: Update on new therapeutics and clinical trials. CNSF. Québec QC . June 2010.

454. Chair: MS Session. CNSF. Québec QC. June 2010.

455. Guest Speaker: Understanding disability in MS: Evolving measures in clinical practice. Beckta Dining & Wine. Ottawa ON. Aug 10 2010.

456. Grand Rounds: Are bone marrow transplants the answer? St. Louis University. St. Louis MI. Sept 24 2010.

457. Keynote Speaker: John L. Trotter Research Program. Are bone marrow transplants the answer? NMSS. St. Louis MI. Sept 23 2010.


458. Grand Rounds: Are bone marrow transplants the answer? Washington University. St. Louis MI. Sept 24 2010.

459. Guest Speaker: Satellite Symposium: Multiple Sclerosis and Movement Disorders: How can we improve therapeutic approaches to meet patient needs? Multiple Sclerosis: early treatment and maintenance to maximize long-term therapeutic benefit with disease-modifying drugs. EFNS. Geneva. Sept 26 2010.

460. Guest Speaker: Optimizing treatment in MS. Bliss Fine Foods. Saskatoon SK. Sept 30 2010.

461. Neuroscience Grand Rounds Speaker: Treatment of multiple sclerosis: Past, present and future. Saskatoon SK. Oct 1 2010.

462. Stanley F. Waterman Multiple Sclerosis Research Lecture Series: Stem cell based therapies: The promise and challenges of treating MS. New England MS Society Chapter of the NMSS. Marlborough MA. October 23 2010.

463. Guest Speaker: Should any treatment decisions be made based on MRI, such as change from IFN to DMD, even if there is no clinical evidence of disease activity? 4

th World

Congress on Controversies in Neurology (CONy). Barcelona Spain. Oct 30 2010.

464. Guest Speaker: How to treat a highly active RRMS patient after one disease modifying drug (DMD) has failed. 4

th World Congress on Controversies in Neurology (CONy).

Barcelona Spain. Oct 30 2010.

465. Guest Speaker: SSIF Conference on Multiple Sclerosis: Future treatments and goals. New challenges in treatment: benefits and risk: The importance of patient monitoring during new treatments. Vienna Austria. November 13 2010.

466. Guest Speaker: NOVARTIS MS/Parkinson’s: A Canadian Perspective. ECTRIMS Update. Ottawa ON. Nov 16 2010.

467. Guest Speaker: Assessing and defining sub-optimal treatment responses in MS: A risk-to-benefit discussion of therapies. Hamilton ON. Nov 25 2010.

468. Neurology Rounds: MS 2010: Year in Review – Key Developments in MS Care. Trillium Health Centre. Mississauga ON. Nov 26 2010.

469. Presenter: Treatment of primary and secondary progressive MS. 2010 Meeting of the European Charcot Foundation. Rome Italy. Dec 2 2010.

470. Presenter: Exploring the mode of action of cladribine. 2010 Meeting of the European Charcot Foundation. Rome Italy. Dec 3 2010.

471. Keynote Speaker: endMS Conference. Stem Cells. Whistler BC. Dec 6-9 2010.

472. Guest Speaker: National Congress: Les Rencontres de Neurologies. Première ligne de traitement et optimisation du bénéfice thérapeutique au long cours. Paris France. Dec 14 2010.

473. Guest Speaker: Bayer WebEx. MS 2011: A new perspective in treatment of MS. Montréal QC. Jan 25 2011.


474. Faculty Speaker: QUINTILES CME Initiative: Clinical management of multiple sclerosis: Optimizing function and improving quality of life in the post-treatment world. The Palm Downtown. Los Angeles CA. Feb 1 2011.

475. Faculty Speaker: QUINTILES CME Initiative: Clinical management of multiple sclerosis: Optimizing function and improving quality of life in the post-treatment world. Harris’. San Francisco CA. Feb 2 2011.

476. Faculty Speaker: QUINTILES CME Initiative: Clinical management of multiple sclerosis: Optimizing function and improving quality of life in the post-treatment world. Donovan’s Steak House. Phoenix AZ. Feb 3 2011.

477. Guest Speaker: The potential use of haematopoietic stem cells for the treatment of MS. University of Toronto Neuroinflammation Symposium. Toronto ON. Feb 4 2011.

478. Faculty Presenter: CME Multiple Sclerosis Virtual Grand Rounds. Selection of treatment: Choosing treatment after a diagnosis of relapsing MS. Cleveland Clinic. March 2011-March 2012.

479. Guest Speaker: New emerging treatments in MS. ISNI 2011. Annual Israel Society of Neuroimmunology Conference. April 29 2011.

480. Guest Speaker: Managing the daily symptoms of MS. Bayer GP CME Event. Mamma Teresa’s Restaurant. Ottawa ON. May 2 2011.

481. Guest Speaker: Treatment individualization: Different patients, different needs. OPTIMIST Meeting. St. Petersburg Russia. May 2011.

482. Guest Speaker: Pain and multiple sclerosis. MS Society of Canada Ottawa Chapter. Ottawa ON. May 10 2011.

483. Keynote Lecturer: MS treatment: Updates-Early intervention and refractory cases management. Hong Kong. May 14 2011.

484. Keynote Lecturer: MS treatment updates – Future outlooks. Hong Kong. May 14 2011.

485. Guest Speaker: No disease activity: Where and how has this been used? What can constitute no activity? How to weight different domains of activity. International Advisory Committee on Clinical Trials in MS. Washington DC. May 19 2011. Lecturer: Long term impact of current therapies for MS. CMSC Annual Meeting. Montréal QC. June 1 2011.

486. Lecturer: Making an accurate diagnosis in multiple sclerosis: The utility of CSF in diagnosing MS. CMSC Annual Meeting. Montréal QC. June 1 2011.

487. Guest Speaker: The potential use of bone marrow-derived stem cells as a treatment for MS. UK MS Society. London UK. June 23 2011.

488. Commentator: Debate: Should MS be treated by escalation or induction therapy? Part of MS Session: Therapies of Multiple Sclerosis. 5

th World Congress on Controversies in

Neurology. Beijing China. Oct 14 2011.

489. Presenter: Debate: Biomarkers can be useful for diagnosis and prognosis in MS. Part of MS Session: Therapies of Multiple Sclerosis. 5

th World Congress on Controversies in


Neurology. Beijing China Oct 14 2011.

490. Lecturer: Neurology Grand Rounds: Bone marrow transplantation in multiple sclerosis. UMDNJ, New Brunswick NJ. Nov 2 2011.

491. Guest Speaker: Managing the new and emerging therapies for multiple sclerosis. MS Care. Boston MA. Nov 10 2011. Guest Speaker: Seizing the window of opportunity: Treating early for long term safety and efficacy. MS Symposium Egyptian MS Society. Cairo Egypt. Nov 24 2011.

492. Lecturer: Individualized treatment from the first demyelinating event. European Charcot Foundation Symposium. Dec 2011.

493. Guest Speaker: Review of DMS’s and their role in treating CIS. Regional MEA CIS Advisory Board Meeting on New insights in diagnosis and management. Raffles Hotel. Dubai UAE. March 2012.

494. Guest Speaker: Impact of adherence on outcomes in MS: Data and Ideas. Regional MEA CIS Advisory Board Meeting on New insights in diagnosis and management. Raffles Hotel. Dubai UAE. March 2012.

495. Guest Speaker: Case studies in the treatment of CIS. Regional MEA CIS Advisory Board Meeting on New insights in diagnosis and management. Raffles Hotel Dubai UAE. March 2012.

496. Guest Speaker: Interferon-beta: An effective early treatment with long-term benefits. Grand Hyatt Hotel. Dubai UAE. March 2012.

497. Guest Speaker: Interferon-beta: An effective early treatment with long-term benefits. Radisson Blu Diplomat Hotel. Bahrain. March 2012.

498. Guest Speaker: Interferon-beta: An effective early treatment with long-term benefits. Jordan Sheraton Amman. Amman Jordan. March 2012.

499. Lecturer: Teriflunomide. CONy MS Scientific Program. Vienna Austria. March 9 2012.

500. Guest Speaker: Theoretical considerations for future treatments. CMSC: Evolving concepts in the management on multiple sclerosis. Coral Gables FL. March 24 2012.

501. Guest Speaker: Treatment optimization in MS: Dawn of a new era. Hot Topics in Neurology. Toronto ON. April 14 2012.

502. Guest Speaker: From early first line treatment to long-term outcomes: Emerging data from BENEFIT 5 and BENEFIT 8. Betaferon Council Meeting. Warsaw Poland. May 5 2012.

503. Facilitator: Workshop: Communication of early and sustained stabilization of MS and prolonged life expectancy with Betaferon. Warsaw Poland. May 5 2012.

504. Guest Speaker: Personalized therapy: What findings may guide treatment decisions? Warsaw Poland. May 5 2012.


505. Guest Speaker: Novel therapies in multiple sclerosis: A critical analysis. What’s new in multiple sclerosis? Autoimmunity 2012 Congress. Granada Spain. May 10 2012.

506. Case Study Presenter: Treatment failure due to lack of adherence. SSIF CME Annual Meeting in Multiple Sclerosis. Valencia Spain. May 18 2012.

507. Lecturer: Assessment of treatment response. SSIF CME Annual Meeting in Multiple Sclerosis. Valencia Spain. May 19 2012.

508. Guest Speaker: Progressive MS: Innovative Therapies: Oral therapies. Top Seminars in Multiple Sclerosis. Baveno Italy. May 25 2012.

509. Meet the Expert: Progressive MS: Innovative Therapies: Teriflunomide. Top Seminars in Multiple Sclerosis. Baveno Italy. May 25 2012.

510. Lecturer: Knowledge in bloom: The past, present and future of MS care. Canadian Association of Neuroscience Nurses. Ottawa ON. June 7 2012.

511. Guest Speaker: MS Society: Multiple Sclerosis Update 2012. Thunder Bay ON. June 20 2012.

512. Guest Speaker: Stem Cells Discussion. Sydney Australia. Aug 16 2012.

513. Guest Speaker: Clinical experience in MS. Melbourne Australia. Aug 16 2012.

514. Guest Speaker: What to expect with teriflunomide, side effects and how to manage. Nurse Advisory Board Meeting. Melbourne Australia. Aug 17 2012.

515. Guest Speaker: Clinical experience in MS. Sydney Australia. Aug 17 2012.

516. Guest Speaker: Emerging therapies in MS. Sydney Australia. Aug 18 2012.

517. Panel Member: CCSVI can cure MS. Ask the Experts Panel. Sydney Australia. Aug 18 2012.

518. Guest Speaker: Emerging therapies in multiple sclerosis. GENZYME Neurology

Clinical Weekend 2012. Darling Harbour Sydney Australia. Aug 18 2012.

519. Guest Speaker: Stem cell transplantation in MS. GENZYME Neurology Clinical Weekend 2012. Darling Harbour Sydney Australia. Aug 19 2012.

520. Guest Speaker: Treatment optimization in MS. GENZYME Neurology Clinical Weekend 2012. Darling Harbour Sydney Australia. Aug 19 2012.

521. Guest Speaker: Mesenchymal stem cells in the treatment of MS. Quebec City QC. Sept 7 2012.

522. Guest Speaker: Regimen of fingolimod treatment. Mitsubishi Round Table Discussion. Oct 11 2012.

523. Guest Speaker: Optimization of MS treatment outcomes. Merck Serono MS Symposium. Cairo Egypt. Oct 18 2012.


524. Guest Speaker: MS treatment: The new oral alternative. Mexican Academy of Neurology. Cancun Mexico. Nov 2012.

525. Discussion Panel Member: Early treatment vs late treatment of MS. MS Update Program: The Latest in Research & Treatment in Multiple Sclerosis. MNI. Montréal QC. Nov 16 2012.

526. Guest Speaker: Clinical considerations in the use of fingolimod: First dose, monitoring and treatment optimization. NOVARTIS MS Nurses National Advisory Board Meeting. Toronto ON. Dec 8 2012.

527. Guest Speaker: Managing aggressive MS. TEVA Practicum in Neurology 2013. Chicago IL. Feb 21 2013.

528. Guest Speaker: 2013 Annual Meeting of Multiple Sclerosis: Oral immunomodulator in multiple sclerosis: From innovative science to clinical practice. Bangkok Thailand. Mar 6 2013.

529. Grand Rounds Speaker: The changing landscape for treatment of RRMS. Grand Rounds. UMass. Boston MA. Mar 12 2013.

530. Grand Rounds Speaker: Treatment optimization in RRMS. Grand Rounds. Lahey Clinic. Burlington MA. Mar 14 2013.

531. Guest Speaker: Clinical management of MS: Are we getting confused with treatment alternatives available today? Merck Serono Continuous Health Education Program. April 11 2013.

532. Debate Host: Does interferon therapy delay or prevent the development secondary progressive disease? CONy. Istanbul Turkey. Apr 12 2013.

533. Evolving MS treatment options: Quo Vadis? Meet the Experts Session. CONy. Istanbul Turkey. Apr 13 2013.

534. Chair: Meet the experts: Outcome measures in multiple sclerosis clinical studies; origin of MS: inflammatory or degenerative? Genetic or environmental? CONy. Istanbul Turkey. Apr 13 2013.

535. Section Head: Debate: New players in MS: Teriflunomide. CONy. Istanbul Turkey. Apr 13 2013.

536. Guest Speaker: Multiple Sclerosis. Internal Medicine Academic Half Day Ottawa Hospital Civic Campus. Wed Apr 17 2013.

537. Guest Speaker: Clinical applications of cellular therapy. Workshop on Transplant and Cellular Therapy for Autoimmune Diseasts. Froedtert & Medical college of Wisconsin Clinical Cancer Center. Milwaukee WI. Apr 20 2013.

538. Guest Speaker: Case studies in treating MS. STEP Symposium. Budapest Hungary. Apr 27 2013.

539. Guest Speaker: Special Issues in Women: Multiple sclerosis in pregnancy. 1st Kuwait

North-American Neurology Conference. Kuwait. Apr 28 2013.


540. Guest Speaker: Multiple Sclerosis & Neuro-Ophthalmology: Practical approach to MS mimickers. 1

st Kuwait North-American Neurology Conference. Kuwait. Apr 28 2013.

541. Guest Speaker: Multiple Sclerosis & Neuro-Ophthalmology: Diagnosis of MS –

Changes in criteria. 1st Kuwait North-American Neurology Conference. Kuwait. Apr 28

2013.

542. Guest Speaker: Multiple Sclerosis & Neuro-Ophthalmology: Emerging oral therapies in MS. 1

st Kuwait North-American Neurology Conference. Kuwait. Apr 28 2013.

543. Speaker: Symposia: Stem Cell Therapy for Multiple Sclerosis. Mesenchymal stem cells

as treatment for MS. CMSC. May 30 2013. Orlando FL.

544. Grand Rounds Speaker: Myelo-ablation and ASCT as a treatment for highly aggressive MS. UCSF. June 7 2013.

545. Grand Rounds. The Role of Teriflunomide therapy for relapsing forms of MS. U Cal San Francisco. June 7 2013.

546. Speaker: Symposia: Defining goals at the start of treatment. ENS. Barcelona Spain. June 9 2013.

547. Guest Speaker: Canadian treatment optimization recommendations in MS. NOVARTIS interactive base-cased program. Ottawa ON. June 11 2013.

548. Medical Roundtable. Assessing suboptimal response to treatment in patients with relapsing forms of multiple sclerosis. Orlando FL. June 13 2013.

549. Assessing suboptimal response to treatment in patients with relapsing forms of multiple sclerosis. MS Center of Bravard. Melbourne FL. June 13 2013.

550. Changes in the multiple sclerosis landscape. Wayne State University, Detroit MI. June 18 2013.

551. Grand Rounds: Teriflunomide, a once-daily oral therapy for relapsing forms of MS. Riverhills Neurology. Cincinnati OH. Aug 16 2013.

552. Current and future treatments in MS. MS in Focus Conference. Toronto ON. Oct 24 2013.

553. Benefits of early MS treatment. Canadian MR Imaging in MS Learning Program. Ottawa ON. Oct 28 2013.

554. Chronic Disase Cluster: Multiple Sclerosis. Group for Research in Inflammation and Pathogenesis (GRIP). Ottawa ON. Nov 1 2013.

555. Grand Rounds Speaker: Myeloablation & ASCT: A treatment for aggressive multiple sclerosis. Tisch Multiple Sclerosis Research Center of New York. New York NY. Nov 7 2013.

556. Forensic analysis of the new orals for RRMS. Restaurant le Montego. Quebec City QC. Nov 13 2013.


557. Induction vs escalation of treatment. MS Exchange. Montréal QC. Nov 15 2013.

558. Guest Speaker: Overall efficacy: Clinical benefit and Gilenya’s influence on disease progression (relapses, MRI, disability progression and brain atrophy). Spanish Society of Neurology National Congress. Barcelona Spain. Nov 20 2013.

559. When to start, when to shift, when to stop. European Charcot Foundation. Nov 29 2013. Baveno Italy.

560. MS Pathophysiology. Residents’ ½ day. The Ottawa Hospital. December 3 2013.

561. Role for immunoablation and AHSCT in MS. endMS Conference. St Sauveur QC. Dec 13 2013.

562. Invited Lecturer: New oral treatments for MS. ISNI 2013. Mitzpe Ramon Israel. Dec 19 2013.

563. Moderator: New oral treatments for MS. ISNI 2013. Mitzpe Ramon Israel. Dec 20 2013.

564. Disease-modifying treatments in multiple sclerosis. Residents ½ day. The Ottawa Hospital Civic Campus. Jan 14 2014.

565. Neuroscience Rounds: An oral debate on treating MS. The Ottawa Hospital Civic Campus. Jan 17 2014.

566. Invited Speaker: Current disease modifying drugs: Evaluating the evidence. MS Nurse Meeting. Ottawa ON. Jan 31 2014.

567. Invited Speaker: Where clinical trial and clinical practice meet: The changing landscape in the treatment of multiple sclerosis. Ottawa ON. Feb 5 2014.

568. Invited Speaker: Treatment of MS: Starting and staying on the right track. Neurology Update Mumbai 2014. Mumbai India. Feb 22 2014.

569. Invited Speaker: Multiple sclerosis: The road ahead. Neurology Update Mumbai 2014. Mumbai India. Feb 22 2014.

570. Invited Speaker: Patient & Caregivers Session: MS. Multiple sclerosis: The road ahead. Neurology Update Mumbai 2014. Mumbai India. Feb 22 2014.

571. Guest Speaker: Disease modifying medications for multiple sclerosis: Do the benefits outweigh the risks? Health Canada, Marketed Health Products Directorate. Ottawa ON. Mar 5 2014.

572. Guest Speaker: Evolving management of MS with oral therapies: New insights and new directions. 19

th Taiwan Neurological Society Congress. Taipei Taiwan. Apr 12 2014.

573. Debate Host: MS/Dementia/Movement Disorders, Cell based therapies hold particular

promise for treating MS. CONy. Berlin Germany. May 8 2014.

574. Guest Speaker: MS/Dementia/Movement Disorders, Session on Ocrelizumab. CONy. Berlin Germany. May 8 2014.


575. Debate Coordinator: Can we aim for a disease-free status with contemporary MS therapies. CONy. Berlin Germany. May 10 2014.

576. Guest Speaker: Where clinical trial and clinical practice meet: The changing landscape in the treatment of MS. Restaurant La Chronique. Montréal QC. May 13 2014.

577. Guest Speaker: Importance of early treatment in MS. Merck Serono Symposia: Optimizarea Management – Ului Terapeutic in Scleroza Multipla. Bucharest Romania. May 16 2014.

578. Guest Speaker: Clinical MS Management Aspects: Defining the goals of MS therapies:

The Canadian approach. ISS Bayer Symposium. Munich Germany. May 24 2014.

579. Rounds "Update on new therapies for RRMS: Focus on Teriflunomide". Jewish General Hospital, Montreal QC. Sept 23 2014.

580. Neurosicence Grand Rounds: “Aggressive Disease Warrants Aggressive Treatment: Immunoablation and Autologous Haematopoietic Stem Cell Treatment for MS”. University of Vermont. Burlington, VT. Oct 17 2014.

581. Guest Speaker: “The Evolving MS Treatment goal: No Evidence of Disease Activity (NEDA)”. Marriott, Montreal, QC. Oct 18 2014.

582. Guest Plenary Speaker: Secondary progressive MS: What have we learned where should we go? MS Xchange Conference. Montreal QC. November 7 2014.

583. Guest Speaker: Patient Education Program. “Living With MS- An informative event for

people living with MS and their care partners. Boston, MA. Nov 23 2014.

584. Guest Speaker: “Choosing Among a Growing Array of Treatment for Relapsing MS". On behalf of EMD Serono. Cambridge, ON Nov 24 2014.

585. Keynote Speaker: On behalf of the MS Society of Canada: an in person and online interactive meeting about Relapsing Remitting MS. Ottawa, ON. Dec 1 2014.

586. Invited Speaker: “Aggressive Treatment for Multiple Sclerosis Rationale and Approach”. Wayne State University 10

th Annual MS Symposium. Birmingham, MI. Dec 6 2014.

587. Guest Speaker: “Choosing among a growing array of MS treatments for RRMS”. On

behalf of EMD Serono. Toronto, ON. Dec 13 2014.

588. Guest Speaker: CME titled “ECTRIMS/ACTRIMS 2014 New Research and Updates in Multiple Sclerosis Presented in Boston, MA on Sept 10-13, 2014”. Bekta Dining and Wine, Ottawa ON. January 26, 2015.

589. Guest Speaker: “MS Duels” Orals vs Injectables in MS; is this the start of new platform therapies or just a novelty? On behalf of EMD Serono. Montreal, QC. February 5, 2015.

590. Organizer and Speaker: CME titled “MS for the general Practitioner-what you should know”. Ottawa Conference and Event Center. Ottawa, ON. February 27, 2015.


591. Debate Host: “Is the measurement of brain atrophy the most suitale surrogate marker of MS progression”? CONy. Budapest, Hungary. March 27 2015.

592. Debate Host: “Discontinuation of disease-modifying therapies in patients with long-term stable disease is safe and appropriate”. CONy. Budapest, Hungary. March 27 2015.

593. Neuroscience Grand Rounds: “Disease activity free, No evidence of disease activity-NEDA and RIO scores in MS”. Hôpital Régional De Saint-Jérôme, Saint-Jérôme, QC. May 6 2015.

594. Plenary Speaker: “Treatment Sequencing in MS”. Practicum in Neurology 2015, Montreal, QC. May 23 2015.

595. Dalhousie University Neuroscience Rounds: "Stem Cell Therapy in MS". Halifax, NS.

June 17, 2015.

596. Neuroscience Grand Rounds Speaker: “Choosing Among a Growing Array of Treatments for Relapsing MS”. Royal University Hospital and University of Saskatchewan. Saskatoon, SK. June 19 2015.

597. “Faces of MS’’. Webinar presented to BC & Alberta’s MS nurses on behalf of TEVA Canada. June 26, 2015.

598. Teaching Symposium: “Stem cells and MS”. Excemed Preceptorship on advances in

Multiple Sclerosis and Neuro-Myelits Optica. Vancouver, BC. July 6, 2015.

599. PeerVoice: An online venue designed to fill the unmet needs of the medical community by reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. “Progressive Multiple Sclerosis: Is there Light at the End of the Tunnel”? This activity is supported by educational funding from Biogen International GmbH.

http://www.peervoice.com/progressive-multiple-sclerosis-there-light-end-tunnel?pres=1&person_id=104041409&specialty=94&ProfID=12#featured-presentations

Other Activities Ad Hoc Reviewer: Neurology Experimental and Molecular Pathology Clinical and Investigative Medicine Journal of Neuroimmunology Experimental Cell Research Journal of Neurology Annals of Neurology Canadian Journal of Neurological Sciences Journal of Neurological Sciences Editorial Board: Journal of Neurological Sciences Multiple Sclerosis International Journal of MS Care Multiple Sclerosis and Demyelinating Disorders




Grant Reviewer: Medical Research Council of Canada Multiple Sclerosis Society of Canada Physicians Services Incorporated of Ontario Fonds de la Recherche en Santé du Québec Canadian Institutes of Health Research National Institutes of Health Physician Examiner: Medical Council of Canada (1994-1999) BASIC RESEARCH FUNDING: 1990-92: Cellular basis of immune regulation in multiple sclerosis, Multiple Sclerosis

Society of Canada. $123,000 Sole P.I. 1991-92: Regulatory effects of Betaseron

Interferon- (IFN-) on the growth and activity

of human T cells, Berlex Laboratories. $63,488 Sole P.I. 1993-: Canadian Collaborative Genetics Project in MS, Co-Investigator, Multiple

Sclerosis Society of Canada. Estimated budget $5,000,000. Co-investigator 1993-95: The mechanism of T-cell induced brain injury: relevance to MS, Multiple

Sclerosis Society of Canada. $125,000. Sole P.I. 1993-94: The potential regulatory role of Betaseron

Interferon- (IFN-) in T cell

interactions, Berlex Biotechnology Laboratories. $72,000. Sole P.I. 1994-96: The role of Rebif

in controlling suppressor cell function and inducing

lymphocytic apoptosis in multiple sclerosis, Ares-Serono, Switzerland. $33,500. Sole P.I.

1995-97: T cell heat shock protein Interactions in multiple sclerosis, Multiple Sclerosis

Society of Canada. $128,000. Sole P.I. 1997-99: The generation, immortalization and characterization of MS T cells, Multiple

Sclerosis Society of Canada. $120,000. Sole P.I.

1997-99: Establishing and understanding CD28/B7 interactions in MS disease, Multiple

Sclerosis Society of Canada. $160,000. Co-P.I. 1999-02: Role of T cells in multiple sclerosis immunopathogenesis: Investigation of

regulatory properties, Multiple Sclerosis Society of Canada. $291,789. Sole P.I. 1999-00: T cells in MS: Correlation of cytokine profiles and perforin molecules with

disease activity and modulation by Interferon-1a (AVONEX™) therapy, Biogen Canada. $125,625. Sole P.I.

2001-03: Immunological determinants of disease progression in response to therapy,

Multiple Sclerosis Society of Canada. $137,594. Co-P.I. 2002-04: The role of T cells in MS: Friends or foes, Multiple Sclerosis Society of

Canada. $165,000. Sole P.I.


2002-03: A novel in vitro model of immune-induced demyelination, Multiple Sclerosis

Society of Canada. $34,917. Co-P.I.

2003: Virological and immunological studies in pediatric multiple sclerosis. Wadsworth

Foundation Grant. Co-investigator

2008-11 The role of T cell-mediated ADCC in alemtuzumab induced destruction of

CD52+ cells in MS. Genzyme Inc. $142,000. Sole P.I.

CLINICAL RESEARCH FUNDING:

1994-96: A multi-centre, randomized double-blind, placebo controlled, Phase III study of

subcutaneous Rebif (recombinant-human interferon-beta) in the treatment of

secondary-progressive multiple sclerosis, Ares-Serono. (SPECTRIMS study).

$505,500. Co-investigator

1994-96: A double blind placebo controlled multi-centre study of oral myelin in the

treatment of early relapsing-remitting multiple sclerosis, AutoImmune Inc., USA.

(MYLORAL study). $450,000. Co-investigator

1994-01: A multi-centre, randomized double-blind, placebo controlled, phase III study of

subcutaneous Rebif (recombinant-human interferon-beta) in the treatment of

relapsing-remitting multiple sclerosis, ARES-SERONO, Switzerland. (PRISMS

study) $219, 900. Co-investigator

1995-2000: A multi-centre, randomised, double-blind, placebo-controlled study of Rebif

(recombinant-human interferon-beta) in patients with relapsing multiple sclerosis,

Ares-Serono, Switzerland. (OWIMS study). $253,800. Co-investigator 1995-96: Multiple sclerosis burden of illness study in Canada, Berlex Canada Inc.

$105,000.00. Co-investigator 1996-98: Double-blind, randomized, placebo-controlled, parallel group study of safety and

efficacy of Ro 45-2081 in patients with relapsing-remitting multiple sclerosis, Hoffman-La Roche Limited, Switzerland (Lenercept study). $314,300. Co-investigator

1996-01: A randomised, double-blind, placebo-controlled study of Avonex™ (Interferon-

1a) in the treatment of subjects as high risk for development of multiple sclerosis following the first onset of an isolated demyelinating event, Biogen Medical Research Department, USA. (CHAMPS study). $720,000. Co-investigator

1996-98: A randomized, third-party blinded, placebo-controlled, rising single-dose study of

subcutaneous rhuIL-10 (SCH 52000) in patients with relapsing-remitting multiple sclerosis with Gd-enhanced MRI evidence of disease activity, Schering-Plough Research Institute, USA. $726,000. Co-investigator


1998-99: A randomized, double-blinded, placebo-controlled, rising multiple-dose phase 1b study of subcutaneous rhuIL-10 (SCH 52000) in patients with multiple sclerosis, Schering-Plough Research Institute, USA. $134,925. Co-investigator

1997-98: Phase II Study of Hu23F2G in acute exacerbations of multiple sclerosis, ICOS

Corporation, USA. $118,250. Co-investigator

1998-02: A randomized double-blind, placebo-controlled study to evaluate the efficacy of

AVONEX

in the treatment of secondary progressive multiple sclerosis, Biogen

Medical Research Department, USA. (IMPACT study.) $231,000. Co-

investigator

1998-02: Multicentre randomized placebo-controlled double blind study to evaluate the

efficacy and safety of intravenous immune globulin (IVIg) in patients with

secondary progressive multiple sclerosis, Bayer, Germany. (ESIMS study.)

$764,340. Co-investigator 1999-01: Pilot MRI study of PEG-Intron (SCH 54031) in ambulatory subjects with

relapsing multiple sclerosis, Schering Canada, Inc. $384,744. Co-investigator 1999-00: A randomized, multicentre, double-blind, placebo-controlled safety, tolerability

and dose evaluation study of intravenous Antegren (Natalazumab) at three dose levels using magnetic resonance imaging in subjects with multiple sclerosis, Elan Pharmaceuticals, Inc. $90,492. Co-investigator

1999-02: Micellar Paclitaxel for the treatment of secondary progressive multiple sclerosis:

A phase 2 study, Angiotech Pharmaceuticals, Inc. $155,050. Co-investigator

1999-03: A multinational, multicentre, double-blind, placebo controlled study to evaluate

the efficacy, tolerability and safety of glatiramer acetate for injection in primary

progressive multiple sclerosis, Teva Marion Partners, Inc. (PROMISE study).


2000-02: A multinational, multicentre, randomized, double-blind, placebo-controlled study

to evaluate the efficacy, tolerability and safety of 2 Doses (5mg and 50mg) of

glatiramer acetate orally administered in relapsing remitting multiple sclerosis

patients. Teva Marion Partners, Inc, (CORAL study.) $145,392. Co-investigator 2000-01: Double-blind, randomized, placebo-controlled study to evaluate the safety and

tolerability of Mesopram in patients with multiple sclerosis, Berlex Canada. $370,680. Co-investigator

2000-01: Systematic reviews of the efficacy and safety of four medical uses of marijuana,

Medical Research Council of Canada. $202,698. Co-P.I. 2000-02: A multi-centre, open-label antigenicity and safety study of a human serum-free

pre-formulated solution of Avonex® (Interferon beta-1a) administered

intramuscularly to patients with relapsing multiple sclerosis. Biogen Inc. $212,500. Co-investigator


2000-03: A phase II study of the safety and efficacy of Teriflunomide (HR1726) in multiple sclerosis with relapses, Aventis Pharma, France. $1,034,670. Co-investigator

2000-05: Multiple sclerosis as an autoimmune disease. Treatment of poor prognosis

patients with multiple sclerosis using intensive immunoablative therapy followed

by immune cell depleted autologous stem cell transplantation (ASCT), Multiple

Sclerosis Society of Canada. $4,500,000. Co-P.I. 2002-04: A phase II, randomized, double-blind, placebo controlled study to evaluate the

preliminary efficacy, pharmacokinetics and immunogenicity of BMS-188667 administered to subjects with relapsing-remitting multiple sclerosis, Bristol-Myers Squibb. $92,500. Co-investigator

2002-05: A randomized, double-blind placebo-controlled, study to compare the effects of

different dose regimens of IGIV-Chromatography (IGIV-C), 10% treatment on relapse rates in patients with multiple sclerosis, Bayer, Germany. $169,645. Co-investigator

2002-03: Double-blind, randomized, multicentre, placebo-controlled, parallel-group phase

IIa study to evaluate the safety and tolerability of oral Mesopram (ZK 117137) up to 1.0 mg/d for up to 14 weeks in an intraindividual dose-escalation regimen in patients with clinically definite relapsing-remitting or secondary progressive multiple sclerosis, Schering AG. $126,963. Co-investigator

2002-04: Long-term efficacy and safety phase IV follow-up of the PRISMS cohort.

(Formerly known as: A multicentre, randomized, double-blind, placebo

controlled, phase III study of subcutaneous Rebif in the treatment of relapsing-

remitting multiple sclerosis). Aeros-Serono, Geneva. $264,856. Co-investigator

2002-05: Double-blind, placebo controlled, randomized, parallel group, multicenter, phase

III study in patients with a first clinical demyelinaing event suggestive of multiple

sclerosis to evaluate the safety, tolerability, and efficacy of 8 MIU (250 mcg)

interferon beta-1b (Betaseron) given subcutaneously every other day over a period

of up to 24 months. (BENEFIT Study).Bayer Healthcare Pharmaceuticals.

$157,193.75. Co-investigator

2003: Description and course of cognitive dysfunction in patients with multiple sclerosis

who lack neurological disability. A pilot study on neuropsychological evaluation

and MRI abnormalities. Cognitive (Caims): Serono Canada Inc. Co-P.I. 2003-05: A double-blind, randomized, placebo-controlled, parallel group, safety study of

Natalizumab in combination with glatiramer acetate (GA) in subjects with relapsing-remitting multiple sclerosis (MS), Biogen, Cambridge, MA. $173,265.95. Co-investigator

2003-: Extension of Protocol HMR 1726D/2001, A phase II study of the safety and

efficacy of Teriflunomide (HR1726) in multiple sclerosis with relapses, Aventis Pharma. $1,034,670. Co-investigator


2003-04: Double-blind, randomized, placebo-controlled, parallel-group, multicenter study evaluating safety, tolerability and effect on MRI lesion parameters of FTY720 vs placebo in patients with relapsing Multiple Sclerosis, Novartis Pharma, Switzerland. $313,725. Co-investigator

2003-04: A randomized, double-blind, placebo-controlled study to evaluate the safety,

tolerability and efficacy of NBI-5788 in patients with relapsing Multiple Sclerosis,

Neurocrine BioSciences. $52,072. Co-investigator

2003-04: A randomized, rater-blinded, multicenter, parallel-group study comparing the

efficacy and safety of Betaseron 250g subcutaneously every other day with

Avonex 30g intramuscularly once per week in relapsing remitting multiple

sclerosis patients previously treated with Avonex, Berlex Laboratories, USA:

(ABOVE Study). $12,943.75. Co-investigator

2004-08: Open label, multicentre, phase III extension of the double-blind, placebo

controlled BENEFIT study (no. 304747) to obtain long-term follow-up data of

patients with clinically definite MS and patients with a first demyelinating event

suggestive of MS treated with 8 MIU (250µg) interferon beta-1b (Betaseron)

given sc every other day. Bayer Healthcare Pharmaceuticals. $157,193.75. Co-

investigator

2004-05: A multi-center, randomized, single-blind, parallel group study to compare the

efficacy, tolerability and safety, of Copaxone to that of high dose interferon

(Betaseron or Rebif) in the treatment of relapsing multiple sclerosis, TEVA

(ACHIEVE study). $22,000. Co-investigator

2004-06: An open-label, baseline-to-treatment crossover clinical trial to evaluate the safety,

tolerability, pharmacokinetics and effects of vitamin B12 when used in

combination with Interferon treatment in patients with relapsing remitting

multiple sclerosis with MRI activity. Vitamin B12 Transition Therapeutics,

Toronto, Canada. $53,040. P.I.

2004-: A randomized, multinational, double-blinded, placebo-controlled, parallel group

design pilot study to extimate the tolerability, safety, pharmacokinetics, and

pharmacodynamic effects of Teriflunomide for 24 weeks when added to treatment

with glatiramer acetate in subjects with multiple sclerosis, Sanofi-Aventis (PDY

6046). $83,526. Global P.I.

2004-: A randomized, double-blind, placebo-controlled, parallel group design study to

evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the

frequency of relapses and delaying the accumulation of physical disability in

subjects with multiple sclerosis with relapses, Aventis Phase III. Protocol #:

HMR1726D/3001. $590,499. Co-investigator


2004-06: A 24-week, randomized, double-blind, parallel group, placebo-controlled, dose finding, safety, tolerability and efficacy study of the human anti-IL-12 antibody ABT 874 in subjects with multiple sclerosis with a 24-week double-blind, active extension phase, Abbott Laboratories, USA. $60,840. Co-investigator

2004-07: Retrospective, exploratory, blinded study to evaluate serum levels of antiglycans

antibodies in MS patients. Glycominds Ltd. Sole P.I.

2004-08: A phase II/III. randomized, double blind, parallel-group, placebo-controlled,

multicenter study to evaluate the safety and efficacy of Rituximab

(MabThera/Rituxin) in adults with primary progressive MS, Genentech, USA.

(OLYMPUS study). $904,800. Co-investigator

2004-: A double-blind, placebo controlled multicenter study to evaluate the efficacy and

safety of MBP8298 in subjects with secondary progressive multiple sclerosis,

BioMS (Eli-Lilly), Canada. (MAESTRO #1). $601,088.80. Global P.I.

2004-05: Implementation study of treatment optimization recommendations comparing

subjects continuing treatment with INF-B-1a 30mcg qw IM (Avonex) or

glatiramer acetate 20mg qd SC (Copaxone) to those randomized to IFN-B-1a

44mcg tiw SC (Rebif), in a multicenter study of subjects with RRMS currently on

disease-modifying therapy. (IMPLEMENT study): Serono USA. $24,263.

Global P.I.

2004: An extension to the double-blind, randomized, placebo-controlled, parallel-group,

multicentre study evaluating safety, tolerability and effect on MRI lesion

parameters of FTY720 vs. placebo in patients with relapsing Multiple Sclerosis.

Novartis Extension, Novartis Pharmaceuticals Canada Inc. $569,907. Co-

investigator

2004-07: International, randomized, multicentre, phase IIIb study in patients with relapsing-

remitting Multiple Sclerosis comparing over a treatment period of 104 weeks:

double-blinded safety, tolerability, and efficacy of Betaseron/Betaferon 250µg

(8MIU) and Betaseron/Betaferon 500µg (16 MIU), both given subcutaneously

every other day, and rater-blinded safety, tolerability, and efficacy of

Betaseron/Betaferon s/c every other day with Copaxone 20mg s/c once daily,

Bayer Schering Pharma AG, Germany. (BEYOND Study). $266,857.50. Co-

investigator

2004-07: Serono Pfizer phase IV, multicentre, open label, randomized study of Rebif® 44

mcg administered three times per week by subcutaneous injection compared with

Copaxone® 20mg administered daily by subcutaneous injection in the treatment of

relapsing remitting multiple sclerosis, Merck Serono (REGARD study). $54,591.

Co-investigator


2004-06: Open-label of AVP-923 (Destromethorphan/Quinidine) in patients with

pseudobulbar affect, INC Research. $26,632.25. Co-investigator

2004-06: Mitoxantrone (Novantrone) preceding treatment with glatiramer aetate (copaxone)

VS chronic treatment with glatiramer acetate alone in relapsing forms of MS,

TEVA Neuroscience. (NC-100 study). $46,220. Co-investigator

2005: Detecting cognitive impairments using the computerized test of information

processing (CTIP), Multiple Sclerosis Society of Canada. $13,600. Co-P.I.

2005-07: Double-blind, placebo-controlled, 21-week, parallel group study to evaluate safety

and efficacy of oral fampridine-SR (10 mg bid) in subjects with multiple sclerosis.

Fampridine-SR (4AP): Accorda Therapeutics. $17,222. Co-investigator

2005-06: Burden of pain in multiple sclerosis patients: A Canadian Burden of Illness Study,

Bayer/Pharmideas. $4,488.50. Co-investigator

2005-06: A Phase 1, open-label, multicentre study to evaluate the safety and activity of

Rituximab (MabThera/Rituxan) in adults with relapsing remitting multiple

sclerosis, Genentech, USA. $26,250.80. Co-investigator

2005-06: A phase 2a magnetic resonance imaging study of the safety and efficacy of

MLN1202 in patient with multiple sclerosis, Millennium, USA. $17,000. Co-

investigator

2005-06 : Multicenter, single arm, open-label, phase IIIb study to evaluate the safety and

antigenicity of Rebif (IFNß-1a) RNF, in subjects with relapsing forms of multiple

sclerosis, EMD Serono. $22,000. Co-investigator

2005-06: A randomized, double-blind, placebo-controlled, parallel groups study to assess

the effects of L-000124467 on disease activity in patients with relapsing remitting

multiple sclerosis as measured by MRI, Merck Frosst Canada. $10,152.95. Co-

investigator

2005- : A multi-center, double-blind, randomized study comparing the combined use of

Interferon Beta-1a and glatiramer acetate to either agent alone in patients with

relapsing remitting multiple sclerosis (CombiRx-Phase III), NIH, USA. $79,710.

Co-investigator

2005- : HMR1726D/ 2003 Randomized, multinational, double-blinded, placebo-

controlled, pilot study to extimate the tolerability, safety, pharmacokinetics, and

pharmacodynamic effects of Teriflunomide for 24 weeks when added to treatment

with Interferon-ß in subjects with multiple sclerosis, Sanofi-Aventis (PDY 6045).

$238,264. Global P.I.


2005- : Serono 25643 is a phase III, randomized, double-blind, three-arm, placebo-

controlled, multicentre study to evaluate the safety and efficacy of oral cladribine

in subjects with relapsing remitting multiple sclerosis (RRMS). Merck Serono,

Switzerland. $64,260. Co-investigator

2006-07: A double blind, randomised, placebo controlled, parallel group study of Sativex®

when added to the existing treatment regimen, in the relief of central neuropathic

pain in subjects with multiple sclerosis, GW Pharmaceuticals, UK. $15,209.39.

Co-investigator

2006: A phase IV, observational, open label, multicentre comparison study of newly

developed and validated MusiQoL (Multiple Sclerosis International Quality of

Life questionnaire) instrument with health-related QoL (MSQOL-54)

questionnaire in subjects with relapsing forms of multiple sclerosis on Rebif®

therapy. (COMPARE study). $62,335. Co-investigator

2006- : A 12 month double-blind randomized multi-center active controlled parallel group

study comparing the efficacy and safety of 0.5mg and 1.25mg fingolimod

(FTY720) administered orally once daily VS interferon

administered IM once weekly in patients with relapsing remitting multiple

sclerosis with optional extension, Novartis, Switzerland. $154,546.70. Co-

investigator

2006-08: Comparison of structural biomarkers of axonal integrity in optic neuritis:

correlating VEP, MRI and optical coherence tomography measurements, Multiple Sclerosis Society of Canada. $180,536. Co-P.I.

2006-12: Long term outcomes following immunoablative therapy and autologous stem cell

transplant for poor prognosis multiple sclerosis, Multiple Sclerosis Society of Canada. $2,419,701. Co-P.I.

2007- : A phase III, randomized, double-blind, placebo-controlled, multicentre clinical

trial of Rebif new formulation

(44mcg tiw and 44mcg ow) in subjects at high risk

of converting to multiple sclerosis, Merck Serono, Switzerland (REFLEX study).


2007: Randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study

to investigate the MRI efficacy and the safety of six months' administration of

Firategrast (150 – 1200mg twice daily) in subjects with relapsing-remitting

multiple sclerosis. $76,299.60. Co-investigator

2007- : An open-label follow-on study to assess the ongoing safety of MBP8298 in

subjects with secondary progressive multiple sclerosis, BioMS (Eli Lilly)

(MAESTRO #2). $256,392.50. Global P.I.


2007- : International, multicentre, phase IIIb study of subcutaneous every-other-day

treatment of patients with relapsing multiple sclerosis with (Phase A) double-

blind Betaseron/Betaferon 250µg or 500µg or open-label Betaseron/Betaferon

250µg and (Phase B) open-label Betaseron/Betaferon 500µg. (BEYOND Follow-

up). $108,368. Co-investigator

2007-08: A two-arm, randomised, double-blind, control group-compared, multicenter,

phase IIIb study with monthly MRI and biomarker assessments to evaluate the

efficacy, safety, and tolerability of Rebif® new formulation (IFN-beta-1a) in

subjects with relapsing remitting multiple sclerosi, EMD Serono (IMPROVE

Study). $9,650. Co-investigator

2007-11: The safety of two doses of teriflunomide (7 and 14mg) in patient with multiple

sclerosis with relapses, Sanofi-Aventis Canada Inc. Short title: LTS 6050.

$217,098.70. Co-investigator

2008-09: Long-term extension of PDY 6045 and PDY 6046 of Teriflunomide when added

with interferon or glatiramer acetate in MS, Sanofi-Aventis Inc. $119,252.

Global P.I.

2008: A double-blind, randomized, multicenter, placebo-controlled, parallel-group study

comparing the efficacy and safety of 1.25mg FTY 720 administered orally once

daily VS placebo in patients with primary progressive multiple sclerosis, Novartis

Pharmaceuticals, Switzerland. $1,145,419.60. Co-investigator

2008: A 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel-

group study comparing the efficacy and safety of 0.5mg and 1.25mg fingolimod

(FTY 720) administered orally once daily VS placebo in relapsing-remitting

multiple sclerosis. Novartis Pharmaceuticals, Switzerland. $190,092.50. Co-

investigator

2008: A four-arm, randomized, double-blind, placebo-controlled, multicenter Phase II

study to evaluate the safety, tolerability and efficacy as assessed by frequent MRI

measures of three doses of Atacicept monotherapy in subjects with relapsing

multiple sclerosis (RMS) over a 36 week treatment course. (Atacicept in RMS).

Merck Serono Inc., Germany. $304,785. Co-investigator

2008: A two-arm, randomized, double-blind, placebo-controlled, multicenter Phase II

study to evaluate safety and tolerability and to explore the neuroprotective effect

of Atacicept as assessed by optical coherence tomography (OCT) in subjects with

optic neuritis (ON) as clinically isolated syndrome (CIS) over a 36 week treatment

course (Protocol 28156 Atacicept in optic neuritis, Phase II), Merck Serono Inc.,

Germany. $97,110. Co-investigator


2008: A phase IIIb, double-blind, placebo-controlled, muticenter, parallel group,

extension trial to evaluate the safety and tolerability of oral cladribine in subjects

with relapsing remitting multiple sclerosis who have completed Trial 25643

(Clarity), Merck Serono Inc. $128,631.15. Co-investigator

2008: A phase III, randomized, rater-blinded study comparing two annual cycles of

intravenous low- and high-dose alemtuzumab to tiw subcutaneous interferon beta-

1a (Rebif) in patients with relapsing remitting multiple sclerosis who have

relapsed on therapy (CAMMS 324), Genzyme Corporation, USA. $136,824. Co-

investigator.

2008-11: Two year treatment with teriflunomide 7mg od and 14mg od VS placebo in

patients with a first clinical episode suggestive of MS, Sanofi-Aventis, France.


2008-11 A new clinical test for measuring information processing in MS patients: The

Computerized Tests of Information Processing (CTIP) – Longitudinal follow-up

(ISPMS 2). Multiple Sclerosis Society of Canada. $69,289 Co-P.I.

2008-13: A phase 3 randomized, rater-blinded study comparing two annual cycles of

intravenous alemtuzumab to 3-times weekly subcutaneous interferon beta-1a

(Rebif

) in treatment-naïve patients with relapsing-remitting multiple sclerosis,

Genzyme Corporation, USA (CAMMS323). $102,596. Co-investigator

2008: Extension study of the BENEFIT (304747) and BENEFIT Follow-up (305207)

Studies to Further Evaluate the Progress of Patients With First Demyelinating

Event Suggestive of Multiple Sclerosis. $49,237.50. Co-investigator

2009: A phase II, double-blind, randomized,multi-center, adaptivedose-ranging,

placebo-controlled, parallel-group study evaluating safety, tolerability and efficacy

on MRI lesion parameters and determining the dose response curve of BAF312

given orally once daily in patients with relapsingremitting multiple sclerosis

(CBAF312A2201). Novartis. $17, 3647.5. Co-investigator

2009: Double-blind, placebo-controlled, randomized, parallel-group Phase II study in

subjects with relapsing forms of multiple sclerosis (MS) to evaluate the safety,

tolerability, and effects of two doses of CDP323 over 24 weeks with a rater-blind

MRI follow-up over 12 weeks.(UCB C32322). Co-investigator

2009: Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-

up data in patients with clinically definite MS and patients with a first

demyelinating event at high risk of converting to MS, treated with Rebif New

Formulation (REFLEXION). Merck Serono International. $125, 288. Co-

investigator


2009: A Phase III, randomized, double-blind, placebo-controlled, multi-center clinical

trial of oral cladribine in subjects with a first clinical event at high risk of

converting to MS (ORACLE MS). Merck Serono International. $32,424.6. Co-

investigator

2009: Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-

finding study to evaluate the efficacy, safety, and tolerability of three doses of

ACT-128800, an oral S1P1 receptor agonist, administered for twenty-four weeks

in patients with relapsing-remitting multiple sclerosis (Actelion). Actelion

Pharmaceutical Canada Inc. $323,232.91. Co-investigator

2009: A phase IIIb, double-blind, placebo-controlled multicenter, parallel group,

extension trial to evaluate the safety and tolerability of oral cladribine in subjects

with relapsing-remitting multiple sclerosis who have completed Trial 25643

(CLARITY). Co-investigator

2009: A 14 week, randomized, double blind, placebo-controlled, parallel group study to

evaluate the efficacy, safety and tolerability of nerispirdine 50mg, 100mg and

200mg in patient with multiple sclerosis (DRI110566 Fatigue). Co-investigator

2009: A multicenter, randomized, double-blind, parallel-group, placebo-controlled study

to evaluate the efficacy and safety of PEGylated Interferon Beta-1a (BIIB017) in

subjects with relapsing multiple sclerosis (Biogen 105MS301). Co-investigator

2009: A phase III double-blind, randomized, placebo-controlled trial of Minocycline in

clinically isolated syndromes (CIS) (Minocycline in CIS) $10,000.00 per patient.

Co-investigator

2009: CONCEIVE (COgnition and Neuroimaging in CIS: Effects of Interferon in Very

Early MS) – an investigator-driven clinical protocol to study cognitive change

with fMRI and to evaluate the effect of early drug therapy. Bayer Healthcare.

$329,838. P.I.

2009: The cognitive impact of anticholinergic drugs (ACD) used for urinary dysfunction

in multiple sclerosis (MS). TOHAMO Innovation Funds. P.I.

2010: Chronic Cerebrospinal Venous Insufficiency in relation to multiple sclerosis.

Torres C, Chakraborty S, Hogan MJ, Freedman MS, Lum C, Bussiere M,

Cameron I, Schweitzer M. MS Society of Canada. $140,166.00. Co-Investigator

2010: Epidemiology of anti-JCV antibody prevalence in multiple sclerosis patients:

JEMS.Biogen Canada. $174, 932.00. P.I

2010: Multicenter, double-blind, randomized, parallel-group, monotherapy, active-

control study to determine the efficacy and safety of daclizumab high yield Process


(DAC HYP) versus AVONEX (Interferon B-1a) in patients with relapsing-

remitting multiple sclerosis.Biogen Canada. $88,924.00. P.I.

2010: A single arm, open-label, multicenter study evaluating the long-term safety and

tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in

patients with relapsing forms of multiple sclerosis. Protocol No. CFTY720D2399.

Novartis Pharmaceuticals Canada. $237,068.00. P.I

2010: Open-label extension study of oral fampridine-SR in MS. Biogen Canada Inc.

$10,696.00. P.I

2010: Dose blind extension study to the CBAF312A2201 study to evaluate long-term

safety, tolerability and efficacy of BAF312 given orally in patients with relapsing

multiple sclerosis. Novartis Parmaceuticals Canada. $89,434.00. P.I

2010: CAMMS03409 - An extension protocol for multiple sclerosis patients who

participated in Genzyme-sponsored studies of Alemtuzumab. Genzyme

Corporation. $320,201.00. P.I

2010: AC-058B202: Multicentre, randomized, double-blind, parallel-group extension to

study AC-058B201. Actelion Pharmaceutical Canada Inc. $175,988.40. P.I

2010: Controlled high risk AVONEX multiple sclerosis prevention study in ongoing

neurological surveillance (Champions Continuation Study). Biogen Canada Inc.

$32,194.50. P.I

2010: Prospective observational long-term safety registry of MS patients who have

participated in cladribine clinical trials. Merck Serono International S.A.

$31,200.00. P.I

2010: A multinational, multicenter, single visit, exploratory pharmacogenetic trial and

long-term follow-up of the PRISMS (prevention of relapses and disability by

Interferon Beta-1a subcutaneously in multiple sclerosis) Trial. Merck Serono

International S.A. $32,760.00. P.I

2011: Molecular determinants of brain plasticity and human application. CFI New

Initiatives Fund (NIF). uOBMRI-oriented application. Submitted September

2011.

2011- Autologous mesenchymal stem cell transplantation: A potential cell-based

treatment for inflammatory forms of multiple sclerosis. Applied to Multiple

Sclerosis Society of Canada. Jan 2011. (LOI under review)

2011: A 6-month, randomized, active comparator, open-label, multi-center study to

evaluate patient outcomes, safety and tolerability of Fingolimod 0.5 mg/day in


patients with relapsing forms of multiple sclerosis who are candidates for MS

therapy change from previous disease modifying therapy (EPOC). Novartis

Pharmaceuticals Canada Inc. $53,910.00. P.I

2011: Multi-center, two-arm, non-comparative, observational, 96-week Phase IV study

to evaluate treatment adherence when using RebiSmart for self-injection of Rebif

in multi-dose cartridges in subjects with relapsing multiple sclerosis (RMS). EMD

Serono Canada Inc. $19,353.90. P.I

2011: TERIVA - Immune response to influenza vaccine in patients with MS on

Teriflunomide Treatment. Sanofi-Aventis Canada Inc. $53,089.13. P.I

2011: Efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis

who are treated with Interferon-Beta. Sanofi-Aventis Canada Inc. $109,496.40. P.I

2011-17: Ocrelizumab in adults with primary progressive multiple sclerosis. Hoffmann-La

Roche Limited. $114,847.20. P.I Oratorio

2011: Phase 1B, randomized, placebo-controlled dose study of IV infusion of human

placenta-derived cells (PDA001). Celgene Corporation. $18,925.40. P.I

2011: Long term outcomes of patients that received stem cell transplant for MS -

clinical, radiological, neuropsychological and health utility evaluations.

Submitted to MS Society of Canada Oct. 2011.

2011: Financial barriers to implementation of immune ablation and hematopoietic stem

cell transplantation (IA/HSCT) for multiple sclerosis (MS). AHSC AFP

Innovation Fund, TOHAMO. Submitted November 2011.

2012: Autologous mesenchymal stem cell transplantation: Exploring the potential for

this cell-based treatment for inflammation and repair in multiple sclerosis.

Multiple Sclerosis Society of Canada. Applied September 2012. $4,412,841/47.

2012: Regulatory role of innate immune cells in pro-inflammatory autoimmune T cell

responses. CIHR. Applied September 2012. $525,134.72

2012: Brief international cognitive assessment for multiple sclerosis (BICAMS):

Canadian contribution to the international validation project. Walker, L, Rees L,

Cousineau D, MacLean H, Taylor-Sussex R, Berard J, Freedman MS. University

of Ottawa Brain and Mind Research Institute. Applied Sept 20 2012. $40,000.00

2012-14: Canadian Multi-Center Observational Study of Tysabri in Early Relapsing-

Remitting Multiple Sclerosis (RRMS) in Anti-JCV Antibody Negative Patients

(COSTAN) Biogen Inc.


2012-15: A Randomized, Double-Blind (with respect to Ocrelizumab dose) and Rater-Blind

(versus comparator), Parallel-Group Study to Evaluate the Efficacy and Safety of

Two Doses of Ocrelizumab in Comparison to Interferon Beta-1a in Patients with

Relapsing Multiple Sclerosis Hoffmann-La Roche Limited Opera

2012-15: Efficacy of Natalizumab on Reducing Disability Progression in Subjects with

Secondary Progressive Multiple Sclerosis Biogen Idec Canada Inc. Ascend

2013-14: Lung volume recruitment for lung function and cough impairment in multiple

sclerosis. McKim D, Srour N, Freedman MS. The Lung Association. Accepted.

Dec 2012. Department of Medicine Research Priority Award. $39,433.00. Co-

PI.

2013 Brief international cognitive assessment for multiple sclerosis (BICAMS):

Canadian contribution to the international validation project. Walker L ,Rees L,

Freedman MS, Cousineau D, MacLean H, Taylor-Sussex R, Berard J. uOBMRI.

$40,000.00

2013-14: A 12-Month, Randomized, Rater-and-Dose-Blinded Study to Compare the

Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once

Daily with Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in

Patients with RRMS Novartis Pharmaceutical Corporation 2312 $161,062.20

2013-14: BENEFIT 11 A long-term follow-up study (16401) of the BENEFIT (304747),

BENEFIT (305207) studies and BENEFIT Extension (311129) Study to further

evaluate the progress of patients with first demyleinating event suggestive of

multiple sclerosis Bayer Inc. $16,961.25

2013-14: Circulating glycerophospholipidome as a cerebral white matter disease. Hogan

MJ, Bennett S, Freedman MS, Dowlatshahi D, Glikstein R. Co-Investigator.

DoM Developmental Research Awards Program. 2013. $41,169.00

2013-15: A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled,

Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults with

Relapsing-Remitting Multiple Sclerosis NIH Sub Site Acclaim $267,606.00

2013-15: A Multicenter, Multinational, Observational Study to Collect Information on

Safety and to Document the Drug Utilization of Fampyra® When Used In Routine

Medical Practice (LIBERATE) Quintiles Inc. $23,430.00

2013-16: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to

Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in

Subjects With First Episode of Acute Optic Neuritis Bioen Idec Canada Inc.

Renew $19,798.00


2013-16: A Phase II Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the

Efficacy and Safety of Tcelna™ in Subjects with Secondary Progressive Multiple

Sclerosis Opexa Therapeutics, Inc $186,865.00

2013-18: A multicenter, randomized, double-blind, parallel-group, placebo-controlled

variable treatment duration study evaluating the efficacy and safety of Siponimod

(BAF312) in patients with secondary progressive multiple sclerosis. Novartis

Pharmaceuticals Canada Inc BAF2304 $156,827.10

2013-19: Long term, prospective, multinational, parallel-cohort study monitoring safety in

patients with MS newly started with fingolimod once daily or treated with another

approved disease-modifying therapy Novartis Pharmaceuticals Canada Inc. Pass

$10,342.00

2013-20: Open-label, single-arm extension study to the double-blind, randomized,

multicenter, placebo-controlled, parallel-group study comparing the efficacy and

safety of 0.5 mg FTY720 administered orally once daily versus placebo in patients

with PPMS. Novartis Pharmaceuticals Canada Inc $235,932.00 2306E1

2014-16: A Multicenter, Open-Label Study Evaluating the Effectiveness of Oral Tecfidera

(Dimethyl Fumarate) on MS Disease Activity and Patient-Reported Outcomes in

Subjects with Relapsing-Remitting Multiple Sclerosis in the Real-World Setting

(PROTEC) Biogen Idec Canada Inc. $47,157.00

2014-16: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial To

Evaluate The Safety and Efficacy of Eculizumab in Patients with Relapsing

Neurolmyelitis Optica (NMO) Quintiles Canada Inc. $74,811.10 301

2014-17: A Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety

and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP),

Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study

205MS301 Biogen Idec MA $16,950.00 Extend

2014-17: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging

Study to Assess the Efficacy, Safety, tolerability, and Pharmacokinetics of

BIIB033 in Subjects with Relapsing Forms of Multiple Sclerosis When Used

Concurrently with Avonex Biogen Idec MA $187,419.00Synergy

2014-18: A Phase III, Open-Label, Extension Trial of ECU-NMO-301 to Evaluate the

Safety and Efficacy of Eculizumab in Patients with Relapsing Neuromyelitis

Optica (NMO) $123,754.00 302

2014-18: MEsenchymal Stem cell therapy for CAnadian MS patients-MESCAMS Multiple

Sclerosis Research Foundation $2,290,000.00


2014-19 An Investigator-Initiated, Multicenter, Phase IV, Open-Label, Study to Evaluate

the Biological Basis for Susceptibility or Resistance to Disease Progression in

Relapsing-Remitting Multiple Sclerosis Patients Treated in Routine Practice with

Gilenya for 5y Novartis Pharmaceutical Canada Inc. $142,750.00 Igloo

2015-16: A retrospective non-interventional multicenter study to compare relapse rate

among patients with relapsing mulitple sclerosis who switch to fingolimod versus

those who switch to other disease modifying therapies (SWITCH STUDY) Novartis Pharmaceutical Corporation $21,450.00

2015-19: A Long term follow-up study for Multiple Sclerosis patients who have completed

the alemtuzumab Extension Study (CAMMS03409). Sanofi-Aventis Canada Inc.

$112,392.00 Topaz

2015-16 Long-term follow-up at 10-years of patients enrolled in the fingolimod Phase II

program in relapsing multiple sclerosis (CFTY720D2201E2) Novartis

Pharmaceuticals Canada Inc. $ 74,061.00

PUBLICATIONS:

Books

1. Freedman MS. Editor, Special Issue. Clinical Trends in Neurology. June 2005.

2. Freedman MS (editor). Advances in Neurology. Multiple Sclerosis and Demyelinating

Diseases. Published by Lippincott Williams & Wilkins. Volume 98. 2006.

Book Chapters

1. Freedman MS, Antel JP, Richman D: Immune-mediated disorders. In: Johnston MV,

MacDonald R, Young AB (eds.), Principles of Drug Therapy in Neurology. FA Davis Company: Philadelphia, 1992, pp 178-205.

2. Antel JP, Freedman MS: The immunologic basis for immunosuppressive and

immunoregulatory therapy in M.S. In: Herndon RM (ed), Multiple Sclerosis: Current Status of Research and Treatment, Demos Pub: New York, 1994, pp. 157-174.

3. Antel JP, Freedman MS, Pioro E, Preul M, Arnold DL. Clinical-laboratory correlations

in motor neuron disease: Assessment of upper motor neuron dysfunction. In: C. Clifford Rose (ed.), Proceedings Forbes H. Norris Memorial Volume, ALS from Charcot to the present and into the future, Smith-Gordon: London, 1994, pp. 35-42.


4. Freedman MS. PRISMS-Studie – Ergebnisse der 4-Jahres-Auswertung: Klinische Dosis-Wirkungs-Beziehung der Interferon-beta-1a-Therapie bei MS. Multiple Sklerose. Kausalorienterte, symptomatische und rehabilitative therapie. Springer, 2001, 105-108

5. Freedman MS, Matusevicius D. Immune System, Overview. Encyclopedia of

Immunology. April 2003. 6. Atkins HL, Freedman MS. Immunoablative therapy as a treatment for aggressive

multiple sclerosis. In: Neurologic Clinics. February 2005. 23:1. pp. 273-300. 7. Atkins H, Freedman MS. Chapter 19 Immunosuppression, in: Cook S (ed), Handbook of

Multiple Sclerosis, Taylor & Francis, New York, pages 423-441, 2006. 8. Freedman MS. Editor, Special Issue. Clinical Trends in Neurology. June 2005. 9. Thompson EJ, Freedman MS. Cerebrospinal fluid analysis in the diagnosis of multiple

sclerosis. Adv. Neurol. 98:147-60, 2006. 10. Freedman MS. Cerebrospinal Fluid. Neuroimmunology in Clinical Practice. Blackwell

Publishing. 2008:Ch 3.6. 54-56. 11. Badve MS, Freedman MS. Multiple Sclerosis. In Diseases and Disorders. Ed. Wendy

Horobin, Marshall Cavendish Corporation, New York. 2008:589-592. Invited Book Reviews 1. Freedman MS. Multiple Sclerosis Immunology, Pathology, and Pathophysiology.

Edited by Herndon RM. 239 pp, ill, New York, Demos Medical Publishing. Neurology. 2003. 61:1633.

2. Freedman MS. Human Embryonic Stem Cells. Edited by S. Sullivan, CA. Cowan and K. Eggan. Wiley, 2007. Canadian Journal of Neurological Sciences.

Editorials 1. Freedman MS, Atkins HL. Suppressing immunity in advancing MS: Too much too late,

or too late for much? Neurology 2004. 62:168-9. Co-primary author 2. Freedman MS and Pachner AR. Neutralizing antibodies to biological therapies: A touch

of gray vs a black and white story. Neurology 2007. 69:1386-87. Co-author

3. Freedman MS. Time is brain also in multiple sclerosis. Mult Scler 2009. 15:1133–

1134. 4. Freedman MS, Cohen JA. Meta-analysis of bone marrow transplantation treatment

studies: mixing ‘apples and oranges’. Mult Scler. 2011. 17(2):131-2. Primary author.

5. Freedman MS, Ucelli A.. Neurorepair with mesenchymal stem cells: Hope or hype? Lancet Neurol. 2012:2(11):123-125.

6. Freedman MS. The use of natalizumab for treatment of MS: Do the risk still outweigh the gains? Can J Neurol Sci. 2012:39:559-560.


Journal Articles 1. Freedman M, Clark BD, Cruz TF, Gurd J, Brown IR: Selective effects of LSD and

hyperthermia on the synthesis of synaptic proteins. Brain Research 1981. 207:129-145. Primary researcher

2. Koven IH, Freedman M, Miller D, Reece S, Maitland A, Sigurdson E, Blackstein ME:

Macro-creatine kinase 2: A possible marker of gastro intestinal cancer? Surgery 1983. 94:631-634. Primary researcher (all the experiments and paper writing).

3. Freedman MS and MacDonald RD: Herpes zoster ophthalmicus with delayed cerebral

infarction and meningoencephalitis. Can J Neurol Sci 1987. 14:312-314. Primary researcher

4. Freedman MS, Schneiderman JH, Turley J, DePetrillo AD: Neurological complications

following intra-arterial CIS-platinum chemotherapy. Can J Neurol Sci 1987. 14:325. Primary researcher.

5. Freedman MS: The current status of multiple sclerosis. Modern Medicine of Canada

1987. 42:GP21-29.

6. Freedman M and Antel JP: Immunoregulatory circuits in multiple sclerosis: Is there a short? (Editorial) Ann Neurol 1988. 24:183-84. Primary writer

7. Freedman MS and Gray TA: Vascular headache: A presenting symptom of multiple

sclerosis. Can J Neurol Sci 1989. 16:63-66. Primary researcher 8. Antel JP, Freedman M, Brodovsky S, Francis GS, Duquette P: Activated suppressor cell

function in severely disabled multiple sclerosis patients. Ann Neurol 1989. 25:204-07. Primary researcher

9. Farmer JP, Antel JP, Freedman M, Cashman NR, Villemure JG: Characterization of

lymphoid cells isolated from human gliomas. J Neurosurgery 1989. 71:528-533. Co-primary researcher (performed up to 50% of experiments and assisted with the writing of the manuscript.)

10. Ruijs TCG, Freedman MS, Grenier Y, Olivier A, Antel JP: Human oligodendrocytes are

susceptible to cytolysis by major histocompatibility complex class I-restricted lymphocytes. J Neuroimmunol 1990. 27:89-97. Co-primary researcher (performed up to 50% of experiments and assisted with the writing of the manuscript.)

11. Freedman MS, Loertscher R, Cashman NR, Duquette P, Blain M, Antel JP:

Immunoregulatory properties of T-cell lines derived from the systemic and intrathecal compartments: A phenotypic and functional study. Ann Neurol 1990. 27:258-265. Primary researcher

12. Yong VW, Yong FP, Moumdjian R, Ruijs TCG, Freedman MS, Cashman N, Antel JP:

-interferon from CD8 or CD4 lymphocytes is a mitogen for human adult astrocytes. PNAS 1991. 88:7016-7020. Co-researcher (performed some of the experiments and assisted in the preparation of the manuscript.)

13. Freedman MS, Blain M, Antel JP: Differential responses of CD4+CD45RA+ and

CD4+CD29+ subsets to activated CD8+ cells: Enhanced stimulation of the


CD4+CD45RA+ subset by cells from patients with multiple sclerosis. Cell Immunol 1991. 133:306-316. Primary researcher

14. Freedman MS, Ruijs TCG, Blain M, Antel JP: Phenotypic and functional characteristics

of activated CD8+ cells: A CD11b-CD28- subset mediates non-cytolytic functional suppression. Clin Immunol Immunopathol 1991. 60:254-267. Primary researcher

15. Freedman MS, Ruijs TCG, Selin LK, Antel JP: Peripheral blood T cells lyse fresh

human brain-derived oligodendrocytes. Ann Neurol 1991. 30:794-800. Primary researcher

16. Freedman MS, Muth KL, Trotter JL, Yoshizawa CN, Antel JP: Prospective serial

analysis of interleukin-2 and soluble interleukin-2 receptor in patients with relapsing-remitting multiple sclerosis. Neurology 1992. 42:1596-1601. Primary researcher

17. Johns LD, Babcock G, Green D, Freedman M, Sriram S, Ransohoff RM: Transforming

growth factor-expression in forebrain and brainstem astrocyte primary cultures. Brain Research 1992. 585:229-236. Co-researcher (performed some of the experiments and assisted in the preparation of the manuscript.)

18. Couldwell WT, Yong VW, Dore-Duffy P, Freedman MS, Antel JP: Production of

soluble autocrine inhibitory factors by human glioma cell lines. J Neurol Sci 1992. 110:178-185. Co-researcher (performed some of the experiments and assisted in the preparation of the manuscript.)

19. Freedman MS, Buu NN, Kanani A, Ruijs TCG, Williams K, Antel JP: Differential

expression of heat shock proteins by human glial cells. J Neuroimmunol 1992. 41:231-238. Primary researcher

20. The IFNb Multiple Sclerosis Study Group*: Interferon- -

remitting multiple sclerosis: Clinical results of a multicentre, randomized, double blind, placebo-controlled trial. Neurology 1993. 43:655-661. Co-investigator

21. Paty DW, Li DKB, The MS/MRI Study Group*, is effective in relapsing-remitting

multiple sclerosis: II - MRI analysis results of a multicentre randomized, double-blind placebo control trial. Neurology 1993. 43:662-667. Co-investigator

22. D'Souza SD, Antel JP, Freedman MS: Cytokine induction of heat shock protein

expression in human oligodendrocytes: an IL-1 mediated mechanism. J Neuroimmunol 1994. 50:17-24. Primary supervisor

23. Prabhakar S, Kurien E, Gupta RS, Zielinski S, Freedman MS: Heat shock protein

immunoreactivity in CSF: Correlation with oligoclonal banding and demyelinating disease. Neurology 1994. 44:1644-48. Primary supervisor

24. The IFN Multiple Sclerosis Study Group* and the University of British Columbia

MS/MRI Analysis Group: Interferon- 1b in the treatment of MS: Final outcome of the randomized controlled trial. Neurology 1995. 45:1277-1285. Co-investigator

25. Ebers GC, Sadovnick AD, Risch NJ and the Canadian Collaborative Study Group*: A

genetic basis for familial aggregation in multiple sclerosis. Nature 1995. 377:150-151. Co-investigator


26. Sadovnick AD and the Canadian Collaborative Study Group*: Evidence for genetic basis of multiple sclerosis. Lancet 1996. 347:1728-1730. Co-investigator

27. Ebers GC, Kukay K, Bulman DE, Sadovnick AD, Rice G, Anderson C, Armstrong H,

Cousin K, Bell RB, Hader W, Paty DW, Hashimoto S, Oger J, Duquette P, Warren S, Gray T, O’Connor P, Nath A, Auty A, Metz L, Francis G, Paulseth JE, Murray TJ, Pryse-Phillips W, Nelson R, Freedman M, Brunet D, Bouchard J-P, Hinds D, Risch N: A full genome search in multiple sclerosis. Nature Genetics 1996. 13:472-476. Co-investigator

28. The IFN Multiple Sclerosis Study Group* and the University of British Columbia

MS/MRI Analysis Group: Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years. Neurology 1996. 47:889-894. Co-investigator

29. Freedman MS T cell-human glial cell interactions: 1) In vitro

induction of T cell expansion by human glial cells. J. Neuroimmunol 1997. 74:135-142. Primary Researcher

30. Freedman MS, Bitar R, Antel J. T cell-human glial Cell interactions: 2) Relationship

between heat shock protein expression and susceptibility to cytolysis. J. Neuroimmunol 1997. 74:143-148. Primary researcher

31. Melegos DN, Freedman MS, Diamandis EP. Prostaglandin D synthase concentration in

cerebrospinal fluid and serum of patients with neurological disorders. Prostaglandins 1997. 54:463-474. Co-primary researcher (performed up to 50% of experiments and assisted with the writing of the manuscript.)

32. The Canadian Burden of Illness Study Group*. Burden of illness of multiple

sclerosis: Part I: Cost of Illness. Can J Neurol Sci 1998. 25:23-30. Co-investigator 33. The Canadian Burden of Illness Study Group*. Burden of illness of multiple

sclerosis: Part II: Quality of life in multiple sclerosis. Can J Neurol Sci 1998. 25:31-38. Co-investigator|

34. Freedman MS. The immunology of MS lesion generation. The Chronicle of Neurology

& Psychiatry 1998. 3(7):17-18. 35. Sadovnick AD, Risch NJ, Ebers GC and the Canadian Collaborative Study Group*.

Canadian collaborative project on genetic susceptibility to MS, phase 2: rationale and method. Can J Neurol Sci 1998. 25:216-21. Co-investigator

36. Francis GS, Freedman MS, Antel JP. Failure of intravenous immunoglobulin to arrest

progression of multiple sclerosis: A clinical and MRI based study. Mult Scler 1998. 3:370-376. Co-primary researcher (assisted with up to 50% of the research and writing of the manuscript.)

37. Zeine R, Pon R, Ladiwala U, Antel JP, Filion LG, Freedman MS. Mechanism of T

cell-induced human oligodendrocyte cytotoxicity: Relevance to multiple sclerosis. J. Neuroimmunol 1998. 87:49-61. Primary supervisor

38. The PRISMS Study Group*. Randomised, double-blind, placebo-controlled study of

interferon -1a in relapsing-remitting multiple sclerosis. Lancet 1998. 352:1498-1504.


39. Freedman MS. The immunology of MS lesion generation. The Chronicle of Neurology

& Psychiatry 1998. 3(7):17-18. 40. Freedman MS, Ransohoff R, Talbot PJ and Zamvil S. Highlights from the fifth

international congress of the international society of neuroimmunology. J Neuroimmunol 1999. 97:4-8.

41. The Lenercept

multiple sclerosis Study Group* and The University of British

Columbia MS/MRI Analysis Group. TNF Neutralization in Multiple Sclerosis: Results of a randomized, placebo-controlled multicenter study. Neurology 1999. 53:457-465. Co-investigator

42. Li DKB, Paty DW, the UBC MS/MRI Analysis Research Group and the PRISMS Study

Group*. Magnetic resonance imaging results of the PRISMS trial: A randomized, double blind, placebo-controlled study of interferon--1a in relapsing-remitting multiple sclerosis. Ann Neurol 1999. 46:197-206. Co-investigator

43. Freedman MS and the OWIMS Study Group. Evidence of interferon -1a dose response

in relapsing-remitting MS: The OWIMS Study. Neurology 1999. 53:679-686. Primary author and co-investigator

44. Oger J and MS Freedman. Consensus statement of the Canadian MS Clinics Network

on: the use of disease modifying agents in multiple sclerosis. Can J Neurol Sci 1999. 26:274-275. Co-author

45. Smith-Walker L, Della Malva L, Freedman M, Tellier A and B Collins. Stability of

performance on measures of subcortical functioning in the early phase of relapsing-remitting multiple sclerosis. J Int Neuropsych Soc 1999. 5:96. Co-investigator

46. Ebers GC, Yee IM, Sadovnick AD, Duquette P and the Canadian Collaborative Study

Group*. Conjugal multiple sclerosis: population-based prevalence and recurrence risks in offspring. Ann Neurol 2000. 48:927-31. Co-investigator

47. Steckley JL, Dyment DA, Sadovnick AD, Risch N, Hayes C, Ebers GC and the

Canadian Collaborative Study Group*. Genetic analysis of vitamin D related genes in Canadian multiple sclerosis patients. Neurology 2000. 54(3):729-32. Co-investigator

48. Sadovnick AD, Yee IM, Ebers GC and the Canadian Collaborative Study Group*.

Factors influencing sib risks for multiple sclerosis. Clin Genet 2000. 58(6):431-5. Co-investigator

49. Jacobs LS, Beck RW, Simon JH, et al, and the CHAMPS Study Group*. Intramuscular

interferon beta-1a therapy initiated during a first demyelinating even in multiple sclerosis. N Engl J Med 2000. 343:898-904. Co-investigator

50. Freedman M. Clinical applications of BMT aim to stop autoimmune disease in its tracks. Advances in Immunotherapy 2000. 7(1):13-17.

51. Blumhardt LD, Chofflon M, Comi G, Freedman MS, Hartung H-P, Khan O, Lisak R,

Paty DW and Rivera V. Multiple Sclerosis: an overview of the clinical data related to key issues raised by interferon beta therapy. J Drug Assessment 2001. 4:1-7. Co-writer


52. The PRISMS (Prevention of Relapses and Disability by Interferon--1a Subcutaneously in Multiple Sclerosis) Study Group* and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon--1a in relapsing MS. Neurology 2001. 56:1628-1636.

53. Maclean HJ and MS Freedman. Immunologic therapy for relapsing-remitting multiple sclerosis. Current Neurology and Neuroscience reports 1:277-285, 2001.

54. SPECTRIMS Study Group*. Hughes RAC et al. Randomized controlled trial of

interferon-beta-1a in secondary progressive multiple sclerosis: Clinical Results. Neurology 2001. 56:1496-1504. Co-investigator

55. SPECTRIMS Study Group*. Li DKB et al. Randomized controlled trial of interferon-

beta-1a in secondary progressive multiple sclerosis: MRI Results. Neurology 2001. 56: 1505-1513. Co-investigator

56. Dyment DA, Willer CJ, Scott B, Armstrong H, Ligers A, Hillert J, Paty DW, Hashimoto

S, Devonshire V, Hooge J, Kastrukoff L, Oger J, Metz L, Warren S, Hader W, Power C, Auty A, Nath A, Nelson R, Freedman M, Brunet D, Paulseth JE, Rice G, O'Connor P, Duquette P, Lapierre Y, Francis G, Bouchard JP, Murray TJ, Bhan V, Maxner C, Pryse-Phillips W, Stefanelli M, Sadovnick AD, Risch N, Ebers GC. Genetic susceptibility to MS: a second stage analysis in Canadian MS families Neurogenetics 2001. 3:145-151. Co-investigator

57. Ligers A, Dyment DA, Willer CJ, Scott B, Armstrong H, Cousin K, Rice G, Bell RB,

Hader W, Paty DW, Hashimoto S, Oger J, Duquette P, Warren S, Gray T, O'Connor P, Nath A, Auty A, Metz L, Francis G, Paulseth JE, Pryse-Phillips W, Nelson R, Freedman MS, Brunet D, Bouchard JP, Hillert J, Sadovnick, Risch N and G Ebers. The genetic contribution of the HLA-DR in DRB1 locus to MS susceptibility. Am J Hum Genet 2001. 69:900-903. Co-investigator

58. CHAMPS Study Group*. Interferon -1a for optic neuritis patients at high risk for

multiple sclerosis. Am J Ophthalmol 2001. 132:463-71. Co-investigator 59. Sadovnik AD, Ebers GC, Yee IML and the Canadian Collaborative Research Group*.

Familial risks for MS in offspring of consanguineous matings. Neurology 2001. 56:784-785. Co-investigator

60. Maclean HJ and MS Freedman. Immunologic therapy for relapsing-remitting multiple

sclerosis. Current Neurology and Neuroscience reports 1:277-285, 2001. 61. Freedman MS, Blumhardt LD, Brochet B, Comi G, Noseworthy JH, Sanberg-Wollheim

M, Soelberg Sorensen P. International consensus statement on the use of disease-modifying agents in multiple sclerosis. Mult Scler 2002. 8:19-23. Primary author.

62. Dyment DA, Steckley JL, Willer C, Sadovnik AD, Risch N, Ebers GC and the Canadian

Collaborative Research Group*. No evidence to support CTLA-4 as a susceptibility gene in Canadian families. J Neuroimmunol 2002. 123:193-8. Co-investigator.

63. Beck RW, Chandler DL, Cole SR, et al for the CHAMPS study group*. Inteferon b-1a

for early Multiple Sclerosis: CHAMPS trial subgroup analyses. Ann Neurol 2002. 51:481-490. Co-investigator


64. Murzenok P, Matusevicius D, Freedman MS. Chemokine and chemokine receptor expression. Clinical Immunol 2002. 103:309-16. Supervisor

65. Jeffery D, Bashir K, Buchwald L, Coyle P, Freedman MS, Markowitz C, Rammohan K,

Reder T, Sharief M, Wolinaky J. Optimizing immunomodulatory therapy for MS patients. Int J MS Care. 2002. 201:89-90. Primary author.

66. CHAMPS study group*. Baseline MRI characteristics of patients at high risk for

multiple sclerosis: results from the CHAMPS trial. Controlled High-Risk Subjects Avonex Multiple Sclerosis Prevention Study. Mult Scler 2002. 8:330-8. Co-investigator

67. CHAMPS study group*. MRI predictors of early conversion to clinically definite MS in

the CHAMPS placebo group. Neurology 2002. 59:998-1005. Co-investigator 68. CHAMPS study group*. Predictors of short-term disease activity following a first

clinical demyelinating event analysis of the CHAMPS placebo group. Mult Scler 2002. 8:405-9. Co-investigator

69. Patten SB, Metz LM and the SPECTRIMS Study Group*. Interferon 1a and

depression in secondary progressive MS: data from the SPECTRIMS Trial. Neurology 2002. 59:744-6. Co-investigator

70. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF,

Sandrock AW, Rudick RA, Simon JH, Simonian NA, Tsao EC, Whitaker JN. the IMPACT Investigators*. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002. 59:679-87. Co-investigator

71. Freedman MS, Jeffery DR, Wolinsky JS. MS patient management: Optimizing the

benefits of immunomodulatory therapy. Int J MS Care 2002 Suppl. 72. Filion LG, Graziani-Bowering G, Matusevicius D, Freedman MS. Monocyte-derived

cytokines in multiple sclerosis. Clin Exp Immunol 2003. 131:324-34. Co-primary researcher (performed up to 50% of experiments and assisted with the writing of the manuscript.)

73. Proulx NL, Freedman MS, Chan JW, Toye B, Code CC. Acute disseminated

encephalomyelitis associated with pasteurella multocida meningitis. Can J Neurol Sci 2003. 30:155-158. Supervisor

74. Pon RA, Freedman MS. Study of Herpesvirus saimiri

derived from peripheral blood and CSF of multiple sclerosis patients. J Neuroimmunol 2003. 139:119-132. Supervisor

75. Filion LG, Matusevicius D, Graziani-Bowering GM, Kumar A, Freedman MS.

Monocyte-derived IL12, CD86 (B7-2) and CD40L expression in relapsing and progressive multiple sclerosis. Clin Immunol 2003. 106:127-138. Co-primary researcher (performed up to 50% of experiments and assisted with the writing of the manuscript.)

76. Filion LG, Graziani-Bowering G, Marusevicius D, Freedman MS. Monocyte-derived

cytokines in multiple sclerosis. Clin Exp Immunol 2003. 131:324-34. Co-primary researcher (performed up to 50% of experiments and assisted with the writing of the manuscript.)


77. Willer CJ, Dyment A, Risch NJ, Sadovnick AD, Ebers GC and the Canadian

Collaborative Study Group*. Twin concordance and sibling recurrence rates in multiple sclerosis. PNAS 2003. 100:12877-72. Co-investigator

78. The diagnosis of primary progressive multiple sclerosis. J Neurol Sciences 2006. 145-

152. Freedman MS Member of PROMISE Study Group. Co-investigator

79. Freedman MS, Patry DG, Grand’Maison F, Myles ML, Paty DW, Selchen DH, on behalf of the Canadian MS Working Group. Treatment optimization in multiple sclerosis. Can J Neurol Sci 2004. 31:157-168. Primary author.

80. Freedman MS. Primary progressive multiple sclerosis: Cerebrospinal fluid

considerations. Mult Scler 2004. 10:S31-S35. 81. Phillips JE, Rice G, Frohman E, Vande Gaer L, Scott T, Haas J, Eggenberger E,

Freedman MS, Stuart W, Cunha L et al. A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis. Clin Ther 2004. 26:511-521. Co-investigator

82. Freedman MS, Thompson EJ, Reiber H, Sindic C, Grimsley G, Tourtellotte W, Racke

M, Giovannoni G, Sharief M, Deisenhammer F, Keir G, Sellebjerg S. Recommended standard of cerebrospinal analysis in the diagnosis of multiple sclerosis: report of the Consortium of MS Clinics CSF Task Force. Arch Neurol 2005. 62:865-70. Primary author

83. Dyment DA, Steckley JL, Morrison K, Willer CJ, Cader MZ, DeLuca GC, Sadovnick

AD, Risch N, Ebers GC, for the Canadian Collaborative Study Group*. TCR polymorphisms and multiple sclerosis. Genes Immun 2004. 5:337-342. Co-investigator

84. Hommes OR, Sorensen PS, Fazekas F, Enriquez MM, Koelmel HW, Fernandez O,

Pozzilli C, O'Connor P, Freedman MS (Member, Study Group). Intravenous immunoglobulin in secondary progressive multiple sclerosis: Randomised placebo-controlled trial. Lancet 2004. 25:364:1149-56. Co-investigator.

85. Petkau AJ, White RA, Ebers GC, Reeder AT, Sibley WA, Lublin FD, Paty DW and the

IFNB Multiple Sclerosis Study Group*. Longitudinal analyses of the effects of

neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis.

Mult Scler 2004. 10:126-138. (MS Freedman is a co-investigator and member of the

Study Group).

86. Wolinsky JS and the PROMISE Study Group. The PROMISE Trial: Baseline data

review and progress report. Mult Scler 2004. 10:S65-S72. (MS Freedman is a co-

investigator and member of the Study Group.)

87. Freedman MS, Francis GS, Sanders EA, Rice GP, O’Connor P, Comi G, Duquette P,

Metz L, Murrary TJ, Bouchard JP, Abramsky O, Pelletier J, O’Brien F. Once weekly

interferon beta-1alpha for Multiple Sclerosis Study Group*. Randomized study of one-

weekly interferon beta-1a therapy in relapsing multiple sclerosis: three-year data from the

OWIMS Study. Mult Scler 2005. 41-5. Primary author


88. Freedman MS. Defining the standards of multiple sclerosis research. Clinical Trends in Neurology 2005. 1:20-24.

89. Freedman MS. Patient management in Multiple Sclerosis: A Canadian expert

viewpoint. Part of Medscape® Conference Coverage. American Academy of Neurology

(AAN). 2005. Miami Beach, Florida.

90. Chen JT, Collins DL, Freedman, MS, Atkins HL,and Arnold DL, the Canadian

MS/BMT Study Group*, Arnold DL. Local magnetization transfer ratio signal in

homogeneity is related to subsequent change in MTR in lesions and normal-appearing

white-matter of multiple sclerosis patients. NeuroImage 2005. 25:1272-1278. Co-

primary researcher (contributed up to 50% with the analysis and writing of the

manuscript.)

91. McFarland H, Barkhof F, Calabresi P, Clanet M, Cohen J, Cutter G, Freedman MS,

Lublin F, Metz L, Miller A, Montalban X, Noseworthy J, O’Connor P, Panitch H, Petkau

J, Polman C, Reingold S, Schwid S, Thompson A, Wolinsky J. On behalf of the National

MS Society Advisory Committee on Clinical Trials of New Agents in MS. The future of

MS therapies: redesigning MS clinical trials in a new therapeutic era. Mult Scler 2005.

11:669-676. Co-panel member (assisting with the writing and review of this manuscript)




93. Uitdehaag BM, Kappos L, Bauer L, Freedman MS, Miller D, Sandbrink R, Polman CH.

Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of

multiple sclerosis. A proposal for standardization. Mult Scler 2005. 11:227-31. Co-

writer and investigator (assisting with up to 50% of the analysis and writing of this

manuscript)

94. Chen JT, Collins DL, Freedman MS, Atkins HL, Arnold DL, The Canadian MS/BMT

Study Group. Local magnetization transfer ratio signal in homogeneity is related to

subsequent change in MTR in lesions and normal-appearing white-matter of multiple

sclerosis patients. Neuroimage 2005. 25:1272-8. Co-primary researcher (assisted with

up to 50% of the analysis and the writing of the manuscript.)

95. Freedman MS. Defining the standards of multiple sclerosis research. Clinical Trends in

Neurology 2005. 1:20-24.

96. Francis GS, Rice GP, Alsop JC. PRISMS Study Group. Interferon beta-1a in MS:

results following development of neutralizing antibodies in PRISMS. Neurology 2005.

65:48-55. (MS Freedman is a co-investigator and member of the Study Group.)

97. Gold R, Rieckmann P, Chang P, Abdalla J. PRISMS Study Group. The long-term

safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Rice+GP%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Alsop+JC%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22PRISMS+Study+Group%22%5BCorporate+Author%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Gold+R%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Rieckmann+P%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Chang+P%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Abdalla+J%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22PRISMS+Study+Group%22%5BCorporate+Author%5D


sclerosis: 4-year data from the PRISMS study. Eur J Neurol 2005. 12:649-56. (MS

Freedman is a co-investigator and member of the Study Group.)

98. Oger J, Francis G, Chang P. on behalf of the PRISMS Study Group. Prospective

assessment of changing from placebo to IFN beta-1a in relapsing MS: The PRISMS

study. J Neurol Sci 2005. 237:45-52. (MS Freedman is a co-investigator and member of

the Study Group.)

99. Freedman MS. Defining the standards of multiple sclerosis research. Clinical Trends in

Neurology 2005. 1:20-24.




101. Karussis D, Biermann LD, Bohlega S, Boiko A, Choffon M, Fezekas F, Freedman MS,

Gebeily S, Gouider R, Havrodova E, Jakab G, Karabudak R, Miller A, the International

Working Group for Treatment Optimization in MS. A recommended treatment algorithm

in relapsing multiple sclerosis: report of an international consensus meeting. Eur J

Neurology 2006. 13:61-71. Co-writer (responsible for up to 50% of the manuscript)

102. Banwell BL, Reder AT, Krupp LB, Tenembaum S, Eraksoy M, Boiko A, Pohl D,

Freedman MS, Schelensky L and Antonijevic I. A multicenter review of the safety and

tolerability of interferon beta-1b in pediatric multiple sclerosis, based on the data

collected and discussed in the expert group. Neurology 2006. 66:472-6. Co-investigator

and author (assisting with up to 50% of the analysis and the writing of the manuscript).

103. Kinkel RP. IM interferon -1a delays definite multiple sclerosis 5 years after a first

demyelinating event. The CHAMPIONS Investigators Group. Neurology 2006.

66:678-84. (MS Freedman is a co-investigator and member of the Study Group.)

104. O’Connor PW, Li D, Freedman MS, Bar-Or A, Rice GPA, Confavreux C, Paty DW,

Stewart JA, Scheyer R. On behalf of the Teriflunomide Multiple Sclerosis Trial Group

and the University of British Columbia MS/MRI Research Group. A phase II study of the

safety and efficacy of Teriflunomide in multiple sclerosis with relapses. Neurology 2006.

66:894-900. Co-author (assisting with up to 50% of the analysis and writing of the paper)

105. Costello F, Coupland S, Hodge W, Lorello GR, Koroluk J, Pan YI, Freedman MS,

Zackon DH, Kardon RH. Quantifying axonal loss after optic neuritis with optical

coherence tomography. Ann Neurol 2006. 59:963-9. Co-researcher (assisting with up to

50% of the analysis and writing of the manuscript)

106. Chen JT, Collins DL, Atkins HL, Freedman MS, Galal A, Arnolg DL, Canadian MS

BMT Study Group. Brain atrophy after immunoablation and stem cell transplantation in

multiple sclerosis. Neurology 2006. 66:1935-7. Co-primary researcher (assisted with

up to 50% of the analysis and the writing of the manuscript.)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Oger+J%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Francis+G%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Chang+P%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22On+behalf+of+the+PRISMS+Study+Group%22%5BCorporate+Author%5D


107. Thompson EJ, Freedman MS. Cerebrospinal fluid analysis in the diagnosis of multiple

sclerosis. Adv Neurol 2006. 98:147-60. Co-author

108. Kappos L, Traboulsee A, Constantinescu C, Erälinna J-P, Forrestal F, Jongen P, Pollard

J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D. PRISMS Study

Group*. Neurology 2006. 67:930-1. Co-investigator

109. Freedman MS. New perspectives in multiple sclerosis: An expert interview with Mark

S. Freedman, HBSc, MSc, MD. Medscape Neurology & Neurosurgery. 2006. 8(2).

110. Freedman MS. Disease-modifying drugs for multiple sclerosis: current and future

aspects. Expert Opinion on Pharmacotherapy 2006. (Suppl. 1) S1-10.

111. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, Montalban X,

Barkhof F, Bauer L, Jakobs P, Pohl C, Sandbrink R. Treatment with interferon beta-1b

delays conversion to clinically definite and McDonald MS in patients with clinically

isolated syndromes. Neurology 2006. 67:1242-9. Co-researcher (assisting with up to

50% of the analysis and writing of the manuscript)

112. Freedman MS. New perspectives in multiple sclerosis: An expert interview with Mark

S. Freedman, HBSc, MSc, MD. Medscape Neurology & Neurosurgery. 2006. 8(2).

113. Kuhle J, Pohl C, Mehling M, Edan G, Freedman MS, Hartung H-P, Polman CH, Miller

DH, Montalban X, Barkhof F, Bauer L, Dahms S, Lindberg R, Kappos L and Sandbrink

R. Lack of association between antimyelin antibodies and progression to multiple

sclerosis. New England Journal of Medicine 2007. 356:371-8. Co-researcher (assisting

with up to 50% of the analysis and writing of the manuscript)

114. Saikali P, Antel Jp, Newcombe J, Chen Z, Freedman MS, Blain M, Cayrol R, Prat A,

Hall JA, Arbour N. NKG2D-mediated cytotoxicity toward oligodendrocytes suggests a

mechanism for tissue injury in multiple sclerosis. J Neuroscience 2007. 27:1220-1228.

Co-researcher and supervisor

115. O’Connor KC, McLaughlin KA, De Jager PL, Chitnis T, Bettelli E, Xu C, Robinson WH,

Cherry SV, Bar-Or A, Banwell B, Fakaura H, Fukazawa T, Tenembaum S, Wong SJ,

Tavakoli NP, Idrissova Z, Viglietta V, Rostasy K, Pohl D, Dale RC, Freedman MS,

Steinman L, Buckle GJ, Kuchroo VK, Hafler DA, Wucherpfennig KW. Self-antigen

tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat

Med 2007. 211-217. Co-researcher (assisting with up to 50% of the analysis of

experiments and writing of the manuscript)

116. Feasby T, Banwell B, Benstead T, Bril V, Brouwers M, Freedman MS, Hahn A, Hume

H, Freedman J, Pi D, Wadsworth L. Guildeines on the use of intravenous immune


globulin for neurologic conditions. Transfus Med Rev 2007. 21:S57-107. Co-author

(responsible for the entire section on Multiple Sclerosis)

117. Metz I, Lucchinetti CF, Openshaw H, Garcia-Merino A, Lassmann H, Freedman MS,

Azzarelli B, Kolar OJ, Atkins HL, Brück W. Autologous hematopoietic stem cell

transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis.

Brain 2007. 130:1254-62. Co-researcher (assisting with up to 50% of the analysis and

writing of the manuscript)

118. Duddy M, Niino M, Adatia F, Hebert S, Freedman MS, Atkins HL, Kim HJ, and Bar-Or

A. Distinct effector cytokine profiles of memory and naive human B cell subsets and

implication in multiple sclerosis. J Immunol 2007. 178:10. Co-primary researcher

(assisted with up to 50% of the analysis and the writing of the manuscript.)

119. Reicker LI, Tombaugh TN, Walker L, Freedman MS. Reaction time: An alternative

method for assessing the effects of multiple sclerosis on information processing speed.

Arch Clin Neuropsychol 2007. 22:655-664. Co-primary researcher (assisted with up

to 50% of the analysis and the writing of the manuscript.)

120. Chen JT, Kuhlmann T, Jansen GH, Collins DL, Atkins HL, Freedman MS, O’Connor

PW, Arnold DL. Canadian MS/BMT Study Group. Voxel-based analysis of the

evolution of magnetization transfer ratio to quantify remyelination and demyelination

with histopathological validation in a multiple sclerosis lesion. Neuroimage 2007.

36:1152-8. Co-primary researcher (assisted with up to 50% of the analysis and the

writing of the manuscript.)

121. Nielsen JM, Moraal B, Polman CH, Poppe P, de Vos M, Freedman MS, Kappos L,

Barkhof F, Bauer L, Pohl C, Sandbrink R, Hartung H-P, Uitdehaag BMJ. Classification

of patients with a clinically isolated syndrome on signs and symptoms is supported by

magnetic resonance imaging results. Mult Scler 2007. 13:717-721. Co-researcher

(assisting with up to 50% of the analysis and writing of the manuscript)

122. Kappos L, Freedman MS, Polman CH, Edan G, Hartung H-P, Miller DH, Montalbán X,

Barkhof F, Radü E-W, Bauer L, Dahms S, Lanius V, Christoph P and Sandbrink R, for

the BENEFIT Study Group. Early versus delayed interferon beta-1b treatment after a first

clinical event suggestive of multiple sclerosis: Impact on disability. Lancet 2007.

370:389-97. Co-researcher (assisting with up to 50% of the analysis and writing of the

manuscript)

123. Freedman MS. Bone marrow transplantation: Does it stop MS progression. J Neurol

Sci 2007. 259:85-89. Main writer of this review.

124. Banwell B, Krupp L, Kennedy J, Tellier R, Tenembaum S, Ness J, Belman A, Boiko A,

Bykova O, Waubant E, Mah J, Stoian C, Kremenchutzky M, Bardini MR, Ruggieri M,

Rensel M, Hahn J, Weinstock-Guttman B, Yeh A, Farrell K, Freedman MS, Iivanainen


M, Sevon M, Bhan V, Dilenge M-E, Stephens D, and Bar-Or A. Clinical features and

viral serologies in pediatric multiple sclerosis: results of a multinational study. Lancet

Neurol 2007. 6:773-81. Co-researcher (assisting with up to 50% of the analysis and


125. Dahms S, Edan G, Freedman MS, Hartung H-P, Kappos L, Atihlasri F, Miller D,

Montalban X, Polman CH, Poppe PA, Radue EW, Devos ML, Wagner K. MRI effects of

interferon-beta1b in the BENEFIT Study: Integrated 2-year results. Arch Neurol 2007.


manuscript)

126. Piwko C, Desjardins OB, Bereza BG, Machado M, Jaszewski B, Freedman MS,

Einarson TR, Iskedjian M. Pain due t multiple sclerosis: analysis of the prevalence and

economic burden in Canada. Pain Res Manag 2007. 12:259-65. Co-researcher (assisting


127. Chen Z, Freedman MS. Correlation of specialized CD16+ γδ cells with disease course

and severity in multiple sclerosis. Journal of Neuroimmology 2008. 194:147-152.

Supervisor

128. Chen JT, Collins DL, Atkins HL, Freedman MS, Arnold DL, for the Canadian MS/BMT

Study Group. Magnetization transfer ratio evolution with demyelination and

remyelination in multiple sclerosis lesions. Ann Neurol 2008. 63:254-262. Co-primary

researcher (assisted with up to 50% of the analysis and the writing of the manuscript.)

129. Polman CH, Reingold SC, Barkhof F, Calabresi PA, Clanet M, Cohen A, Cutter GR,

Freedman MS, Kappos L, Lublin FD, McFarland HF, Metz LM, Miller AE, Montalban

X, O’Connor PW, Panitch H, Richart JR, Petkau J, Schwid SR, Sormani MP, Thompson

AJ, Weinshenker BG, Wolinsky JS. Ethics of placebo-controlled clinical trials in

multiple sclerosis: A reassessment. Neurology 2008. 70:1134-1140. Co-author

(assisting with up to 50% of the writing of the manuscript)

130. Darlington PJ, Podjaski C, Horn KE, Costantino S, Blain M, Saikali P, Chen Z, Baker

KA, Newcombe J, Freedman MS, Wiseman PW, Bar-Or A, Kennedy TE, Antel JP.

Innate immune-mediated neuronal injury consequent to loss of astocytes. J Neuropathol

Exp Neurol 2008. 67:590-599. Co-researcher (assisting with up to 50% of the analysis

and writing of the manuscript)

131. Fazekas F, Lublin FD, Li D, Freedman MS, Hartung H-P, Rieckmann P, Sorenson P,

Maas-Enriquez M, Sommerauer B, Hanna K. Intravenous immunoglobulin in relapsing-

remitting multiple sclerosis: a dose-finding trial. Neurology 2008. 71:265-71. Co-

researcher (assisting with up to 50% of the analysis and writing of the manuscript)

132. Polman C, Kappos L, Freedman MS, Edan G, Hartung HP, Miller DH, Montalban X,

Barkhof F, Selmaj K, Uitdehaag BM, Dahms S, Bauer L, Pohl C, Sandbrink R, BENEFIT


Investigators. Subgroups of the BENEFIT Study: Risk of developing MS and treatment

effect of interferon beta-1b. J Neurol 2008. 255:470-487. Co-researcher (assisting with

up to 50% of the analysis and writing of the manuscript)

133. Vollmer T, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, Campagnolo D,

Deutsch F, Arnold DL. Glatiramer acetate after induction therapy with mitoxantrone in

relapsing multiple sclerosis. Mult Scler 2008. 14. 663-670. Co-researcher (assisting


134. Freedman MS, Hughes B, Micol DD, Bennett R, Cuffel B, Divan V, LaVallee N, Al-

Sabbagh A. Efficacy of disease modifying therapies in relapsing remitting multiple

sclerosis: A systematic comparison. European Neurology 2008. 60:1-11. Primary

author

135. Chen Z, Freedman MS. CD16(+) gammadelta T cells mediate antibody dependent

cellular cytoxicity: Potential mechanism in the pathogenesis of multiple sclerosis. Clin

Immunol 2008. 128:219-227. Supervisor

136. Freedman MS. Induction vs. escalation of therapy for relapsing multiple sclerosis: The

evidence. Neurol Sci 2008. 29. S47-S51. Main writer of this review.

137. Ramagopalan SV, Valdar W, Dyment DA, DeLuca GC, Orton S-M, Yee IM, Criscuoli

M, Ebers GC, Sadovnick, for the Canadian Collaborative Study Group. No effect of

preterm birth on the risk of multiple sclerosis: A population based study. BMC

Neurology 2008. 31:181-4. (MS Freedman is a member of the Study Group.)

138. Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, Galetta

SL, Hutchinson M, Johnson RT, Kappos L, Kira J, Lublin FD, McFarland HF, Montalban

X, Panitch H, Richert J, Reingold SC, Polman CH. Differential diagnosis of suspected

multiple sclerosis: A consensus approach. Mult Scler 2008. 14:1157-1174. Co-author

(responsible for the entire section on spinal cord presentation)

139. Freedman MS, Forrestal F. Canadian Treatment Optimization Recommendations (TOR)

as a predictor of disease breakthrough in patients with multiple sclerosis treated with

interferon beta-1a: analysis of the PRISMS study. Mult Scler 2008. 14(9):1234-41.

Primary researcher

140. Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B,

Uitdehaag BMJ on behalf of the REGARD study group. Comparison of subcutaneous

interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the

REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study. a multicentre,

randomized, parallel, open-label trial. Lancet Neurol 2008. 7:903-914. (MS Freedman is

a co-investigator and member of the Study Group.)


141. Arnold DL, Campagnolo D, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK,

Vollmer T. Glatiramer acetate after mitoxantrone induction improves MRI markers of

lesion volume and permanent tissue injury in MS. J Neurol 2008. 255:1473-1478. Co-

investigator.

142. MacLean HJ, Freedman MS. Multiple Sclerosis: following clues from cause to cure.

Lancet Neurol 2009. 8:6-8. Co-writer of this review.

143. Ramagopalan SV, Valdar W, Criscuoli M, DeLuca GC, Dyment DA, Orton SM, Yee IM,

Ebers GC, Sadovnick AD. Canadian Collaborative Study Group. Age of puberty and

the risk of multiple sclerosis: a population based study. Eur J Neurol. 2009. 16:342-7.

(MS Freedman is a member of the CCSG.)

144. Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, Marinucci LN,

Blight AR. Fampridine MS-F203 Investigators. Sustained-release oral fampridine in

multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009.

373(9665):732-8. (MS Freedman is a co-investigator and member of the Study Group.)

145. Ramagopalan SV, Valdar W, Dyment DA, DeLuca GC, Yee IM, Giovannoni G, Ebers

GC, Sadovnick AD. Canadian Collaborative Study Group. Association of infectious

mononucleosis with multiple sclerosis. A population-based study. Neuroepidemiology.

2009. 32(4):257-62. (MS Freedman is a co-investigator and member of the Study

Group.)

146. Freedman MS, Laks J, Dotan N, Altstock RT, Dukler A, Sindic CJM. Anti--glucose

based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first

neurological event. Mult Scler. 2009. 15:422-430. Primary researcher

147. Moraal B, Pohl C, Uitdehaag BMJ, Polman CH, Edan G, Freedman MS, Hartung H-P,

Kappos L, Miller DH, Montalbán X, Lanius V, Sandbrink R, Barkhof F. MRI predictors

for conversion to multiple sclerosis in the BENEFIT Study. Arch Neurol. 2009.


manuscript)

148. Siritho S, Freedman MS. The prognostic significance of cerebrospinal fluid in multiple

sclerosis. J Neurol Sci. 2009:279:21-5. Supervisor

149. O'Connor P, Comi G, Montalban X, Antel J, Radue EW, de Vera A, Pohlmann H,

Kappos L. FTY720 D2201 Study Group. Oral fingolimod (FTY720) in multiple

sclerosis: two-year results of a phase II extension study. Neurology. 2009. 72:73-9. (MS

Freedman is a co-investigator and member of the Study Group.)

150. Reingold SC, Steiner JP, Polman CH, Cohen JA, Freedman MS, Kappos L, Thompson

AJ, Wolinsky JS. The challenge of follow-on biologists for treatment of multiple

sclerosis. Neurology. 2009. 73:552-559. Co-author (assisting with up to 50% of the

http://www.ncbi.nlm.nih.gov/pubmed/19122034?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=20

http://www.ncbi.nlm.nih.gov/pubmed/19122034?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=20



151. Smith AM, Walker LA, Freedman MS, Demeulemeester C, Hogan MJ, Cameron I.

fMRI investigation of disinhibition in cognitively impaired patients with multiple

sclerosis. J Neurol Sci. 2009. 28:58-63. Co-researcher (assisting with up to 50% of the

analysis and writing of the manuscript)

152. Nielsen JM, Pohl C, Polman CH, Barkhof F, Freedman MS, Edan G, Miller DH, Bauer

L, Sandbrink R, Kappos L, Uitdehaag BMJ. MRI characteristics are predictive for

CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome.

BMC Neurology. 2009. 9:19. Co-researcher (assisting with up to 50% of the analysis


153. Freedman MS, Laks J, Dotan N, Altstock RT, Dukler A, Sindic CJ. Anti-Glc(alpha

1,4)Glc(alpha)IgM antibodies for predicting the development of relapsing-remitting

multiple sclerosis after the first neurological event. Mult Scler. 2009. 4:422-430.

Supervisor

154. Freedman MS, Cohen B, Dhib-Jalbut S, Jeffery D, Reder AT, Sandberg-Wollhaim M,

Weinstock-Guttman B. Recognizing and treating suboptimally controlled multiple

sclerosis: Steps toward regaining command. Curr Med Res Opin. 2009. 25:2549-2470.

Primary author (main person responsible for the organization, writing and editing of the

manuscript).

155. Bar-Or A, Oger J, Gibbs E, Niino M, Aziz T, Renoux C, Alatab S, Shi FD, Campagnolo

D, Jalili F, Rhodes S, Yamashita , Fan B, Freedman MS, Panitch H, Arnold DL,

Vollmer T. Serial combination therapy: Is immune modulation in multiple sclerosis

enhanced by initial immune suppression? Mult Scler. 2009. 15:959-964. Co-researcher

(assisting with up to 50% of the analysis and writing of the manuscript)

156. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X,

Barkhof F, Radü EW, Metzig C, Bauer L, Lanius V, Sandbrink R, Pohl C. Long-term

effect of early treatment with interferon beta-1b after a first clinical event suggestive of

multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.

Lancet Neurol. 2009. 8:987-97. Co-researcher (assisting with up to 50% of the analysis


157. Hawker K, O’Connor P, Freedman MS. Calabresi PA, Antel J, Simon J, Hauser S,

Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH, OLYMPUS Trial Group.

Rituximab in patients with primary progressive multiple sclerosis: Results of a

randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009.


manuscript)


158. Costello F, Hodge W, Pan YI, Freedman M, DeMeulemeester C. Differences in retinal

nerve fiber layer atrophy between multiple sclerosis subtypes. J Neurol Sci. 2009.


manuscript).

159. De Jager PL, Chibnik LB, Cui J, Reischl J, Lehr S, Simon KC, Aubin C, Bauer D,

Heubach JF, Sandbrink R, Tyblova M, Lelkova P. Steering committee of the

BENEFIT study. Steering committee of the BEYOND study. Steering committee of the

LTF study. Steering committee of the CCR1 study, Integration of genetic risk factors into

a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score.

Lancet Neurol. 2009. 8:1111-9. (MS Freedman is a co-investigator and member of the

Study Group.)

160. Atkins H, Freedman MS. Immune ablation followed by autologous hematopoietic stem

cell transplantation for the treatment of poor prognosis multiple sclerosis. Methods of

Molecular Biology. 2009. 549:231-46. Co-writer of this review

161. Moraal B, Pohl C, Uitdehaag BM, Polman CH, Edan G, Freedman MS, Hartung HP,

Kappos L, Miller DH, Montalban X, Lanius V, Sandbrink R, Barkhof F. Magnetic

resonance imaging predictors of conversin to multiple sclerosis in the BENEFIT Study.

Arch Neurol. 2009. 66(11):1345-52.

162. Freedman MS, Uccelli A, Bar-Or A, Atkins H, Karussis D, Frassoni F, Lazarus H,

Scolding N, Slavin S, Le Blanc K. The Therapeutic Potential of Mesenchymal Stem Cell

Transplantation as a Treatment for Multiple Sclerosis: Consensus report of the

International MSCT Study Group. Mult Scler. 2010. 16:503-510. Leader of the

consensus group.

163. Pasquini MC, Griffith LM, MD, Arnold DL, MD, Atkins HL, Bowen JD, Chen JT,

Freedman MS, Kraft GH, Mancardi GL, Muraro PA, Nash RA, Racke MK, Storek J,

Saccardi R. Workshop Summary, Hematopoietic Stem Cell Transplantation for Multiple

Sclerosis: Collaboration of the CIBMTR and EBMT to Facilitate International Clinical

Studies. Accepted for publication. Biol Blood and Marrow Transplant. 2010.

16(8):1076-1083. Co-author (main author responsible for the Multiple Sclerosis section).

164. Freedman MS Amato MP, Atkins HL, Athanassios F, Griffith LM, Kerr D, Martin R,

Massacesi L, Muraro P, Nash R, Pasquini M, Saccardi R, Sormani MP, Mancardi G.

(Consensus on the concept of a prospective trial with HSCT in MS. Haematopoietic Stem

Cell Transplantation for Severe Autoimmune Diseases. Florence, Italy, Bone Marrow

Transplantation. 2010. 45: S8-S10. Key writer of this review.

165. Petzold A, Altintas A, Andreoni L, Bartos A, Berthele A, Blankenstein MA, Buee L,

Castellazzi M, Cepok S, Comabella M, Constantinescu CS, Deisenhammer F, Deniz G,

Espino M, Fainardi E, Franciotta D, Freedman MS, Giedraitis V, Gilhus NE,

Giovannoni G, Glabinski A, Grieb P, Hartung HP, Hemmer B, Herukka SK, Hintzen R,


Ingelsson M, Jackson S, Jacobsen S, Jafari N, Jalosinski M, Jarius S, Kapaki E, Kieseier

BC, Koel-Simmelink MJ, Kornhuber J, Kuhle J, Kurzepa J, Lalive PH, Lannfelt L,

Lehmensiek V, Lewczuk P, Livrea P, Marnetto F, Martino D, Menge T, Norgren N,

Papuc E, Paraskevas GP, Pirttila T, Rajda C, Rejdak K, Ricny J, Ripova D, Rosengren L,

Ruggieri M, Schraen S, Shaw G, Sindic C, Siva A, Stigbrand T, Stonebridge I, Topcular

B, Topcular B, Trojano M, Tumani H, Twaalfhoven HA, Vécsei L, Van Pesch V,

Vanderstichele H, Vedeler C, Verbeek MM, Villar LM, Weissert R, Wildemann B, Yang

C, Yao K, Teunissen CE. Neurofilament ELISA validation. J Immunol Methods. 2010.

352(1-2):23-31. Co-researcher (helped to design protocol, analyze some of the data and

assist with analysis and writing of the manuscript).

166. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Sorensen PS, Vermersch

P, Chang P, Hamlett A, Musch B, Greenberg J for the CLARITY Study Group. A

placebo-controlled trial or oral cladribine for relapsing multiple sclerosis. N Engl J Med.

2010. 362:416-426. (MS Freedman is a member of the CLARITY Study Group.)

167. Cohen JA, Barkhof F, Comi G, Hartung H-P, Khatri BO, Montalban X, Pelletier J, Capra

R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S,

Kappos L, for the TRANSFORMS Study Group. Oral fingolimod or intramuscular

interferon for relapsing multiple sclerosis. N Eng J Med. 2010. 1-14. (MS Freedman is

a member of the TRANSFORMS Study Group.)

168. Kahn O, Filippi M, Freedman MS, Barkhof F, Dore-Duffy P, Lassman H, Trapp B, Bar-

Or A, Zak I, Siegel MJ, Lisak R. Chronic cerebrospinal venous insufficiency and multiple

sclerosis. Ann Neurol. 2010. 67:286-290. Co-writer of this opinion paper.

169. Walker LAS, Mendella PD, Stewart AF, Freedman MS, Smith AM. Meaningful change

in cognition in multiple sclerosis: Method matters. Can J Neurol Sci. 2011. 38(2):282-

8. Co-researcher (helped to design protocol, analyze some of the data and assist with

analysis and writing of the manuscript).

170. Martino G, Franklin RJM, Baron Van Evercooren A, Kerr DA, and the Stem Cells in

Multiple Sclerosis (STEMS) Consensus Group*. Stem cell transplantation in multiple

sclerosis: Current status and future prospects. Nat Rev Neurol. May 2010. 6:247-255.

Co-writer of this review with the consensus group.

171. Vosoughi R, Freedman MS. Therapy of MS. Clinical Neurology and Neurosurgery.

Clin Neurol Neurosurg. 2010. 112:365-385. Supervisor

172. Newell MK, Tobin RP, Cabrera JH, Sorensen M, Huckstep A, Villalobos-Menuey EM,

Harvey CP, Burnett M, Buddiga A, McCrea E, Bar-Or A, Freedman MS, Nalbantoglu J,

Arbour N, Zamvil S, Antel J. TLR-Mediated B Cell Activation Results in Ectopic CLIP

Expression that Promotes B Cell-Dependent Inflammation. J Leuko Biol. 2010. 88.

4:779-89. Co-researcher (helped to design protocol, analyze some of the data and assist


with analysis and writing of the manuscript).

173. Vosoughi R, Freedman MS. MS & ALS: A case report. Int J MS Care. 2010. 12:142-

145. Supervisor

174. O'Connor KC, Lopez-Amaya C, Gagne D, Lovato L, Moore-Odom NH, Kennedy J,

Krupp L, Tenembaum S, Ness J, Belman A, Boyko A, Bykova O, Mah JK, Stoian CA,

Waubant E, Kremenchutzky M, Ruggieri M, Bardini MR, Rensel M, Hahn J, Weinstock-

Guttman B, Yeh EA, Farrell K, Freedman MS, Iivanainen M, Bhan V, Dilenge M,

Hancock MA, Gano D, Fattahie R, Kopel L, Fournier AE, Moscarello M, Banwell B,

Bar-Or A. Anti-myelin antibodies modulate clinical expression of childhood multiple

sclerosis. J Neuroimmunol. 2010. 223(1-2):92-9. Co-researcher (helped to design

protocol, analyze some of the data and assist with analysis and writing of the manuscript).

175. Darlington PJ, Boivin M-N, Renoux C, Frencois M, Galipeau J, Cohen JA, Freedman

MS, Atkins HL, Solchaga L, Bar-Or A. Reciprocal Rh1 and Th17 regulation by

mesenchymal stem cells: Implication for MS. Ann Neurol. 2010. 68:540-5. Co-

researcher (helped to design protocol, analyze some of the data and assist with analysis

and writing of the manuscript).

176. Tombaugh TN, Berrigan LI, Walker L, & Freedman MS. The Computerized Test of

Information Processing (CTIP) offers an alternative to the PASAT for assessing cognitive

processing speed in individuals with multiple sclerosis. Cog Behav Neurol. 2010.

23:3192-198. Co-researcher (helped to design protocol, analyze some of the data and

assist with analysis and writing of the manuscript).

177. Costello F, Hodge W, Pan YI, Eggenberger E, Freedman MS. Using retinal architecture

to help characterize multiple sclerosis patients. Can J Ophthalmol. 2010. 45:620-6. Co-

researcher (helped in protocol design, data analysis and writing of manuscript).

178. Chen Z, Freedman MS T cells and multiple sclerosis: Friends, foes, or both?

Autoimmunity Reviews. 2011. 364-367. Supervisor

179. Nielsen JM, Pohl C, Polman CH, Barkhof F, Freedman MS, Edan G, Miller DH, Bauer

L. Sandbrink R, Kappos L, Uitdehaag BM. Correction: Prognostic implications of a

carefully performed neurological assessment in patients with a first event suggestive of

multiple sclerosis. BMC Neuro. 2011. Feb 4:11:19. Co-researcher (helped in protocol

design, data analysis and writing of manuscript).

180. Vosoughi R, Freedman MS. Managing relapsing-remitting multiple sclerosis following

first drug failure. Future Medicine. 2011. 1(2):115-126. Supervisor

181. Uccelli A, Laroni A, Freedman MS. Mesenchymal stem cells for the treatment of

multiple sclerosis and other neurological diseases. Lancet Neurol. 2011. 10:649-656.

http://www.ncbi.nlm.nih.gov/pubmed/20381173



Co-writer of this review.

182. Freedman MS, Metzig C, Kappos L, Polman CH, Edan G, Hartung H-P, Miller DH,

Montalban X, Yarden J, Spector L, Fire E, Dotan N, Schwenke S, Lanius V, Sandbrink R,

Pohl C. Predictive nature of IgM anti-a-glucose serum biomarker for relapse activity and

EDSS progression in CIS patients: A BENEFIT study analysis. Co-researcher (helped in

protocol design, data analysis and writing of manuscript). Mult Scler. 2012. 18(7):966-

73.

183. Hartung H-P, Freedman MS, Polman C, Edan G, Kappos L, Miller D, Montalban X,

Barkhof F, Petkau J, White R, Sahajpal V, Knappertz V, Beckmann K, Lanius V,

Sandbrink R, and Christoph Pohl C for the BENEFIT Study Group. Interferon & [beta]-

1b neutralizing antibodies 5 years after clinically isolated syndrome. Neurol. 2011.

77(9):835-843. Co-researcher (helped in protocol design, data analysis and writing of

manuscript).

184. Freedman MS, Bar-Or A, Oger J, Traboulsee A, Patry D, Young C, Olsson T, Li D,

Hartung H-P, Krantz M, Ferenczi L, Verco T. A phase III study evaluating the efficacy

and safety of MBP8298 in secondary progressive MS. Neurol. 2011. 18:77(16):1551-

1560. Global principal investigator and lead of manuscript committee. (Designed

protocol as head of steering committee, analyzed the data and was main writer of the

manuscript.)

185. Patsopoulos NK, Esposito F, Reischi J, Lehr S, Bauer D, Heubach J. Sandbrink R, Pohl

C, Edan G, Kappos L, Miller D, Montalbán J, Polman CH, Freedman MS, Hartung H-P,

Amason BGW, Comi G, Cook S, Filippi M, Goodin DS, Jeffrey D, O’Connor P, Ebers

GC, Langdon D, Reder AT, Traboulsee A, Zipp F, Schimrigk J, Hiller J, Behlo M, Booth

DR, Broadley S, Brown MA, Browning BL, Browning SR, Butzkueven H, Carroll WM,

chapman C, Foote SJ, Griffiths L, Kermode AG, Kilpatrick TJ, Lechner-Scott J, Marriott

M, Mason D, Moscato P, Heard RN, Pender MP, Perreau VM, Perera D, Rubio JP, Scott

RJ, Slee M, Stankovich J, Stewart GJ, Taylor BV, Tubridy N, Willoughby E, Wiley J,

Matthews P, Filippo MB, Compston A, Haines J, Hauser SL, McCauley J, Ivinson A,

Oskenberg JR, Pericak-Vance M, Sawcer, SJ, De Jager PL, Hafler DA, de Bakker PIW,

the BSP MS Genetics Working Group and the Steering Committee of Studies evaluating

IFNb-1b and a CCR1-antagonist, ANZgene Consortium, GeneMSA, International

Multiple Sclerosis Genetics Consortium. Genomewide meta-analysis identifies novel

multiple sclerosis susceptibility. Ann Neurol. 2011. 70(6):897-912. Co-researcher

(helped in protocol design, data analysis and writing of manuscript).

186. Freedman MS. Improving long-term follow-up studies of immunomodulatory therapies.

Neurol. 2011:76(Suppl 1):S35-S38.

187. Freedman MS. Long-term follow-up of clinical trials of MS therapies. Neurol. 2011.

76(Suppl1):S26-34.


188. O’Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H,

Truffinet P, Miller A, Freedman MS for the TEMSO Trial Group. Randomized trial of

oral teriflunomide for relapsing multiple sclerosis. NEJM. 2011. 365:14:1993-1303.

189. Freedman MS. Introduction to research in MS. MS in Focus. 2011. Issue 17.

190. Freedman MS. Multiple sclerosis therapeutic strategies. Neurol: Clinical Practice. Dec

2011. p.66-68.

191. Saccardi R, Freedman MS, Sormani MP, Atkins HL, Farge D, Griffith LM, Kraft G,

Mancardi GL, Nash R, Pasquini M, Martin R, Muraro P on behalf of the European Blood

and Marrow Transplantation Group (EBMT), the Center for International Blood and

Marrow Research (CIBMTR) and the aHSCT in MS International Study Group. A

prospective, randomized, controlled trial of autologous haematopoietic stem cell

transplantation for aggressive multiple sclerosis: A position paper. Mult Scler J. 2012.

18(6):825-834.

192. Walker LAS, Cheng A, Berard J, Berrigan LI, Rees LM, Freedman MS. Tests of

information processing speed: What do people with multiple sclerosis think about them?

Int J MS Care. 2012. 14:92-99 Co-researcher (helped in protocol design, data analysis

and writing of manuscript).

193. Smith AM, Walker LAS, Freedman MS, Berrigan LI, St. Pierre J, Hogan MJ, Cameron

I. Activation patterns in multiple sclerosis on the Computerized Tests of Information

Processing. J Neurol Sci. 2012. 312(1-2)131-137.

194. Comi G, De Stefano N, Freedman MS, Barkhof F, Polman H, Uitdehaag BMJ, Casset-

Semanaz F, Hennessy B, Moraga MS, Rocak S, Stubinski B, Kappos L. Comparison of

two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical

demyelinating event suggest of multiple sclerosis (REFLEX): A phase 3 randomised

controlled trial. Lancet Neurol. 2012. 11(1):33-41.

195. Confavreux C, Li DK, Freedman MS, Truffinet P, Benzerdjeb H, Wang D, Bar-Or A,

Traboulsee AL, Reimen LE, O’Connor PW for the Teriflunomide Multiple Sclerosis

Trial Group. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing

multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler J. 2012.

18(9):1278-89.

196. Freedman MS, Ucelli A. Neurorepair with mesenchymal stem cells: Hope or hype?

Lancet Neurol. 2012. 11(2):123-125.

197. Freedman MS, Wolinsky JS, Wamil B, Confavreux C, Comi G, Kappos L, Olsson T,

Miller AE, Benzerdjeb H, Li H, Simonson C, O'Connor P. Teriflunomide added to

interferon- in relapsing multiple sclerosis: A randomized phase II trial. Neurol. 2012.


78:1877-1885.

198. Freedman MS. Do not treat from CIS onset: Evaluate disease course and prognosis first

– No (treat). Mult Scler J. 2012. 18:4:394-5.

199. Polman CH, Balcer LJ, Banwell B, Barkhof F, Calabresi P, Clanet M, Cohen JA, Comi

G, Cutter GR, Freedman MS, Goodman AD, Kappos L, Kieseier BC, Lubetzki C, Lublin

FD, Miller A, Montalban X, O’Connor P, Petkau J, Pozzilli C. Disability outcomes in

multiple sclerosis trials: Current status and future prospects. Lancet Neurol. 2012.

11:467-476. (Member of the International Advisory Committee on Clinical Trials in

Multiple Sclerosis).

200. Walker LAS, Berard JA, Berrigan LI, Rees LM, Freedman MS. Detecting cognitive

fatigue in multiple sclerosis: Method matters. J Neurol Sci. 2012. 316:86-92.

201. Greene DN, Schmidt RL, Wilson AR, Freedman MS, Grenache DG. Cerebrospinal

fluid myelin basic protein is frequently ordered but has little value: a test utilization study.

Am J Clin Pathol. 2012. 138(2). 262-72.

202. Penner IK, Stemper B, Calabrese P, Freedman MS, Polman CH, Edan G, Hartung HP,

Miller DH, Montalbán X, Barkhof F, Pleimes D, Lanius V, Pohl C, Kappos L, Sandbrink

R. Effects of interferon beta-1b on cognitive performance in patients with a first event

suggestive of multiple sclerosis. Mult Scler. 2012. 18(10):1466-71.

203. Cruce R, Vosoughi R, Freedman MS. Cognitive impact of anticholinergid medication in

MS: Adding insult to injury? Multiple Sclerosis and Related Disorders. 2012. 1(4):156-

161.

204. Miller AE, O'Connor P, Wolinsky JS, Confavreux C, Kappos L, Olsson TP, Truffinet P,

Wang L, D'Castro L, Comi G, Freedman MS. for the Teriflunomide Multiple Sclerosis

Trial Group. Pre-specified subgroup analyses of a placebo-controlled phase III trial

(TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler. 2012. 18(11).

1625-1632.

205. Costello F, Hodge W, Pan YI, Burton JM, Freedman MS, Stys PK, Trufyn J, Kardon R.

Sex-specific differences in retinal nerve fiber layer thinning after acute optic neuritis.

Neurol. 2012. 30:79(18). 1866-72.

206. Khoshnam M, Freedman MS. Disease-specific therapy of idiopathic inflammatory

demyelinating disorders. Expert Rev Neurother. 2012. 12(9). 1113-24.

207. Ucelli A, Laroni A, Freedman MS. Mesenchymal stem cells as treatment for MS –

progress to date. Mult Scler. 2012. 18(9):1278-89.













208. Selchen D, Bhan V, Blevins G, Devonshire V, Duquette P, Grand’Maison F,

Kremenchutzky M, Lapierre Y, Li D, von Riedemann SJ, Freedman MS. MS, MRI and

the 2010 McDonald criteria: A Canadian expert commentary. Neurol. 2012. 79:23. S2.

209. Cruce R, Freedman MS. Timely therapeutic interventions and long-term therapeutic

benefits in multiple sclerosis. Hot Topics in Neurology & Phychiatry. 2012. 5:137-17.

210. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP,

Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL,

Margolin DH, Oyuela P, Panzara MA, Compston DA, CARE-MS II Investigators.

Alemtuzemab for patients with relapsing remitting multiple sclerosis after disease-

modifying therapy: A randomised controlled phase 3 trial. Lancet. 2012.

380(9856):1829-39.

211. Wolinsky JS, Narayana PA, Nelson F, Datta Sushmita, O’Connor P, Confavreux C, Comi

G, Kappos L, Olsson TP, Truffinet P, Wang L, Miller A, Freedman MS for the

Teriflonomide Multiple Sclerosis Oral (TEMSO) Trial Group. Magnetic resonance

imaging outcomes from a phase III trial of teriflunomide. Mult Scler J.

2013:19(10):1310-9.

212. Darlington PJ, Touil T, Doucet JS, Gaucher D. Zeidan J, Gauchat D, Corsini R, Kim HJ,

Duddy M, Jalili F, Arbour N, Kebir H, Chen J, Arnold DL, Bowman M, Antel J, Prat A,

Freedman MS, Atkins H, Sekaly R, Chenier R, Bar-Or A; Canadian MS/BMT Study

Group. Diminished Th17 (not Th1) responses underlie multiple sclerosis disease

abrogation after hametopoietic stem cell transplantation. Ann Neurol. 2013.

Mar:73(3):341-54.

213. Atkins HL, Freedman MS. Hematopoietic stem cell therapy for multiple sclerosis: Top

10 lessons learned. Neurotherapeutics. 2013. 10:68-76.

214. Kremenchutzky M, Yeung M, Vorobeychik G, Grand’Maison F, Duquette P, Antel J, Lee

L, Ma C, Yong VW, Hill M, Marriott J, Topor T, Freedman MS, Bhan V, Riddehough

A, Lee A, Lam K, Thibault M, Blevins G, Cerchiaro G, Metz L, Eliasziw M, Traboulsee

T, Kang H, Cheng Y, Zhao G. Application and a proposed modification of the 2010

McDonald criteria for the diagnosis of multiple sclerosis in a Canadian cohort of patients

with clinically isolated syndromes. Mult Scler J. 2013;20(4):458-63.

215. Freedman MS, Selchen D, Arnold DL, Prat A, Banwell B, Yeung M, Morgenthau D,

Lapierre Y, on behalf of the Canadian Multiple Sclerosis Working Group. Treatment

optimization in MS: Canadian MS Working Group updated recommendations. Can J

Neurol Sci. 2013. 40:307-323.

216. Selmaj K, Li DK, Hartung H-P, MD; Hemmer B, Kappos L, Freedman MS, Stüve O,

Rieckmann P, Montalban X, Ziemssen T, Auberson LZ, Pohlmann H, Mercier F, Dahlke

F, Wallström E. Siponimod for patients with relapsing-remitting multiple sclerosis


(BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol. 2013.

12(8)756-67.

217. Freedman MS. Fingolimod versus intramuscular interferon for patients with multiple

sclerosis who have a suboptimal response to interferon-therapy. J Neurol.

2013;260(8):2023-32.

218. Uccelli A, Laroni A, Freedman MS. Mesenchymal stem cells as treatment for MS –

progress to date. Mult Scler. 2013. 19(5):515-9.

219. Menon S, Shirani A, ZhaoY, Oger J, Traboulsee A, Freedman MS, Tremlett H.

Characterizing aggressive multiple sclerosis. J Neurol, Neurosurg and Psychiatry. 2013

Nov;84(11):1192-8..

220. Grand’maison F, Bhan V, Freedman MS, Myles ML, Patry DG, Selchen DG, Moriarty

P, Traboulsee A. Utility of the Canadian Treatment Optimization Recommendations

(TOR) in MS care. Can J Neurol Sci. 2013. 40(4):527-35.

221. Freedman MS. Present and emerging therapies for multiple sclerosis. Continuum.

2013. 19:968-91. Aug 2013.

222. Berrigan LI, Lefevre JA, Rees LM, Berard J, Freedman MS. Walker LA. Cognition in

early relapsing-remitting multiple sclerosis: Consequences may be relative ito working

memory. J Int Neuropsychol Soc. 2013. 19(8):938-949.

223. O’Connor PW, Lublin FD, Wolinsky JS, Confavreux C, Comi G, Freedman MS, Olsson

TP, Miller AE, Dive-Pouletty C, Bégo-Le-Babousse G, Kappos L. Teriflunomide

reduces relapse-related neurological sequelae, hospitalizations and steroid use. J Neurol.

2013:260(10):2472-80.

224. Bar-Or A, Freedman MS, Kremenchutzky M, Menguy-Vacheron F, Bauer D, Jodi S,

Truffinet P, Benamor M, Chambers S, O’Connor PW. Teriflunomide effect on immune

response to influenza vaccine in patients with multiple sclerosis. Neurol. 2013.

81(6):552-8.

225. Walker LAS, Berard JA, Atkins HL, Bowman M, Lee H, Freedman MS. Cognitive

change and neuroimaging following immunoablative therapy and hematopoietic stem cell

transplantation in multiple sclerosis: A pilot study. Multiple Sclerosis and Related

Disorders. 2013:3;129-135.

226. Freedman MS, Kaplan JM, Markovic-Plese S. Insights into the mechanisms of the

therapeutic efficacy of alemtuzumab in multiple sclerosis. Clinical & Cellular

Immunology. 2013:4:4.


227. Menon S, Shirani A, Zhao Y, Oger J, Traboulsee A, Freedman MS, Tremlett H.

Characterising aggressive multiple sclerosis. J Neurol Neurosurg Psych.

2013:8;84(11):1192-8.

228. Freedman MS. Teriflunomide in relapsing multiple sclerosis: therapeutic utility. Ther

Adv Chronic Dis. 2013:4(5):192-205.

229. De Stefano N, Comi G, Kappos L, Freedman MS, Polman CH, Uitdehaag BM,

Hennessy B, Casset-Semanaz F, Lehr L, Stubinski B, Jack DL, Barkhof F. Efficacy of

subcutaneous interferon -1a on MRI outcomes in a randomised controlled trial of

patients with clinical isolated syndromes. J Neurol Neurosurg Psychiatry 2014

Jun;85(6):647-53.

230. AlTahan AM, Alsharoqi I, Bohlega SA, Dahdaleh M, Daif Abdulkader, Deleu D, Esmat

K, Giampaolo D, Freedman MS, Gwilt M, Hosny H, Inshasi JI, Aljimuah M, Khalifa A,

Pakdaman H. Szolics M, Yamout BI, Sahraian MA, Zakaria MF. Characteristics of

multiple sclerosis in the Middle East with special reference to the applicability of

international guidelines to the region. Int J Neurosci. 2014 Sep;124(9):635-41.

231. Edan G, Kappos L, Montalban X, Polman C, Freedman MS, Hartung H-P, Miller D,

Barkhof F, Herrmann J, Lanius V, Stemper B, Pohl C, Sandbrink R, Pleimes D. Long-

term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. J

Neurol Neurosurg Psychiatry. 2013 Nov. Epub ahead of print. Co-Author.

232. Leist TP, Comi G, Cree BA, Coyle PK, Freedman MS, Hartung HP, Vermersch P,

Casset-Semanaz F, Scaramozza M, on behalf of the oral cladribine for early MS

(ORACLE MS) Study Group. Lancet Neurol. Feb 3 2013. Epub ahead of print

233. Clanet MC, Wolinsky JS, Ashton RJ, Hartung H-P, Reingold SC. Risk evaluation and

monitoring in multiple sclerosis therapeutics. Workshop attendee. 2013. Epub ahead of

print.

234. Nagtegaal GJ, Pohl C, Wattjes MP, Hulst HE, Freedman MS, Hartung HP, Miller D,

Montalban X, Kappos L, Edan G, Pleimes D, Beckman K, Stemper B, Polman CH,

Sandbrink R, Barkhof F. Interferon beta-1b reduces black holes in a randomised trial of

clinical isolated syndrome. Mult Scler. 2014;20(2):234-42.

235. Berard JA, Bowman M, Atkins HL, Freedman MS, Walker LAS. Cognitive fatigue in

individuals with multiple sclerosis undergoing immunoablative therapy and

hematopoietic stem cell transplantation. J Neurol Sci. 2014 Jan 15;336(1-2):132-137.

236. Freedman MS. Treatment options for patients with multiple sclerosis who have a

suboptimal response to interferon-b therapy. European J Neurol.. 2014Mar;21(3):377-

387.


237. Pohl C, Polman CH, Miller D, Barkhof F, Edan G, Hartung HP, Kappos L, Freedman

MS, Montalban X, Radue EW, Köchert K, Munger K. White R, Simon KC, Pleimes D,

Sandbrink R. Vitamin D as an early predictor of multiple sclerosis activity and

progression. JAMA. 2014;71(3):306-14.

238. Berrigan L, Fisk J, Walker L, Wojtowicz M, Rees L, Freedman MS, Marrie RA.

Reliability of regression-based normative data for the oral symbol digit modalities test:

An evaluation of demographic influences, construct validity and impairment

classification rates in multiple sclerosis samples. Clin Neuropsychol. 2014;28(2):281-

99.

239. Freedman MS, De Stefano N, Barkhof F, Polman CH, Comi G, Uitdehaag BMJ, Casset-

Semanaz F, Hennessy B, Lehr L, Stubinski B, Jack DL, Kappos L. Patient subgroup

analyses of the treatment effect of subcutaneous interferon b-1a on development of

multiple sclerosis in the randomized controlled REFLEX Study. J Neurol. 2014

Mar;261:3(2014):490-99.

240. Confavreux C, O’Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky

JS, Bagulho T, Delhay J-L, Dukovic D, Truffinet P, Kappos L, for the TOWER Trial

Group. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a

randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014

Mar;13(3):247-56.

241. Ascherio A, Munger K, White R, Köchert K, Simon KC, Polman CH, Freedman MS,

Hartung H-P, Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Radü E-W,

Sandbrink R, Kappos L, Pohl C. Vitamin D as an early predictor of multiple sclerosis

activity and progression. JAMA Neurol. 2014 Mar;71(3):306-14.

242. Freedman MS, Comi G, De Stefano N, Barkhof F, Polman CH, Uitdehaag BMJ, Lehr L,

Stubinski B. Kappos L. Moving toward earlier treatment of multiple sclerosis: Findings

from a decade of clinical trials and implications for clinical practice. MSARD.

2014;3:147-155.

243. Leist TP, Comi G, Cree BA, Coyle PK, Freedman MS, Hartung HP, Vermersch P,

Casset-Semanaz F, Scaramozza M: oral cladribine for early MS (ORACLE MS) Study

Group. Effect of oral cladribine on time to conversion to clinically definite multiple

sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3

randomised trial. Lancet Neurol. 2014 Mar;13(3):257-67

244. Olsson T, Boster A, Fernandez O, Freedman MS, Pozzilli C, Bach D, Berkani O,

Mueller MS, Sidorenko TV, Radue EW. Oral ponesimod in relapsing-remitting multiple

sclerosis: A randomised phase II trial. J Neurol Neurosurg Psychiatry. 2014 Apr 8

245. Correale J, Abad P, Alvarenga R, Alves-Leon S, Arms E, Barahona J, Buzo R, Corono T,

Cristiano E, Gracia F, Bonitto JG, Macias MA, Soto A, Vizcarra D, Freedman MS.


Management of relapsing-remitting multiple sclerosis in Latin-America: Practical

recommendations for treatment optimization. J Neurol Sci. 2014 Apr 15;339(1-2):196-

206

246. Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, Olsson

TP, Benamor M, Bauer D, Truffinet P, Church M, Miller AE, Wolinsky JS, Freedman

MS, O’Connor P; TENERE Trial Group. Mult Scler. 2014:20(6):705-16.

247. Kappos L, Hartung HP, Freedman MS, Boyko A, Radü EW, Mikol DD, Lamarine M,

Hyvert Y, Freudensprung U, Plitz T, van Beek J; ATAMS Study Group. Atacicept in

multiple sclerosis (ATAMS): A randomized, placebo-controlled, double-blind, phase 2

trial. Lancet Neurol. 2014;13(4):353-63.

248. Sartori A, Carle D, Freedman MS. Teriflunomide: A novel oral treatment for relapsing

multiple sclerosis. Expert Opin Pharmacother. 2014 May;15(7):1019-27

249. Zlonkow C, Grimaldi L, Confavreux C, Comi G, Kappos L, Olsson T, Benamor M, Bauer

D, Truffinet P, Miller A, Wolinsky J, Freedman MS, O’Connor P. Teriflunomide versus

subcutaneous interferon-beta-1a in patients with relapsing multiple sclerosis: A

randomised, controlled phase 3 trial. MS Journal. 2014;20(6):705-16.

250. Miller A, MacDonell R, Comi G, Freedman MS, Kappos L, Maeurer M, Olsson T,

Wolinsky J, Bozzi S, Dive-Pouletty C, O’Connor P. Teriflunomide reduces relapses with

sequelae and relapses leading to hospitalizations: Results from the TOWER Study J

Neurol. 2014 Sep;261(9):1781-8

251. Freedman MS. Efficacy and safety of subcutaneous interferon- -1a in patients with a

first demyelinating event and early multiple sclerosis. Expert Opin Biol Ther. 2014

Aug;14(8):1207-14

252. Lublin FD, Reingold JA, Cutter GR, Sorensen PS, Thompson AJ, Wolinsky JS, Balcer

LJ, Banwell BL, Barkhof F, Bebo B, Calabresi PA, Clanet GM, Comi G, Fox RJ,

Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln J, Lubetzki C,

Miller AE, Montalban X, O’Connor P, Petkau J, Pozzilli C, Rudick RA, Sormani MP,

Stuve O, Waubant E, Polman CH. Defining the clinical course of multiple sclerosis: The

2013 revisions. Neurology. 2014 Jul 15;83(3):278-86

253. Lublin F, Bowen J, Huddlestone J, Kremenchutzky M, Carpenter A, Corboy J, Freedman

MS, Krupp L, Paulo C, Hariri R, Fischkoff S. Human Placenta-Derived Cells (PDA-001)

for the Treatment of Adults With Multiple Sclerosis: A Randomized, Placebo-

Controlled, Multiple-Dose Study. Multiple Sclerosis and Related Disorders 2014

Nov;3(6):696-704


254. Freedman MS. Multiple sclerosis: Does aggressive MS warrant aggressive treatment?

Nat Rev Neurol. 2014 Jul;10(7):368-70

255. Munger KL, Köchert K, Simon KC, Kappos L, Polman CH, Freedman MS, Hartung HP,

Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Sandbrink R, Ascherio A, Pohl

C. Molecular mechanism underlying the impact of vitamin D on disease activity of MS.

Ann Clin Transl Neurol. 2014 Aug;1(8):605-17

256. Wolinsky J, Kappos L, Giancarlo C, Freedman MS, Olsson T, Oral teriflunomide for

patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a

randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014

Oct;13(10):977-86

257. Freedman MS. Evidence for the efficacy of interferon beta-1b in delaying the onset of

clinically definite multiple sclerosis in individuals with clinically isolated syndrome.

Therapeutic Advances in Neurological Disorders Nov 2014 7: 279-88

258. Miller A, Wolinsky J, Kappos L, Comi G, Freedman MS, Olsson T, Bauer D, Benamor

M, Truffinet P, O’Connor P. Oral teriflunomide for patients with a first clinical episode

suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-

controlled, phase 3 trial. Canadian Expert Panel Recommendations for MRI Use in MS

Diagnosis and Monitoring. Lancet Neurology 2014 Oct;13(10):977-86

259. V Bhan, Lapierre Y, Freedman MS, Duquette P, Selchen D, Migounov V, Walt L,

Zhang A. Anti-JC Virus Antibody Prevalence in Canadian MS Patients. Can J Neurol

Sci. 2014 Nov 4:1-5

260. Goodman AD1, Bethoux F

2, Brown TR

3, Schapiro RT

4, Cohen R

5, Marinucci LN

5,

Henney HR 3rd5, Blight AR

6; on behalf of the MS-F203, MS-F204, and Extension Study

Investigators; on behalf of the MS-F203 MS-F204 and Extension Study Investigators.

Freedman MS (collaborator). Long-term safety and efficacy of dalfampridine for

walking impairment in patients with multiple sclerosis: Results of open-label extensions

of two Phase 3 clinical trials. Mult Scler. 2015 Jan 12. pii: 1352458514563591.

261. Gibbs E, Karim ME, Oger J; Steering Committee of the BENEFIT study. Antibody

dissociation rates are predictive of neutralizing antibody (NAb) course: a comparison of

interferon beta-1b-treated Multiple Sclerosis (MS) patients with transient versus sustained

NAbs. Clin Immunol. 2015 Mar;157(1):91-101

262. Freedman MS, Abdoli M. Evaluating response to disease-modifying therapy in

relapsing multiple sclerosis. Expert Rev Neurother. 2015 Apr;15(4):407-23.

263. Traboulsee A, Létourneau-Guillon L, Freedman MS, O'Connor PW, Bharatha A,

Chakraborty S, Girard JM, Giuliani F, Lysack JT, Marriott JJ, Metz LM, Morrow SA, Oh




http://www.ncbi.nlm.nih.gov/pubmed/?term=Goodman%20AD%5BAuthor%5D&cauthor=true&cauthor_uid=25583832

http://www.ncbi.nlm.nih.gov/pubmed/?term=Bethoux%20F%5BAuthor%5D&cauthor=true&cauthor_uid=25583832

http://www.ncbi.nlm.nih.gov/pubmed/?term=Brown%20TR%5BAuthor%5D&cauthor=true&cauthor_uid=25583832

http://www.ncbi.nlm.nih.gov/pubmed/?term=Schapiro%20RT%5BAuthor%5D&cauthor=true&cauthor_uid=25583832

http://www.ncbi.nlm.nih.gov/pubmed/?term=Cohen%20R%5BAuthor%5D&cauthor=true&cauthor_uid=25583832

http://www.ncbi.nlm.nih.gov/pubmed/?term=Marinucci%20LN%5BAuthor%5D&cauthor=true&cauthor_uid=25583832

http://www.ncbi.nlm.nih.gov/pubmed/?term=Henney%20HR%203rd%5BAuthor%5D&cauthor=true&cauthor_uid=25583832

http://www.ncbi.nlm.nih.gov/pubmed/?term=Blight%20AR%5BAuthor%5D&cauthor=true&cauthor_uid=25583832

http://www.ncbi.nlm.nih.gov/pubmed/?term=on%20behalf%20of%20the%20MS-F203%2C%20MS-F204%2C%20and%20Extension%20Study%20Investigators%5BCorporate%20Author%5D

http://www.ncbi.nlm.nih.gov/pubmed/?term=on%20behalf%20of%20the%20MS-F203%2C%20MS-F204%2C%20and%20Extension%20Study%20Investigators%5BCorporate%20Author%5D

http://www.ncbi.nlm.nih.gov/pubmed/?term=on%20behalf%20of%20the%20MS-F203%20MS-F204%20and%20Extension%20Study%20Investigators%5BCorporate%20Author%5D









J, Sharma M, Vandorpe RA, Vertinsky TA, Wadhwa VS, von Riedemann S, Li DK.

Canadian Expert Panel Recommendations for MRI Use in MS Diagnosis and Monitoring.

Can J Neurol Sci. 2015 May;42(3):159-67.

265. MacMillan EL, R Tam, Y Zhao, IM Vavasour, DKB Li, J Oger, MS Freedman,

SH Kolind and AL Traboulsee. Progressive multiple sclerosis exhibits

decreasing glutamate and glutamine over two years. Mult Sclerosis Journal. 2015 May

26. pii: 1352458515586086.

266. Mahzari M, Arnaout A, Freedman MS. Alemtuzumab Induced Thyroid Disease in

Multiple Sclerosis: A Review and Approach to Management. Can J Neurol Sci. 2015

May 20:1-8.

267. Rush CA , MacLean HJ

, Freedman MS. Aggressive multiple sclerosis: proposed

definition and treatment algorhytm. Nat Rev Neurol. 2015 Jun 2.

doi:10.1038/nrneurol.2015.85.

Free paper

1. Freedman MS, Kappos L, Polman C, Hartung H-P, Edan G, Miller D, Montalban X,

Bauer L, Dahms S, Pohl C and Sandbrink R. Analysis of neutralizing antibodies in the

Betaferon® in newly emerging multiple sclerosis for initial treatment (BENEFIT) Study.

Free paper. International proceedings. 8th

International Congress of Neuroimmology.

Nagoya (Japan). 2006.

Letters to the Editor 1. Freedman MS, Ruijs TCG, Selin LK, Antel JPA: Heat shock proteins as targets for T

cells in multiple sclerosis-reply. Ann Neurol 1992. 32:410-411. 2. Freedman MS, Muth KL, Trotter JL, Yoshizawa CN, Antel JP: Analysis of interleukin-2

in multiple sclerosis-reply. Neurology 1993. 43:1449-1450. 3. Melegos DN, Freedman MS, Diamandis EP. Prostate-specific antigen in cerebrospinal

fluid. Clinical Chemistry 1997. 43:855. 4. Jeffery D, Bashir K, Buchwald L, Coyle P, Freedman MS, Markowitz C, Rammohan K,

Reder T, Sharief M, Wolinsky J. Optimizing immunomodulatory therapy for MS patients: An integrated management model. J Neurol Sci 2002. 201:89-90.

5. Freedman MS, King J, Oger J, Sharief M, Hartung HP, PRISMS Study Investigators.

Interferons in relapsing remitting multiple sclerosis. Lancet 2003. 361:1822-3. author reply 1823-4.


http://www.ncbi.nlm.nih.gov/pubmed/?term=Mahzari%20M%5BAuthor%5D&cauthor=true&cauthor_uid=25990097

http://www.ncbi.nlm.nih.gov/pubmed/?term=Arnaout%20A%5BAuthor%5D&cauthor=true&cauthor_uid=25990097

http://www.ncbi.nlm.nih.gov/pubmed/?term=Freedman%20MS%5BAuthor%5D&cauthor=true&cauthor_uid=25990097



http://www.ncbi.nlm.nih.gov/pubmed/?term=Rush%20CA%5BAuthor%5D&cauthor=true&cauthor_uid=26032396

http://www.ncbi.nlm.nih.gov/pubmed/?term=MacLean%20HJ%5BAuthor%5D&cauthor=true&cauthor_uid=26032396

http://www.ncbi.nlm.nih.gov/pubmed/?term=Freedman%20MS%5BAuthor%5D&cauthor=true&cauthor_uid=26032396



6. Freedman MS. Comments on the report of the EFNS task force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2007. 14(6).

7. Metz I, Lucchinetti CF, Openhshaw H, Garcia-Merino A, Lassmann H, Freedman MS,

Azzarelli B, Kolar OJ, Atkins HL, Brück W. Autologous hematopoietic stem cell transplantation: The glass seems to be half full for aggressive, early forms of MS and half empty for advanced MS. The Author Published by Oxford University Press on behalf of the Guarantors of Brain. 2007.

8. Galea I, Freedman MS, Thompson EJ. CSF analysis in the 2010 revised McDonald’s MS diagnostic criteria. Ann Neurol 2011 July. 70(1):183.

Abstracts:

1. Freedman M, Cruz T, Gurd J, Brown I: Selective effects of LSD on the synthesis of

synaptic proteins and glycoproteins. Abstract and talk at the Clinical Research Society Meeting in Toronto, 1979.

2. Freedman M, Cruz T, Gurd J, Brown I: Selective effects of LSD on the synthesis of synaptic

proteins and glycoproteins. Abstract and poster session at the XIst International Congress of Biochemistry, (Toronto, July 1979).

3. Freedman M, Cruz T, Gurd J, Brown I: Effect of LSD on molecular events at the synapse.

Abstract and poster session at the International Society of Neurochemistry meetings. (Israel, Sept, 1979).

4. Heikkila J, Freedman M, Brown IR: Sensitivity of brain protein synthesis to hyperthermia

induced by various treatments. Abstract and poster session at the International Society of Neurochemistry meetings, (Israel, Sept, 1979).

5. Freedman M, Koven IH, Gordon A, Blackstein MB, Miller B: Macro CK: A New Marker

for Colorectal Cancer? The Annals RCPSC 15(4):325, 1982.

6. Levitan M, Bruni J, Freedman M: Repetitive Pseudoseizures incorrectly managed as status epilepticus. Can J Neurol Sci 12(2): 192, 1985.

7. Freedman MS and Gray TA: Vascular headache: A presenting symptom of multiple

sclerosis. Can J Neurol Sci 14(2):242-243, 1987.

8. Ruijs TCG, Olivier A, Freedman MS, Antel JP: Generation of cytotoxic lymphocytes for human glial cells in culture. Soc Neurosci Abs, p. 788, 1988.

9. Freedman MS, Loertscher R, Cashman NR, Antel JP: Differential growth of

immunoregulatory T-cell subsets. 7th International Congress of Immunology, p. 609 (Abs92-20), 1989.

10. Ruijs TCG, Olivier A, Freedman MS, Antel JP: Cultured human oligodendrocytes are

susceptible to lysis by MHC class I-directed cytotoxic lymphocytes. Soc Neurosci Abs 15:13, 1989.

11. Freedman MS, Blain M, Antel JP: Comparison of systemic intrathecal immunoregulatory

mechanisms. Neurology 39:417, 1989.


12. Freedman MS, Blain M, Antel JP: Reduced numbers of phenotypic and functional suppressor T cells in cerebrospinal fluid (CSF). Neurology 40(Suppl 1):392, 1990.

13. Yong VW, Yong FP, Freedman M, Antel JP: Cytokines and proliferation of human adult

astrocytes. Neurology 40(Suppl 1):208, 1990.

14. Freedman MS, Blain M, Antel JP: Differential responses of CD4+CD45RA+ and CD4+CD29+ subsets to activated CD8+ cells. FASEB J 4(7):A2256, 1990.

15. Freedman MS, Blain M, Antel JP: Enhanced stimulation of virgin T cells

(CD4+CD45RA+) by activated CD8+ cells in multiple sclerosis. Ann Neurol, 28:244, 1990.

16. Freedman MS, Muth KL, Trotter JS, Yoshizawa CN, Larocca AT, Francis G, Duquette P, Antel JP: Prospective serial analysis of soluble interleukin-2 receptor (sIL-2R) in relapsing-remitting MS. Neurology 41(Suppl 1):219, 1991.

17. Freedman MS, Buu N, Ruijs TCG, Antel JP: The expression of heat-shock protein (hsp 72)

in cultured human brain cells. Can J Neurol Sci 18:236, 1991.

18. Freedman MS, Ruijs TCG, Antel JP: Human oligodendrocytes are killed by peripheral blood T cells. Ann Neurol 30:303, 1991.

19. Freedman MS, Ruijs TCG, Antel JP: The role of heat shock proteins in oligodendrocyte

T cell interaction. J Neuroimmunol (Suppl. 1):112, 1991.

20. Freedman MS, Ruijs TCG, Yong VW, Antel JP: T cell induced lysis of human CNS-derived cells does not correlate with expression of hsp. Neurology 42 (Suppl 3):247, 1992.

21. Freedman MS, Antel JP, De Guzman T, Minuk J: Measurement of IgM antibodies to Gm1

gangliosides in the evaluation of motor neuronopathies. Can J Neurol Sci 19:281, 1992.

22. Freedman MS, Prabhakar S, Gupta RS, Kurien E, Antel JP: CSF immunoreactivity to heat shock protein (hsp60) is elevated in Multiple Sclerosis (MS). Ann Neurol 32:110, 1992.

23. Freedman MS, Zielinski S, Grant I, Antel JP: Correlation of anti-Gm1 ganglioside antibody

reactivity with peripheral nerve and clinical phenotype. Neurology 43 (suppl 2):A343, 1993.

24. Freedman MS, Antel JP, D'Souza SD: Cytokine induced heat shock expression in human oligodendrocytes. Ann Neurol. 34 (2):310, 1993.

25. Freedman MS, Bitar R. T cell-induced lysis of human oligodendrocytes: A heat shock

protein mediated mechanism. J Neuroimmunol. 54:159 (w05.0709), 1994.

26. Stone JE, Freedman MS. Differential effects of recombinant human interferon beta-1b (IFN-1b) on and T cells. J Neuroimmunol. 54:199 (p12.09), 1994.

27. Freedman MS, J. Abiscott, Goldstein R. HSP70 gene polymorphism correlates with cellular

reactivity to HSP in Multiple Sclerosis. Neurology. 45 (suppl 4):A467, 1995.

28. Freedman MS, Nelson RF, Rabinovitch H, Christie S, Denis L, Corman C, Benavente M., Intensive immunosuppressive therapy for progressive multiple sclerosis (MS): Experience using a booster regimen of cyclophosphamide and methylprednisolone. Can J Neurol Sci 23 (Suppl 1):S46, 1996.


29. Zeine R, Pon R, Nguyen V, Freedman MS. Mechanism of T cell cytotoxicity in multiple sclerosis. Ann Neurol. 40:555, 1996. ACTRIMS meeting, Miami, October, 1996.

30. Grenier J-F and the Canadian Burden of Illness Study Group*. Multiple Sclerosis:

Evaluation of the burden of illness in Canada. AAN meeting, Boston, April, 1997.

31. Zeine R and Freedman MS. Mechanism of T cell-induced human oligodendrocyte cytotoxicity: Relevance to multiple sclerosis. ACTRIMS meeting, San Diego, CA, October, 1997. (Mult Scler. 3:405, 1998).

32. Filion LG, Chabot J, Freedman M, Kumar A. Modulation of adhesion molecules with

interferon- in multiple sclerosis patients. ISAC XIX International Congress, Colorado Springs, CO. USA, March, 1998.

33. Christen U, Thuerkauf R, Lesslauer W and the Lenercept Rheumatoid Arthritis and Multiple

Sclerosis Study Groups. Immunogenicity of a human TNFR55-IgG1 fusion protein (Lenercept) in rheumatoid arthritis (RA) and multiple sclerosis (MS) patients. 7th International TNF Congress, Hyannis, MA, May, 1998.

34. The Lenercept

multiple sclerosis Study Group* and The University of British Columbia

MS/MRI Analysis Group. TNF neutralization induces an increase in relapses in patients with multiple sclerosis. Canadian Congress of Neurological Sciences, Montréal, Canada, June, 1998. (Can J Neurol Sci. 25:(Suppl 2) S31).

35. Filion LG, Chabot J, Kumar A and M Freedman. Cytokine alteration of co-stimulatory

molecules in MS. Fifth International Congress of the International Society for Neuroimmunology, Montréal, Canada, August, 1998. (J Neuroimmunol )

36. Pon R and M Freedman. Phenotypic and functional properties of transformed T cell lines

and clones from MS CSF and blood. Fifth International Congress of the International Society for Neuroimmunology, Montréal, Canada, August, 1998.

37. Zeine R, Freedman M and F Mandy. Role of NK receptors in T cell cytotoxicity in

multiple sclerosis. Fifth International Congress of the International Society for Neuroimmunology, Montréal, Canada, August, 1998.

38. Freedman MS and the OWIMS Study Group. Dose dependent clinical and MRI efficacy of

interferon 1a (Rebif

) in multiple sclerosis. American Neurological Association Meeting. Montréal, QC, October, 1998.

39. Freedman MS. Clinical and MRI Efficacy of interferon -1a (Rebif

®) in Relapsing

Remitting Multiple Sclerosis: Special Benefits of High Doses for Patients with Greater Disability. Joint Meeting of the International Cytokine Society and the International Society for Interferon and Cytokine Research, Jerusalem, Israel. October, 1998. Eur Cytokine Network 9:336 (A566).

40. Smith-Walker L, Della-Malva L, Freedman M, Tellier A, Collins B. Stability of

performance on measures of subcortical functioning in early phase relapsing-remitting multiple sclerosis. International Neuropsychological Society Meeting. Boston MA, USA. February, 1999.

41. Matusevicius D and Freedman MS. IFN- - and IFN-

by T cells from multiple sclerosis patients. Presented at the joint ACTRIMS/ECTRIMS meeting. September, 1999. Basel, Switzerland.


42. Matusevicius D and Freedman MS. Elevated production of TNF- by / T cell lines

generated from CSF of MS patients. Presented at the American Neurological Association meeting. October, 1999. Seattle, Washington. (Ann Neurol. 46:470 Abstract 96).

43. Atkins HL, Freedman MS, Antel J, Arnold D, Bence-Bruckler I, Bredeson C, Duquette P,

Huebsch L, Launeville P, Messner H, Sekaly R and P O’Connor. Targeting multiple sclerosis as an autoimmune disease with intensive immunoablative therapy and immunological reconstitution. Canadian Bone Marrow Transplant Meeting.

44. Freedman MS. On behalf of the PRISMS study group. Long-term efficacy of interferon-

beta 1a (Rebif™) in relapsing-remitting MS: 4-year results of the PRISMS Study. American Academy of Neurology Late Breaking News Session. San Diego, CA, May, 2000. (Neurology. 54:2351, #3, 2000).

45. Freedman MS, The immunological rationale for bone marrow transplant, ACTRIMS

Meeting, Boston, MA. October, 2000.

46. Rice G and the PRISMS study group*. Interferon-neutralizing antibodies reduce clinical and magnetic resonance imaging efficacy in multiple sclerosis patients treated with Interferon -1a (Rebif): Observations from the PRISMS 4-year extension study. American Neurological Association Meeting, Boston, MA. October, 2000. (Ann Neurol. 48:477 Abstract 232, 2000.)

47. Zhao GJ, So G, Li DKB, Riddenhough A, Jones C, Paty DW, the PRISMS study group*

and the UBC MS/MRI research group. Changes of the third ventricular width in multiple sclerosis over 2 years. American Neurological Association Meeting, Boston, MA. October, 2000. (Ann Neurol 48:481 Abstract 246, 2000.)

48. Murzenok P, Matusevicius D, and Freedman MS. Chemokine and chemokine receptor

expression in T cells generated from peripheral blood and cerebrospinal fluid of MS patients. American Neurological Association Meeting, Boston, MA. October, 2000. (Ann Neurol. 48:476 Abstract 227, 2000.)

49. Freedman MS, on behalf of the PRISMS study group. Low rate of progression to EDSS 6 in

patients with relapsingremitting multiple sclerosis (RRMS) treated with interferon beta-1a: 4-year data from the PRISMS study. First LACTRIMS meeting, Buenos Aires, Argentina. November, 2000.

50. Freedman MS, on behalf of the PRISMS study group. Endpoints to assess progression of

disability in long-term clinical trials in relapsingremitting multiple sclerosis (RRMS). First LACTRIMS meeting, Buenos Aires, Argentina. November, 2000.

51. Freedman MS, on behalf of the PRISMS study group. Long term safety and tolerability of

interferon beta-1a in relapsingremitting multiple sclerosis (RRMS). First LACTRIMS meeting, Buenos Aires, Argentina. November, 2000.

52. Freedman MS, Matusevicius D, Kumar A and Filion LG. Immunological correlates of

disease progression: The role of monocyte IL-12 secretion and co-stimulatory molecule expression. Neurology 56 Supp 3:A295 (Abstract P04.136).

53. Freedman MS on behalf of the PRISMS study group. Disability progression in RRMS:

treatment effect and functional system determinants of change in PRISMS-4. Neurology. 56 Supp 3:A360 (Abstract P05.119).


54. Pon RA and Freedman MS. Probing the biological role of CNS and blood derived T cells

in MS pathogenesis: Application of a T cell immortalisation technique using Herpesvirus saimiri. International Society for Neuroimmunology Meeting, Edinburgh, Scotland, September 2001. J Neuroimmunol. 118:Abstract #249, p.86, 2001.

55. Murzenok PP and Freedman MS. CCR5 expression and Herpes virus Saimiri

Transformation of T cells in Multiple Sclerosis patients. International Society for Neuroimmunology Meeting, Edinburgh, Scotland, September 2001. J Neuroimmunol. 118:Abstract # 33, p.18, 2001.

56. Matusevicius D, Murzenok P and Freedman MS. Chemokine production and chemokine

receptor expression by and T cell lines generated from blood and CSF of Multiple Sclerosis patients. International Society for Neuroimmunology Meeting, Edinburgh, Scotland, September 2001. J Neuroimmunol. 118:Abstract # 34, p.18, 2001.

57. Green M and Freedman MS. T cell-mediated cytotoxicity in multiple sclerosis (MS):

Comparison of cytotoxic mechanisms between peripheral blood and cerebrospinal fluid derived cells. Platform presentation at the International Society for Neuroimmunology Meeting, Edinburgh, Scotland, September 2001. J Neuroimmunol 118:Abstract #252, p.86, 2001.

58. Filion GL, Matusevicius D and Freedman MS. Monocyte-derived cytokines: Correlation

with disease stage and response to treatment with interferon-. International Society for Neuroimmunology Meeting, Edinburgh, Scotland, September 2001. J Neuroimmunol. 118:Abstract #286, p.97, 2001.

59. Freedman MS on behalf of the OWIMS study group. Three-year results of weekly

interferon in RRMS. ECTRIMS meeting, Dublin, Ireland, September, 2001. Mult Scler. (Suppl 1.)

60. Freedman MS. Bone marrow transplantation in MS: the rationale for the Canadian study.

ECTRIMS meeting, Dublin, Ireland, September, 2001. Mult Scler. (Suppl 1.)

61. Green MLD, Matusevicius D and Freedman MS. IFN- (Avonex) treatment alters the expression of killer inhibitory receptors (KIR) on MS T cells. ECTRIMS meeting, Dublin, Ireland, September, 2001. Mult Scler. 7 (Supplement 1): S99 [Abstract P327], 2001.

62. Matusevicius D, Green MLD and Freedman MS. IFN- (Avonex) treatment modulates

cytokine profile produced by T cells. ECTRIMS meeting, Dublin, Ireland, September, 2001. Mult Scler 7 (Supplement 1): S99 [Abstract P326], 2001.

63. Li D, O'Connor P, Freedman MS, Bar-Or A, Rice G, Confavreux C, Paty D, Stewart J,

Fourre J, Saoud J, Styren S, Scheyer R. Oral teriflunomide is safe and effective in multiple sclerosis with relapses: results of a randomized, placebo controlled phase II study. Teriflunomide Multiple Sclerosis Trial Group. ECTRIMS meeting, Dublin, Ireland, September, 2001.

64. Atkins H, Freedman MS, Bowman MJ, Antel J, Arnold D, Bar-Or A, Bence-Bruckler I,

Cheynier R, Duquette P, Huebsch L, Laneuville P, Lapierre Y, Messner H, O’Connor P, and RP Sekaly. Targeting multiple sclerosis with intensive immunoablative therapy and immunological reconstitution. Hematopoietic stem cell therapy in autoimmune diseases, City of Hope National Medial Center, Duarte CA, October, 2001.


65. Freedman MS and the PRISMS study group. Evidence of an early dose effect of interferon-1a on relapse-free outcomes. American Academy of Neurology, Denver, CO, April, 2002. Neurology. 58(Suppl 3):A456, P06.076, 2002.

66. Freedman MS, Atkins HL, Arnold D, Bowman MJ, and the Canadian MS BMT study

group. Reduction in gadolinium enhancing lesions and clinical stability in Multiple Sclerosis patients receiving a combination of cyclophosphamide and filgrastim (G-CSF) in preparation for stem cell mobilization. Presented at the American Academy of Neurology, Denver, CO, April, 2002. Neurology. 58(Suppl 3):A457, P06.077, 2002.

67. Freedman MS, Atkins HL, Bowman MJ and the Canadian MS BMT Study Group. High

intensity immunosuppression with autologous stem cell transplantation: a treatment for aggressive Multiple Sclerosis. Presented at the Canadian Congress of Neurological Sciences, Vancouver, June 2002. Can J Neurol Sci.

68. Freedman MS, Edan G, Hartung H-P, Kappos L, Miller D, Montalban X, Polman C,

Barkhof F, Bauer L, Ghazi M, Sandbrink R. Betaferon®/Betaseron

® (interferon beta-1b) in

early treatment of multiple sclerosis: the BENEFIT study. Presented at the ACTRIMS/ECTRIMS Meeting, Baltimore MD, Sept. 2002.

69. Freedman MS, Atkins HL, Bowman MJ and the Canadian MS BMT Study Group. High

intensity immunosuppression with autologous stem cell transplantation: a treatment for aggressive Multiple Sclerosis. Presented at the 55

th Annual Meeting of the American

Academy of Neurology, Honolulu, Hawaii. Neurology 60:5(Suppl 1):A85, 2003. (S11.006).

70. Freedman MS, Edan G, Hartung H-P, Kappos L, Miller D, Montalban X, Polman C, Barkhof F, Bauer L, Ghazi M, Sandbrink R. Betaferon

®/Betaseron

® (interferon beta-1b) in

early treatment of multiple sclerosis: the BENEFIT study. Presented at the 55th

Annual Meeting of the American Academy of Neurology, Honolulu, Hawaii. March, 2003. Neurology. 60:5(Suppl 1):A483. March 11, 2003. (P06.114).

71. Freedman MS, Abdalla J, Forrestal F, for the SPECTRIMS Investigators. A multicentre,

randomised, double-blind, placebo-controlled, phase III study of subcutaneous Rebif

in the treatment of secondary progressive multiple sclerosis – 6-year results. European Neurological Society, Istanbul, Turkey. J Neurol. 250 (Suppl 2):142. May, 2003. (P537).

72. Greenway DC, Cheung P, Freedman MS. Oligoclonal bands determination in CSF by

isoelectric focusing using a commercial kit method (HELENA IgG-IEF). Canadian Society for Clinical Chemistry. 2003.

73. Atkins H, Freedman MS, Bar-Or A, Farzaneh J, Ho Jo K, Chen J, Sekaly, Cheynier R, Jalili

F, Chen J, Corsini and the Canadian MS/BMT Study Group. Immune events following immunoablative therapy for the treatment of Multiple Sclerosis (MS). Poster presentation. International Bone Marrow Transplant Registry Meeting. February 2004.

74. Kuhlmann T, Metz I, Brück W, Jansen G, Freedman MS, Atkins HL. A case report:

Histopathology of MS lesions after high-dose chemotherapy and haematopoietic stem cell rescue. Poster presentation. American Academy of Neurology 56

th Annual Meeting. April

27, 2004.

75. Chen JT, Arnold DL, Freedman MS, Atkins HL. The Canadian MS BMT Study Group. The impact of immunoablation with autologous stem cell transplant on lesion remyelination and demyelination in aggressive multiple sclerosis. Poster presentation. American Academy of Neurology 56

th Annual Meeting. April 28, 2004.


76. Freedman MS, Atkins HL, Bowman MJ, Bar-Or A, Arnold DL. The Canadian MS BMT

Study Group. Immune system regeneration following immunoablative therapy and autologous stem cell transplantation for multiple sclerosis. Poster presentation. American Academy of Neurology 56

th Annual Meeting. April 29, 2004.

77. Bar-Or A, Kim HJ, Corsini R, Gauchat D, Cheynier R, Rafick P Sekaly, Atkins HL,

Freedman MS, Jalili F, Bowman M, Théorêt G and the Canadian MS/BMT Study Group. Immune reconstitution in patients with aggressive multiple sclerosis (MS) treated with immune ablation and autologous hemapoeitic stem cell transplant (HSCT). European Neurological Society (ENS) meeting, Barcelona, Spain, June 2004.

78. Goodman A, Bar-Or A, Miller D, Panzara M, Rossman H, Schmierer M, GLANCE

Investigators*. A double-blind, randomized, placebo-controlled, parallel-group safety study of natalizumab (Antegren) in combination with glatiramer acetate (Copaxone) in subjects with relapsing-remitting multiple sclerosis. European Neurological Society (ENS) meeting, Barcelona, Spain, June 2004.

79. Kappos L, Radue EW, Antel J, Comi G, Montalban X, O’Connor P, Bettoni-Ristic O, Korn

A, Hiestand P, Foster CA, FTY720D2201 Study Group*. FTY720: A novel immunomodulator under clinical investigation in multiple sclerosis. European Neurological Society (ENS) meeting, Barcelona, Spain, June 2004.

80. Kappos L, Sandberg-Wolheim M, Uitdehaag B, Erälinna, Traboulsee A, Li D, Forrestal F,

Abdalla J., The PRISMS Study Investigators*. Long-term outcomes of patients treated with IFN beta-1a compare favourably to natural history: 8-year follow-up of the PRISMS cohort. European Neurological Society (ENS) meeting, Barcelona, Spain, June 2004.

81. Li D, O'Connor P, Freedman MS, Bar-Or A, Rice G, Confavreux C, Paty D, Stewart J,

Fourre J, Saoud J, Styren S, Scheyer R on behalf of the Teriflunomide Multiple Sclerosis Trial Group. Oral teriflunomide is safe and effective in multiple sclerosis with relapses: results of a randomised, placebo-controlled phase II study. Poster Presentation 20

th Congress

of the European Committee for Treatment and Research in Multiple Sclerosis. 9th

Annual Meeting of Rehabilitation in MS. Vienna, October 6-9, 2004.

82. Chen J, Narayanan S, Arnold D, Freedman MS, Atkins H and the Canadian MS BMT Study

Group. The effect of immunoablation with autologous stem cell transplantation therapy on dynamic changes of magnetisation transfer ratio in multiple sclerosis patients. Poster Presentation 20

th Congress of the European Committee for Treatment and Research in

Multiple Sclerosis. 9th

Annual Meeting of Rehabilitation in MS. Vienna, October 6-9, 2004.

83. Krupp L, Banwell B, Boiko A, Eraksoy M, Freedman MS, Pohl D, Reder A, Tenembaum S. Treatment of childhood and adolescent MS with interferon-beta-1b. ECTRIMS. Vienna, October 2004.

84. Banwell B, Tellier R, Krupp L, Bar-Or A, Kennedy J, Tenembaum S, Belman A, Ness J,

Hahn J, Waubant E, Mah J, Stoian C, Rensel M, Farrell K, Freedman MS, Bhan V, Dilenge M, Ruggieri M, Iivanainen M, Weinstock-Guttman B, Boiko A. Viral exposures in pediatric multiple sclerosis: Preliminary data from a multinational collaborative study. Poster presentation at the 20


Multiple Sclerosis ECTRIMS. October 2004.

85. Uitdehaag, BMJ, Kappos L, Bauer L. Freedman MS, Miller D, Sandbrink R, Polan CH. Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of MS.


Poster presentation at the 20th

Congress of the European Committee for Treatment and Research in Multiple Sclerosis ECTRIMS. October 2004.

86. Costello F, Coupland S, Zackon D, Lorello G, Koroluk J, Freedman MS. Measurement of

axon loss in optic neuritis with optical coherence tomography. Poster presentation at the 20th

Congress of the European Committee for Treatment and Research in Multiple Sclerosis ECTRIMS. October 2004.

87. Karussis D, Freedman MS, Fazekas F. On behalf of the International Working Group for

Treatment Optimization in MS. A recommended treatment algorithm in relapsing multiple sclerosis. Poster presentation at the 20

th Congress of the European Committee for Treatment

and Research in Multiple Sclerosis ECTRIMS. October 2004.

88. Freedman MS. On behalf of the PRISMS Study Group. Utility of treatment optimization recommendations applied to clinical trial data: Results from the PRISMS Study. Poster presentation at the 20


Multiple Sclerosis ECTRIMS. October 2004.

89. Uitdehaag B, Kappos L, Bauer L, Freedman MS, Miller D, Sandbrink R, Polman C. A standardized approach to assess the contribution of clinical findings to the diagnostic criterion of dissemination in space in first clinical events suggestive for MS. American Academy of Neurology Annual Meeting. April 2005.

90. Banwell B, Tellier R, Krupp L, Bar-Or A, Kennedy J, Tenembaum S, Boiko A, Bykova O,

Belman A, Mah J, Stoian C, Ness J, Rensel M, Hahn J, Weinstock-Guttman B, Yeh A, Waubant E, Farrell K, Freedman MS, Bhan V, Dilenge M, Iivanainen M, Kremenchutzky M, Ruggieri M. Viral exposures in pediatric multiple sclerosis: Preliminary data from a multinational collaborative study. Poster presentation at the American Academy of Neurology Annual Meeting. April 2005.

91. Chen, JT, Collins DL, Arnold D, Freedman MS, Atkins HL. Evidence for acute brain

pseudo-atrophy after treating MS with immunoablation followed by autologous stem cell transplantation. American Academy of Neurology Annual Meeting. April 2005.

92. Tenembaum S, Banwell B, Boiko A, Eraksoy M, Freedman MS, Krupp L, Pohl D, Reder A,

Schelensky L, Antonijevic I. Treatment of Childhood and Adolescent Multiple Sclerosis with Interferon Beta-1b. Poster Presentation at the American Academy of Neurology Annual Meeting. April 2005.

93. Freedman MS, Forrestal FG, on behalf of the PRISMS Study Group, Geneva, Switzerland.

Treatment optimization recommendations (TOR) can predict relapse rates in patients with MS: Analysis of the PRISMS study data. American Academy of Neurology Annual Meeting. April 2005.

94. Freedman MS, Atkins HL, Théorêt G & the Canadian MS BMT Study Group.

Immunoablation followed by autologous stem cell transplantation as a treatment for aggressive multiple sclerosis: 3 year follow-up of the first 6 patients. American Academy of Neurology Annual Meeting. April 2005.

95. Lopez-Amaya C, O’Connor K, Kopel L, Fattahie R, Moore N, Gano D, Fournier A,

Moscarello M, Banwell B, Kennedy J, Krupp L, Tenembaum S, Boiko A, Bykova O, Belman A, Mah J, Stoian C, Ness J, Rensel M, Hahn J, Weinstock-Guttman B, Yeh A, Waubant E, Farrell K, Freedman MS, Bhan V, Dilenge M, Iivanainen M, Kremenchutzky M, Ruggieri


M, Bar-Or A. Anti-myelin antibodies in pediatric MS. Poster presentation at the American Academy of Neurology Annual Meeting. April 2005.

96. Chen

JT, Narayanan S, Collins DL, Freedman MS, Atkins HL, the Canadian MS BMT

Study Group, Arnold DL. All enhancing voxels are not equal: quantifying destruction and repair within gadolinium-enhancing lesions in multiple sclerosis. International Society for Magnetic Resonance in Medicine.

97. Uitdehaag B, Kappos L, Bauer L, Freedman MS, Miller D, Sandbrink R, Polman C. A

standardized approach to assess the contribution of clinical findings to the diagnostic criterion of dissemination in space in first clinical events suggestive for MS. Poster Presentation at the American Academy of Neurology Annual Meeting. April 2005.

98. Freedman MS, Polman C, Kappos L, Edan G, Hartung H-P, Miller D, Montalban X,

Uitdehaag B, Barkhof F, Bauer L, Sandbrink R. The BENEFIT Study: Betaseron

in newly emerging MS for initial treatment. Poster Presentation. Consortium for Multiple Sclerosis Centers. Orlando, Florida. June 2005.

99. Desjardins O, Piwko C, Bereza B, Gordon A, Devonshire V, Freedman MS, Ursell M,

Vicente C, Iskedjian M, Jaszewski B, Einarson TV, Gagni A. Development and pre-testing of a willingness-to-pay instrument for a treatment for pain in Multiple Sclerosis. Poster Presentation. CAHSPR Conference. Montréal, Québec. September 2005.

100. Kappos L, Polman C, Freedman MS, Edan G, Hartung H-P, Miller D, Montalban X,

Barkhof F, Bauer L, Jakobs P, Sandbrink R for the BENEFIT Study Group. Betaferon

in newly emerging multiple sclerosis for initial treatment (BENEFIT): Clinical Results. Poster Presentation. ECTRIMS. Thessaloniki, Greece. September 2005.

101. Nielsen J, Korteweg T, Uitdehaag B, Barkhof F, Edan G, Freedman MS, Hartung H-P,

Kappos L, Miller D, Montalban X, Polman C, Bauer L, Pohl C, Wagner K, Sandbrink R. Validation of the clinical classification scheme using MRI in the BENEFIT Study. Poster Presentation. ECTRIMS. Thessaloniki, Greece. September 2005.

102. Théorêt G, Bowman M, Freedman MS, Atkins HL. Quality of Life in MS patients receiving

high intensity immunoablation followed by autologous stem cell rescue in MS: Effect on quality of life. Poster #367. ECTRIMS. Thessaloniki, Greece. September 2005.

103. Chen JT, Kuhlmann T, Jansen GH, Collins DL, Freedman MS, Atkins HL, Bar-Or A,

Arnold DL and the Canadian MS/BMT Study Group. Histopathological confirmation of voxel-based analysis of in vivo magnetization transfer ratio images to assess remyelination and demyelination following acute focal demyelination in multiple sclerosis. Poster Presentation. Poster #536. ECTRIMS. Thessaloniki, Greece. September 2005.

104. Freedman MS. Combinations of treatments. Platform Presentation. ECTRIMS.

Thessaloniki, Greece. September 2005.

105. Freedman MS. Algorithm: Evidence-based medicine and therapy selection to MS. Platform Presentation. ECTRIMS. Thessaloniki, Greece. September 2005.

106. Freedman MS. BENEFIT: Implications for patient welfare. Platform Presentation.

ECTRIMS. Thessaloniki, Greece. September 2005.

107. Freedman MS, Laks J, Dotan N, Schwarz M, Weishaus O, Dukler A, Miller A, Sindic C. Anti-Glc(alpha 1,4)Glc(alpha)IgM antibodies for predicting the development of relapsing-


remitting multiple sclerosis after the first neurological event. Poster #678. ECTRIMS. Thessaloniki, Greece. September 2005.

108. Vollmer T, Panitch H, Dunn S, Lublin FD, O’Connor PW, Bar-Or A, Freedman MS, Hendin

B, Gazda S, Campagnolo D, Shi F. Induction treatment with Mitoxantrone (Novantrone

) preceding treatment with glatiramer acetate (Copaxone

) a multi-centre, randomized, two-

arm, open-label study in RRMS patients. Poster #342. ECTRIMS. Thessaloniki, Greece. September 2005.

109. Barkhof F, Polman C, Radü E-W, Kappos L, Freedman MS, Edan G, Hartung H-P, Miller

DH, Montalban X, Bauer L, Dahms S, Sandbrink R. On behalf of the BENEFIT Study Group. Betaferon

in newly emerging multiple sclerosis for initial treatment (BENEFIT):

Magnetic resonance imaging outcomes. Poster #583. ECTRIMS. Thessaloniki, Greece. September 2005.

110. Freedman MS, Forrestal FG. On behalf of the PRISMS Study Group. Treatment

optimization recommendations can predict disease breakthrough in patients with MS on disease modifying drugs: Analysis of the PRISMS Study Data. Poster #585. ECTRIMS. Thessaloniki, Greece. September 2005.

111. MacLean H, Freedman MS, Atkins HL, Costello F, Demeulemeester C, Rabinovitch H,

Denis L, Gagnon N. Mitoxantrone in severe relapsing MS: A phase IV experience in 81 patients attests to its safety and efficacy. Poster #646. ECTRIMS. Thessaloniki, Greece. September 2005.

112. Freedman MS, Forrestal FG, on behalf of the PRISMS Study Group. Recommendations for

treatment optimization (TOR) can predict disease breakthrough in patients with MS on treatment: Analysis using the PRISMS Study data. XVIII

th World Congress of Neurology.

Sydney, Australia. November 2005.

113. Kappos L, Freedman MS, Edan G, Hartung HP, Miller D, Montalban X, Barkhof F, Bauer L, Jakobs P, Pohl C, Sandbrink R for the BENEFIT Study Group. Betaseron in newly emerging multiple sclerosis for initial treatment (BENEFIT): Subgroup Anaylses. S02.002. AAN 58

th Annual Meeting. San Diego, USA. April 4, 2006.

114. Chen JT, Freedman MS, Atkins HL, Narayanan S, Arnold D. Immunoablation and

autologous hematopoietic stem cell transplantation may enhance remyelination in acute multiple sclerosis lesions. Platform Presentation. AAN 58

th Annual Meeting. San Diego,

USA. P02.098. April 7, 2006.

115. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, Montalban X, Bauer L, Pohl C, Sandbrink R for the BENEFIT Study Group. Betaseron

® in newly emerging

multiple sclerosis for initial treatment (BENEFIT): Safety, tolerability and adherence outcome. P01.073. AAN 58

th Annual Meeting. San Diego, USA. April 7, 2006.

116. Freedman MS, Kappos L, Polman CH, Edan G, Hartung H-P, Miller D, Montalban X, Bauer

L, Pohl C, Sandbrink R for the BENEFIT Study. Safety, tolerability and adherence to treatment in the BENEFIT Trial. Platform Presentation. CMSC. Scottsdale, AZ. June 2006.

117. Fazekas F, Freedman MS, Hartung H-P, Li D, Lublin F, Rickmann P, Soelberg-Sørensen P,

Maas-Enriquez M, Sommerauer B, Anderesi M. Prevention of relapse with intravenous immunoglobulin study: Initial results of a dose-finding trial in relapsing-remitting multiple sclerosis. Platform Presentation. CMSC. Scottsdale, AZ. June 2006.


118. Freedman MS. Efficacy of up to 8 years of subcutaneous interferon bera-1a treatment in

multiple sclerosis. Poster Presentation. CMSC. Scottsdale, AZ. June 2006.

119. Freedman MS, Kappos L, Polman C, Edan G, Hartung H-P, Miller D, Montalban X, Bauer L, Polh C, Sandbrink R, the BENEFIT Study Group. Safety, tolerability and adherence to treatment in BENEFIT Trial. Poster Presentation. CMSC. Scottsdale, AZ. June 2006.

120. Freedman MS. Early and long-term data: Implications for patient welfare. Poster

Presentation. LACTRIMS. Margarita Island, Venezuela. June 29, 2006.

121. Kappos L, Polman CH, Freedman MS, Edan G, Hartung H-P, Miller D, Montalban X, Barkhof F, Bauer L, Dahms S, Pohl C, Sandbrink R for the BENEFIT Study Group. Betaferon in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT): Clinical outcomes. ENS. Lausanne. September 2006.

122. Kappos L, Polman CH, Freedman MS, Edan G, Hartung H-P, Miller D, Montalban X,

Barkhof F, Bauer L, Dahms S, Pohl C, Sandbrink R for the BENEFIT Study Group. Betaferon in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT): Subgroup analyses. ENS. Lausanne. September 2006.

123. Fazekas F, Freedman MS,

Hartung, Li D,

Lublin F, Rieckmann P, Soelberg-Sørensen P,

Maas-Enriquez M, Sommerauer B,

Anderesi M. Prevention of Relapse With Intravenous

Immunoglobulin Study: Initial Results of a Dose-Finding Trial in Relapsing-Remitting Multiple Sclerosis. ENS. Lausanne. September 2006.

124. Kappos L, Polman CH, Freedman MS, Edan G, Hartung H-P, Miller D, Montalban X,

Barkhof F, Bauer L, Dahms S, Pohl C, Sandbrink R for the BENEFIT Study Group. Betaferon in newly emerging multiple sclerosis for initial treatment (BENEFIT): Clinical outcomes. European Federation of Nurological Sciences. Glasgow. September 4, 2006.

125. Freedman MS. Maximising the benefits of MS treatment: Early intervention with high-

efficacy IFH beta therapy. SCHERING Satellite Symposium. ECTRIMS 2006. Madrid. September 2006.

126. Walker L, Smith A, Freedman MS, DeMeulemeester C. Differential fMRI activation

paterns on the computerised tests of information processing (CTIP) in patients with multiple sclerosis with low expanded disability status scale scores. Poster Presentation. ECTRIMS 2006. Madrid. September 28, 2006.

127. Smith A, Walker L, Freedman MS, DeMeulemeester C. Differential fMRI activation

patterns on a response inhibition task in patients with multiple sclerosis with low expanded disability status scale scores. Poster Presentation. ECTRIMS 2006. Madrid. September 29, 2006.

128. Chen JT, Collins DL, Freedman MS, Atkins HL, Arnold DL. Detection of subpial

demyelination in vivo: Methodology and evaluation in normal subjects and patients with multiple sclerosis. Poster Presentation. ECTRIMS 2006. Madrid. September 29, 2006.

129. Metz L, Lucchinetti CF, Openshaw H, Garcia-Merino A, Lassmann H, Freedman MS,

Azzarelli B, Kolar OJ, Atkins HL, Brück W. Multiple sclerosis pathology after autologous stem cell transplantation: ongoing demyelination and neurodegeneration despite suppressed inflammation. ECTRIMS 2006. Madrid. September 2006.


130. Vollmer T, Panitch H, Freedman MS, Gasda SK. Bar-Or A, Arnold DL. Short term induction with mitoxantrone preceding treatment with glatiramer acetate offers early and pronounced effects on MRI-disease activity in patients with relapsing forms of multiple sclerosis. ECTRIMS 2006. Madrid. September 2006.

131. Kuhle J, Kappos L, Pohl C, Mehling M, Edan G, Freedman MS, Hartung H-P, Miller DH,

Montalbán X, Polman C, Barkhof F, Bauer L, Dahms S, Lindberg RLP, Sandbrink R. Prognostic relevance of antimyelin antibodies for progression to multiple sclerosis after a first demyelinating event: Results from the BENEFIT Study. ECTRIMS 2006. Madrid. September 2006.

132. Costello F, Eggenberger E, Demeulemeester C, Coupland S, MacLean H, Rabinovitch H,

Freedman MS, Pan I, Hodge W. Comparison of retinal nerve fibre layer measurements and visual function among patients with multiple sclerosis. ECTRIMS 2006. Madrid. September 2006.

133. Freedman MS. Treat early, treat right: Optimising MS therapy. ECTRIMS 2006. Madrid.

September 2006.

134. O’Connor P, Li D, Freedman MS, Bar-Or A, Rice G, Confavreux C on behalf of the Teriflunomide Multiple Sclerosis Trial Group. Oral teriflunomide is effective and well tolerated in multiple sclerosis with relapses: results of an open-label 144-week extension study. ECTRIMS 2006. Madrid. September 2006.

135. Tombaugh TN, Reicker LI, Walker L, Freedman MS. Alternatives to the PASAT for

measuring speed of information processing in multiple sclerosis patients: the Adjusting-PASAT and the computerised tests of information processing. ECTRIMS 2006. Madrid. September 2006.

136. Reicker LI, Tombaugh TN, Freedman MS, Walker L. Reaction time: A viable alternative

for assessing processing speed in multiple sclerosis. ECTRIMS 2006. Madrid. September 2006.

137. Freedman MS, Miller A, Schwarz M, Weisshaus O, Altstock RT, Dukler A, Dotan N,

Sindic C. A panel of anti-blycan IgM antibodies for predicting the development of relapsing-remitting multiple sclerosis after the first neurological event. ECTRIMS 2006. Madrid. September 2006.

138. Soucy N, Cardinal K, Theoret G, MacLean H, Freedman MS. Double dose interferon-beta-

1b (500mcg) re-establishes efficacy and lowers neutralising antibodies in patients with breakthrough of multiple sclerosis disease on standard high-dose interferon-beta therapy. ECTRIMS 2006. Madrid. September 2006.

139. Polman C, Kappos L, Freedman MS, Edan G, Hartung H-P, Miller DH, Montalbán X,

Barkhof F, Bauer L, Dahms S, Pohl R, Sandbrink R for the BENEFIT Study. Difference in natural history and treament effect of interferon-beta-1b in CIS patients with mono- vs. multifocal presentations: subgroup analysis of the BENEFIT Study. ECTRIMS 2006. Madrid. September 2006.

140. BENEFIT study group*. Betaseron in newly emerging multiple sclerosis for initial

treatment (BENEFIT): Disability outcomes. Poster Presentation. Poster #M-10. ANA 131st

Annual Meeting. Chicago, IL. October 2006.


141. O’Connor PW, Li D, Freedman MS, Rice GP, Confavreux C, Teriflunomide Multiple Sclerosis Trial Group. Oral teriflunomide is effect and well tolerated in multiple sclerosis with relapses: Results of an open-label 144-week extension study. ANA 131

st Annual

Meeting. Chicago, IL. October 2006.

142. O’Connor KC, McLaughlin KA, De Jager PL, Chitnis T, Bar-Or A, Banwell B, Fukaura H, Tenembaum S, Wong SL, Tavakoli NP, Rosatasy K. Dale RC, Freedman MS, Rwucherpgennig KW, Hafler DA. Autoantibodies recognizing myelin oligodendrocyte glycoprotein are rarely present in the serum of CSF of patients with multiple sclerosis. ANA 131

st Annual Meeting. Chicago, IL. October 2006.

143. Arnold DL, Bar-Or A, Freedman MS, Gazda S, Panitch H, Vollmer T. Reductions in Gd

enhancing lesions observed with glatiramer acetate following a brief and low dose course of mitoxantrone in patients with relapsing remitting multiple sclerosis (RRMS) are paralleled by favorable effects on MRI markers of disease burden and black hole evolution. Poster Presentation. P06-104. 59

th AAN. Boston, MA. April 2007.

144. Bar-Or A, Gibbs E, Masaaki N, Aziz T, Alatab S, Dong Shi F, Campagnolo D, Jalili F,

Freedman MS, Panitch H, Arnold D, Arnold D, Vollmer T, Oger J. Tracking in vivo immune modulation in MS patients treated with glatiramer acetate (GA) alone, or with GA preceded by mitoxantrone, provides novel insights into the mode of action of therapeutic strategies that combine immune suppression and immune deviation. Poster presentation. P01-046. 59


145. Freedman MS, Polman C, Kappos L, Edan G, Hartung H-P, Miller D, Montalban X,

Barkhof F, Bauer L, Dahms S, Pohl C, Sandbrink R. Betaseron® in newly emerging multiple

sclerosis for initial treatment (BENEFIT): Effects of immediate vs early onset of interferon beta-1b treatment. Scientific Platform. S02-004. 59


146. Edan G, Barkhof F, Freedman MS, Hartung H-P, Kappos L, Miller D, Montalban X,

Polman C, Bauer L, Pohl C, Sandbrink R. The BENEFIT Study: Characteristics of placebo-treated patients with a clinically isolated syndrome who do not show any further disease activity over 2 years. Scientific Platform. S22-006. 59


147. McLaughlin KA, O’Connor KC, DeJager P, Chitnis T, Bettelli E, Xu C, Robinson W, Cherry

SV, Bar-Or A, Banwell B, Fukaura H, Tenembaum S, Wong S, Tavakoli NP, Idrissova Z, Viglietta V, Rostasy K, Pohl D, Dale RC, Freedman MS, Steinman L, Khoury S, Weiner H, Kuchroo VK, Wucherpfennig DH. Autoantibodies to myelin oldigodendrocyte glycoprotein in human demyelinating diseases. Scientific Platform. S26-003. 59

th AAN. Boston, MA.

April 2007.

148. Chen JT, Freedman MS, Atkins HL, Arnold D. A controlled study of the acute effect of immunoablation and autologous hematopoietic stem cell transplantation on changes in brain volume, axonal integrity, myelin and parenchymal water in multiple sclerosis. Scientific Platform. S42-008. 59


149. Stewart A, Walker L, Freedman MS, DeMeulemeester, Smith A. A prospective

investigation of cognitive deficits in patients with multiple sclerosis: A pilot study. Poster presented at the annual meeting of the Canadian Psychological Association, Ottawa, ON. June 2007.

149.150. Kappos L, Freedman MS, De Stefano N, Labauge P, Comi G, Strubinski B on behalf of

the REFLEX Study Group. REFLEX: A phase III trial to assess the effect of dosing frequency of interferon beta-1a (Rebif

®) in delaying conversion of patients with a clinically


isolated syndrome to clinically definite multiple sclerosis. Poster Presentation. 17th

Meeting of the European Neurological Society. Rhodes, Greece. June 2007.

150.151. Kappos L, Edan G, Freedman MS, Hartung H-P, Miller D, Montalban X, Polman C,

Barkhof F, Bauer L, Lanius V, Pohl C, Sandbrink R. The BENEFIT Study: Characteristics of patients with potentially benign multiple sclerosis. Poster Presentation. 17

th Meeting of the

European Neurological Society. Rhodes, Greece. June 2007.

151.152. Freedman MS. Use of DMD’s in clinical practice. MS Preceptorship: Updating knowledge on multiple sclerosis. Barcelona, Spain. June 2007.

152.153. Freedman MS, Atkins HL, Arnold D, Bar-Or A and the Canadian BMT Study Group.

Immune ablation and autologous stem cell transplantation for aggressive multiple sclerosis: Interim 5-year report. Prague. ECTRIMS 2007. Poster Presentation. Poster No. 452. October 11-14, 2007.

153.154. Edan G, Freedman MS, Hartung H-P, Kappos L, Miller DH, Montalbán X, Polman CH,

Bauer L, Lanius V, Pohl C, Sandbrink R for the BENEFIT Study Group. Adherence, tolerability and quality of life: interferon beta-1b therapy over 3 years in patients with a first event suggestive of multiple sclerosis. Prague. ECTRIMS 2007. Poster Presentation. October 11-14, 2007.

154.155. Kappos L, Freedman MS, Polman CH, Edan G, Hartung H-P, Miller D, Montalbán X,

Barkhof F, Radü E-W, Bauer L, Lanius V, Dahms S, Pohl C, Sandbrink R for the BENEFIT Study Group. Early versus delayed interferon beta-1b treatment in patients with a first event suggestive of MS: the impact on progression of disability. Prague. ECTRIMS 2007. Poster Presentation. October 11-14, 2007.

155.156. Freedman MS, Edan G, Hartung H-P, Kappos L, Miller DH, Montalbán X, Polman CH,

Bauer L, Lanius V, Pohl C, Sandbrink R for the BENEFIT Study Group. The Betaferon® in Newly Emerging multiple sclerosis For Initial Treatment (BENEFIT) studies: neutralising antibodies did not affect clinical outcomes after 3 years. Prague. ECTRIMS 2007. Poster Presentation. October 12, 2007.

156.157. Freedman MS, Atkins HL, Arnold D, Bar-Or A on behalf of the Canadian BMT Study

Group. Immune ablation and autlogous stem cell transplantation for aggressive multiple sclerosis: Interim 5-year report. Prague. ECTRIMS 2007. 124

th Annual Meeting of

Rehbilitation in MS. Oral Presentation. October 11-14, 2007.

157.158. Kappos L, Comi G, De Stefano N, Freedman MS. Rebif new formulation in patients at risk of converting to multiple sclerosis: A phase III, double blind, placebo-controlled, multicentre trial. Prague. ECTRIMS 2007. Poster Presentation. October 11-14, 2007.

158.159. Hawker K, Freedman MS, O’Connor P, Calabresi P, Antel J-P, Panitch H, Simon J,

Hauser S, Sarkar N. Agarwal S, Langer-Gould A, Smith C. Rituximab in patients with primary progressive multiple sclerosis: Demographics in a Phase II/III randomised, double-blind, placebo-controlled multicentre trial. Prague. ECTRIMS 2007. Poster Presentation. October 11-14, 2007.

159.160. Costello F, Hodge W, Pan I, Coupland S, Demeulemeester C, MacLean H, Rabinovitch

H, Freedman MS. Retinal nerve fibre layer loss after optic neuritis: A prospective study with optical coherence tomography. Prague. ECTRIMS 2007. Poster Presentation. October 11-14, 2007.


160.161. Atkins HL, Freedman MS, Hilliker C, McDiarmid S for the Canadian MSBMT Group. Busulphan dose, regimen-related toxicity and outcome of patients treated with immune ablation and stem cell transplantation. Prague. ECTRIMS 2007. Poster Presentation. October 11-14, 2007.

161.162. Reicker LI, Tombaugh TN, Walker L, Freedman MS. A comparison of methods for

improving the detection of slowed processing speed in multiple sclerosis. 36th

Annual Meeting International Neuropsychological Society. Waikoloa, Hawaii USA. February 2008.

162.163. McFarland H, Lisak R, Panitch H, Rudick MD, Johnson K, Freedman MS, Noseworthy

J, Conwit R, Narayana PA, Utz U, Reingold S, Scott T. Diagnosis criteria and MRI at baseline in Combi-Rx – A preliminary analysis. 60

th AAN. Poster Presentation. April 15,

2008.

163.164. McFarland H, Lisak R, Panitch H, Rudick MD, Johnson K, Freedman MS, Noseworthy J, Conwit R, Narayana PA, Utz U, Reingold S, Scott T. Variability in the EDSS: What does it mean for progression? 60

th AAN. Poster Presentation. April 16, 2008.

164.165. McFarland H, Lisak R, Panitch H, Rudick MD, Johnson K, Freedman MS, Noseworthy

J, Conwit R, Narayana PA, Utz U, Reingold S, Scott T. The modified Rankin score compared to EDSS and MRI measures using CombiRx baseline assessments. 60

th AAN.

Poster Presentation. April 16, 2008.

165.166. Freedman MS, Edan G, Hartung H-P, Kappos L, Miller DH, Montalbán X, Polman CH, Bauer L, Lanius V, Pohl C, Sandbrink R, for the BENEFIT Study Group. Betaseron® treatment after a first event: adherence, tolerability and quality of life. CMSC. Poster Presentation. Denver CO. May 2008.

166.167. Nielsen J, Polman CH, Barkhof F, Freedman MS, Edan G, Kappos L, Miller DH, Bauer

L, Pohl C, Sandbrink R, for the BENEFIT Study Group, Uitdehaag BMJ. The importance of clinically-defined spatial dissemination for prediction of MS risk. CMSC. Platform Presentation. Denver CO. May 2008.

167.168. Siritho S, Freedman MS. What is the natural history of oligoclonal band negative

multiple sclerosis patients? CMSC. Poster Presentation. Poster # S74. Denver CO. May 2008.

168.169. Hartung H-P, Edan G, Freedman MS, Kappos L, Miller DH, Montálban X, Polman CH,

Bauer L, Lanius V, Pohl C, Sandbrink R, for the BENEFIT Study Group. The BENEFIT Studies: Adherence, tolerability and quality of life with Betaferon

® treatment after a first

event suggestive of multiple sclerosis. Poster Presentation. ENS Congress. Nice France. June 2008.

169.170. Hartung H-P, Edan G, Freedman MS, Kappos L, Miller DH, Montálban X, Polman CH,

Bauer L, Lanius V, Pohl CH, Sandbrink R, for the BENEFIT Study Group. Neutralising antibodies do not affect efficacy of Interferon Bera-1b: Further analysis of the Betaferon

® in

newly emerging multiple sclerosis for initial treatment study (BENEFIT). Poster Presentation. ENS Congress. Nice France. June 2008.

170.171. O’Connor PW, Contavreux C, Comi G, Kappos L, Wollinsky JS, Olsson TP, Miller A,

Freedman MS for the Teriflunomide Multiple Sclerosis Trial Group. Oral teriflunomide in patients with relapsing multiple sclerosis: Baseline clinical features of patients in the TEMSO Phase III trial. Poster Presentation. Poster # P193. WCTRIMS. Montréal, QC. September 2008.


171.172. Bastiaan M, Pohl C, Uitdehaag B, Polman C, Edan G, Freedman MS, Hartung H-P,

Kappos L, Miller D, Espejo C, Bauer L, Sandbrink R, Barkhof F. Baseline magnetic resonance imaging predictors for conversion to clinically definite multiple sclerosis and McDonald multiple sclerosis, based on integrated 3-year data from the BENEFIT Study. Parallel Session. WCTRIMS. Montréal QC. September 2008.

172.173. Freedman MS, Atkins HL, Bowman M, for Canadian MS Bone Marrow Transplant

Group. High intensity immunoablation and autologous stem cell treatment for aggressive multiple sclerosis can improve quality of life and fatigue. Poster Presentation. Poster # P46. WCTRIMS. Montréal QC. September 2008.

173.174. Grand’Maison F, Freedman MS, Traboulsee A, Bhan V, Myles M, Patry DG, Selchen D

for the CanTOR investigators. Assessment of the utility of the Canadian Treatment Optimization Recommendations (CanTOR) in the routine care of multiple sclerosis. Poster Presentation. Poster # P54. WCTRIMS. Montréal QC. September 2008.

174.175. Hemmer B, Edan G, Freedman MS, Hartung H-P, Kappos L, Miller D, Montalban X,

Polman CH, Kuhle J, Nessler S, Zhou D, Bauer L, Lanius V, Metzig C, Pohl C, Sandbrink R. Antibodies to native myelin oligodendrocyte glycoprotein do not predict progression from clinically isolated syndrome to multiple sclerosis: Complete analysis of the BEtaferons

® in

Newly Emerging Multiple Sclerosis For Initial Treatment (BENEFIT) Study. Poster Presentation. Poster # P66. WCTRIMS. Montréal QC. September 2008.

175.176. Horga A, Hemmer B, Edan G, Freedman MS, Hartung H-P, Kappos L, Miller D,

Montalban X, Polman CH, Nessler S, Bauer L, Lanius V, Metzig C, Pohl C, Sandbrink R. Antibodies to aquaporin-4 in patients with a clinically isolated syndrome: Analyses from the BENEFIT Study (BEtaferons

® in Newly Emerging Multiple Sclerosis For Initial Treatment).

Poster Presentation. Poster # P67. WCTRIMS. Montréal QC. September 2008.

176.177. Plitz T, Freedman MS, Hartung H-P, Boiko AN, Dahlke F, Kappos L for the ATAMS Study Group. Design of a four-arm, randomized, placebo,-controlled phase II study of 36 weeks of atacicept monotherapy in relapsing multiple sclerosis. Poster Presentation. Poster # P493. WCTRIMS. Montréal QC. September 2008.

177.178. Scherling CS, Smith A, Walker L, Hogan M, Freedman MS. Multiple sclerosis patients

reveal neural compensation during information processing with no additional performance decline: A longitudinal functional magnetic resonance imaging study. Poster Presentation. Poster # P645. WCTRIMS. Montréal QC. September 2008.

178.179. Scherling CS, Smith A, Walker L, Hogan M, Freedman MS. Neural compensation in

cognitively impaired patients with multiple sclerosis during a response inhibition task. Poster Presentation. Poster # P645. WCTRIMS. Montréal QC. September 2008.

179.180. Siritho S, Freedman MS. A comparison of multiple sclerosis patients who have negative

cerebrospinal fluid oligoclonal bands to those with positive testing: Baseline characteristics and prognosis. Poster Presentation. Poster # P881. WCTRIMS. Montréal QC. September 2008.

180.181. Freedman MS, Kappos L, Polman CH, Edan G, Hartung H-P, Miller D, Montalban X,

Barkhof F, Bauer L, Lanius V, Metzig C, Pohl C, Sandbrink R for the BENEFIT Study Group. Impact of early interferon beta-1b treatment on disease evolution over five years in patients with a first event suggestive of multiple sclerosis. Poster Presentation. Poster # P901. WCTRIMS. Montréal QC. September 2008.


181.182. Hawker K, O'Connor P, Freedman MS, Calabresi P, Antel J, Simon J, Hauser S,

Waubant E, Vollmer T, Panitch H, Zhang J, Smith C, Chin P, for the OLYMPUS trial group. Safety and Efficacy of rituximab in Patients with Primary Progressive Multiple Sclerosis: Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial. Poster Presentation. WCTRIMS. Montréal QC. September 2008.

182.183. Chen Z, Freedman M.S. Gamma delta T cells derived from multiple sclerosis patients

mediate antibody dependent cell cytoxicity and potentially regulate humoral immunity. Poster Presentation. International Congress of Neuroimmunology. Fort Worth, Texas. October 26-30, 2008.

183.184. Darlington PJ, Doucet JS, Touil T, Kevir H. Gaucher D, Fawaz L, Zeidan J, Chen J, Jalili

F, Gauchat D, Bowman M, Antel J, Arnold D, Freedman MS, Atkins HL, Sekaly R, Cheynier R, Prat A, Bar-Or A, for the Canadian BMT Study Group. Regulatory NK cells mediate the decreased Th17 responses associated with abrogated new disease activity in MS patients treated with bone marrow transplantation. 61

st AAN Meeting. Seattle WA Poster

Presentation. April 2009.

184.185. Freedman MS, Atkins HL, Bowman M, Canadian BMT Study Group. Neurological recovery following treatment of aggressive MS with immunoablation and autologous stem cell transplantation. 61

st AAN Meeting. Seattle WA Poster Presentation. April 2009.

185.186. Freedman MS, Polman C, Edan G, Hartung H-P, Kappos L, Miller DH, Montalban X,

Metzig C, Lanius V, Pohl C, Sandbrink R. The impact of neutralizing antibodies within 5 years of treatment with interferon beta-1b initiated at the first event suggestive of multiple sclerosis. 61

st AAN Meeting. Seattle WA Poster Presentation. April 2009.

186.187. Hawker K, O’Connor P, Freedman MS, Calabresi P, Antel J, Simon J, Hauser S,

Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH. Efficacy and safety of Rituximab in patients with primary progressive multiple sclerosis (PPMS): Results of a randomized double-blind placebo-controlled multicenter trial. 61

st AAN Meeting. Scientific

Session. Seattle WA April 2009.

187.188. Bowman M, Freedman MS, Atkins HL and the Canadian MS/BMT Study Group. Treatment of aggressive MS with high intensity immunoablation and autlogous stem cell transplant can stabilize or improve disease outcomes without compromising on patient related outcomes. CMSC. Atlanta GA. Poster Presentation. May 2009.

188.189. Chen JT, Atkins HL, Freedman MS, Arnold DL. Pre-treatment predictors of brain

volume changes following immunoablation and haematopoietic stem cell transplantation for treatment of multiple sclerosis. ECTRIMS. Poster Presentation. Dusseldorf, Germany. September 2009.

189.190. Freedman MS, Uccelli A on behalf of the International MSCT Study Group. Exploring

the potential of autologous mesenchymal stem cell transplantation as a treatment for inflammatory forms of multiple sclerosis. ECTRIMS. Oral presentation. September 2009.

190.191. Chen JT, Atkins HL, Freedman MS, Arnold DL. Pre-treatment predictors of brain

volume changes following immunoablation and haematopoietic stem cell transplantation for treatment of multiple sclerosis. ECTRIMS. Poster Presentation. Dusseldorf, Germany. September 2009.


191.192. Freedman MS,A on behalf of the International MSCT Study Group. Exploring the potential of autologous mesenchymal stem cell transplantation as a treatment for inflammatory forms of multiple sclerosis. ECTRIMS. Dusseldorf, Germany. September 2009.

192.193. Freedman MS, Edan G, Hartung HP, Kappos L, Miller D, Montalban X, Polman CH,

Dotan N, Lanius V, Metzig C, Schwenke S, Pohl C, Sandbrink R for the BENEFIT Study Group. Anti-alpha-glucose-based glycan IgM antibodies in patients with a clinically isolated syndrome: analyses from the BEtaferon

® in newly emerging multiple sclerosis for initial

treatment (BENEFIT) study. ECTRIMS. Poster Presentation. Dusseldorf, Germany. September 2009.

193.194. Black J, Freedman MS. Neurofascin immunoreactivity in multiple sclerosis.

ECTRIMS. Poster Presentation. Dusseldorf, Germany. September 2009.

194.195. Wallström E, Selmaj K. Kappos L, Freedman MS, Goodin D, Hartung HP, Montalban X, Hemmer B, Rieckmann P, StüveO, Rochotte E, Grünbauer H, Pohlmann H. Mercier F, Pinheiro J, Leppert D. Reduction of placebo exposure and improved does-finding by an adaptive design and modelling methods, the BAF312 phase II trial for relapsing-remitting multiple sclerosis. ECTRIMS. Poster Presentation. Dusseldorf, Germany. September 2009.

195.196. Grand’Maison F, Bhan V, Freedman MS, Myles JL, Patry D, Selchen D, Traboulsee A.

Assessment of the utility of the Canadian Treatment Optimization Recommendations (CanTOR) in the routine care of multiple sclerosis – final results. ECTRIMS. Poster Presentation. Dusseldorf, Germany. September 2009.

196.197. Freedman MS, Verco T, Ossanna M, Nilsson M, Ferenczi L, Chappell A, Lin D, Arfors

L, Krantz M. A double-blind, placebo-controlled, multi-centre study to evaluate the efficacy and safety of dirucotide in patients with secondary progressive multiple sclerosis. ECTRIMS. Poster Presentation. Dusseldorf, Germany. September 2009.

197.198. Freedman MS, Wolinsky J, Byrnes WJ, Confavreux C, Comi G, Frangin G, Kappos L,

Olsson T, Miller A, O’Connor PW for the Teriflunomide Multiple Sclerosis Trial Group. Oral teriflunomide or placebo added to interferon beta for 6 months in patients with relapsing multiple sclerosis: safety and efficacy results. ECTRIMS. Poster Presentation. Dusseldorf, Germany. September 2009.

198.199. Calabrese P, Penner IK, Freedman MS, Polman C, Edan G, Hartung H-P, Miller D,

Montalban X, Barkhof F, Lanius V, Sandbrink R, Pohl C, Stemper B, Kappos L. Relationship between cognitive performance and neurological disability in early MS. AAN. Poster Presentation. Toronto ON. April 2010.

199.200. Freedman MS, Wolinsky JS, Frangin GA,Confavreux C, Comi G, Byrnes WJ, Kappos

L, Olsson T, Miller A, O’Connor P. Oral Teriflunomide or placebo added to glatiramer acetate for 6 months in patients with relapsing multiple sclerosis: Safety and efficacy results. AAN. Scientific Session. Toronto ON. April 2010.

200.201. Penner IK, Calabrese P, Freedman MS, Polman C, Edan G, Hartung H, Miller D,

Montalban X, Barkhof F, Lanius V, Sandbrink R, Pohl C, Stemper B, Kappos L. Treatment effects of IFNB-1b on cognitive performance in patients with a first event suggestive of MS. AAN. Poster Presentation. Toronto ON. April 2010.


201.202. Cheng A, Walker L, Berrigan L, Smith A, Freedman MS. Longitudinal evaluation of information processing speed for persons with multiple sclerosis. International Neuropsychological Society Meeting. Poster Presentation. Acapulco, Mexico. April 2010.

202.203. Atkins H, Chen J, Bowman M, Arnold D, Freedman MS and the MS-BMT Study

Group. Balancing toxicity and effectiveness: The impact of dose on the central nervous

system (CNS) following autologous stem cell transplantation (ASCT) for multiple sclerosis (MS). Poster Presentation. Canadian Blood & Marrow Transplant Group 2010 Biennial Conference. Vancouver BC. April 2010.

203.204. Freedman MS, Atkins HL, Bowman MJ for the Canadian MS/BMT Study Group. Outcome measurement in patients with aggressive Multiple Sclerosis treated with high intensity immunoablation and autologous stem cell transplantation: Correlation of objective and subjective measures. ACTRIMS 15

th Annual Meeting. San Antonio TX. June 2010.

204.205. Freedman MS, Atkins HL, Bowman MJ for the Canadian MS/BMT Study Group.

Treatment of aggressive MS with high intensity immunoablation and autologous stem cell transplant (IA/ASCT) can stabilize or improve disease outcomes without compromising on patient related outcomes. CNSF. Québec City QC. June 2010.

205.206. Walker LAS, Berrigan L, Rees L, Cheng A, Freedman MS. Self and informant ratings of cognition in MS and healthy controls: Relationship to objective measures. Poster Presentation. Annual Meeting of the National Academy of Neuropsychology. Vancouver BC. October 2010.

206.207. Cognitive change following bone marrow transplant for multiple sclerosis. Bharadia V, Walker LAS, Freedman MS & Atkins HL. Poster presentation. Annual Meeting of the National Academy of Neuropsychology Conference. Vancouver BC. October 2010.

207.208. Confavreux C, O’Connor PW, Freedman MS, Benzerdjeb Wang HS, Bar-Or A for the Teriflunomide Multiple Sclerosis Trial Group. Safety of teriflunomide in the treatment of relapsing multiple sclerosis: Results over an 8-year extension. Poster Presentation. ECTRIMS. Gothenburg Sweden. October 2010.

208.209. Berard J, Walker LAS, Berrigan LI, Cheng A, Rees LM, Freedman MS. Impact of PASAT scoring method when measuring cognitive fatigue in multiple sclerosis. Poster presentation. Annual Meeting of the International Neuropsychological Society. Boston, MA. February 2011.

209.210. Berrigan L, Walker LAS, Rees LM, Cheng A, Freedman MS. Cognitive processing speed is linked to vocational status in individuals with relapsing-remitting multiple sclerosis. Poster presentation. Annual Meeting of the International Neuropsychological Society. Boston, MA. February 2011.

210.211. Rees LM, Walker LAS, Berrigan L, Cheng A, Freedman MS. Learning and memory in

MS: Are difficulties due to acquisition or retrieval of information? Poster presentation. Annual Meeting of the International Neuropsychological Society. Boston, MA. February 2011.

211.212. Cheng A, Walker LAS, Berrigan LI, Rees LM, Freedman MS. Subjective ratings of MS

subjects and healthy controls on tests of information processing speed. Poster presentation. Annual Meeting of the International Neuropsychological Society. Boston, MA. February 2011.


212.213. Comi G, De Stefano N, Freedman MS, Kappos L, Hennessy B, Rocak S, Stubinski B. Efficacy of two dosing frequencies of subcutaneous interferon beta 1-a on risk of conversion to multiple sclerosis in patients with clinically isolated syndrome: Results of a Phase III, randomized, double-blind placebo-controlled, multicenter trial (REFLEX). AAN. Honolulu HI. April 2011.

213.214. De Stefano N, Comi G, Freedman MS, Kappos L, Hennessy B, Lehr L, Stubinski B. Magnetic resonance imaging results from a Phase III, randomized, double-blind, placebo-controlled, multicenter trial of two dosing frequencies of subcutaneous interferon beta-1a in patients with clinically isolated syndrome at high risk of multiple sclerosis (REFLEX). AAN. Honolulu HI. April 2011.

214.215. Foley F, Benedict R, Penner I-K, Kappos L, Edan G, Calabrese P, Freedman MS, Hartung H-P, Miller D, Montalban X, Polman CH, Barkhof F, Lanius V, Beckmann K, Stemper B, Pohl C, Sandbrink R, Pleimes D. Treatment effects of IFNB-1b on paced auditory serial addition test performance in patients with clinically isolated syndrome (CIS). AAN. Honolulu HI. April 2011.

215.216. Kappos L, Comi G, De Stefano N, Freedman MS, Barkhof F, Polman CH, Uitdehaag BMJ, Casset-Semanaz F, Hennessy B, Rocak S, Stubinski B. Efficacy of two dosing frequencies of subcutaneous interferon -1a on risk of conversion from a first demyelinating event to multiple sclerosis: Results of a Phase III, randomized, double-blind, placebo-controlled, multicentre trial (REFLEX). 21

st Meeting of the European Neurological Society

(ENS). Lisbon Portugal. May 2011.

216.217. Comi G, Kappos L, De Stefano N, Freedman MS, Casset-Semanaz F, Hennessy B, Rocak S, Lehr L, Stam Moraga M. Safety of two dosing frequencies of subcutaneous interferon -1a in patients at high risk of conversion to multiple sclerosis: Results of the Phase III, randomized, double-blind, placebo-controlled REFLEX trial. 21

st Meeting of the

European Neurological Society (ENS). Lisbon Portugal. May 2011

217.218. De Stefano N, Comi G, Freedman MS, Kappos L, Polman C, Uitdehaag B, Casset-Semanaz F, Hennessy B, Rocak S, Stubinski B, Barkhof F. MRI results from a phase III, randomized, double-blind, placebo-controlled, multi-centre trial (REFLEX) of two dosing frequencies of subcutaneous interferon -1a in patients with a first demylinating event suggestive of multiple sclerosis. 21

st Meeting of the European Neurological Society (ENS).

Lisbon Portugal. May 2011.

218.219. Nelson F, Miller A, O’Connor P, Confavreux C, Comi G, Kappos L, Olsson T, Freedman MS, Benzerdjeb H, Truffinet P, Wang L, Wolinsky J for the Teriflunomide Multiple Sclerosis Trial Group and the MRI Analysis Center in Houston, US. 21

st Meeting

of the European Neurological Society (ENS). Lisbon Portugal. May 2011.

219.220. Comi G, Kappos L, De Stefano N, Freedman MS, Casset-Semanaz F, Hennessy B, Rocak S, Lehr L, Stam Moraga M. Safety of subcutaneous IFN beta-1a in patients with CIS: The REFLEX Study. 25

th Annual Meeting Consortium of Multiple Sclerosis Centers

(CMSC). Montréal QC. June 1-4 2011.

220.221. Freedman MS, Comi G, De Stefano N, Kappos L, Barkhof F, Polman CH, Uitdehaag BMJ, Casset-Semanaz F, Hennessy B, Rocak S, Stubinski B. Efficacy of sc IFN beta-1a weekly or three times weekly in patients with CIS. 46

th Annual Congress of the Canadian

Neurological Sciences Federation (CNSF). Vancouver BC. June 15-17 2011.


221.222. Darlington PJ, Touil T, Doucet J-S, Boivin M-N, Fawaz L, Roberts M, Freedman MS, Atkins HL, Bar-Or A, on behalf of the Canadian MS/BMT Study Group. Modulation of human Th17 cell responses by natural killer cells: Implication for autologous hematopoietic stem cell transplantation in multiple sclerosis. Federation of Clinical Immunological Studies. Washington DC. June 23-26 2011.

222.223. Stubinski B, Kappos L, Freedman MS, Comi G, De Stefano N, Barkhof F, Polman CH, Uitdehaag BMJ,Casset-Semanaz F, Hennessy B, Stam Moraga M, Rocak S. Efficacy and safety of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis: results of the Phase III, randomized, double-blind, placebo-controlled REFLEX trial. PACTRIMS. Singapore. Aug 28-30 2011.

223.224. Kappos L, Comi G, De Stefano N, Freedman MS, Barkhof F, Polman CH, Uitdehaag

BMJ, Casset-Semanaz F, Hennessy B, Rocak S, Stubinski B. Clinical and radiological efficacy of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first demyelinating event: results of a Phase III, randomized, double-blind, placebo-controlled, multicentre trial (REFLEX). Amsterdam. ECTRIMS. October 2011.

224.225. Freedman MS, Comi G, Kappos L, De Stefano N, Hennessy B, Haller S, Stam Moraga M, Lehr L, Stubinski B. Safety and immunogenicity of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis: results of the Phase III, randomized, double-blind, placebo-controlled, REFLEX Trial. Amsterdam. ECTRIMS. October 2011.

225.226. Polman CH, De Stefano N, Kappos L, Freedman MS, Barkhof F, Uitdehaag B, Hennessy B, Casset-Semanaz F, Rocak S, Stubinski B, Comi G. Efficacy of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event: Subgroups of the Phase III, randomized, double-blind, placebo-controlled, multicentre REFLEX Trial. Amsterdam. ECTRIMS. October 2011.

226.227. Freedman MS, Comi G, De Stefano N, Kappos L, Barkhof F, Polman CH, Uitdehaag BMJ, Hennessy B, Rocak S, Stubinski B. Efficacy of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event: the Rebif FLEXible dosing in early multiple sclerosis (REFLEX) Study – outcomes in patients stratified by the 2010 MacDonald Criteria. Amsterdam. ECTRIMS. October 2011.

227.228. Comi G, De Stefano N, Kappos L, Freedman MS, Barkhof F, Polman CH, Uitdehaag BMJ, Lehr L, Rocak S, Stubinski B. Treatment of patients with a first clinical demyelinating event: what have we learnt from trials of interferon and glatiramer acetate? Amsterdam. ECTRIMS. October 2011.

228.229. O’Connor P, Lublin F, Wolinsky J, Comi G, Kappos L, Freedman MS, Olsson T, Miller A, Burrell A, Dive-Pouletty A, Grand A, Confavreux C. Effect of teriflunomide on relapses leading to healthcare resource use: Results from the TEMSO Study. Amsterdam. ECTRIMS. October 2011.

229.230. Cruce R, Vosoughi R, Freedman MS. Anticholinergic medication for bladder dysfunction in multiple sclerosis can adversely affect cognitive functioning. Amsterdam. ECTRIMS. October 2011.

230.231. Miller A, O’Connor P, Wolinsky J, Confavreux C, Comi G, Kappos L, Olsson T, Truffinet P, Wang L, Freedman MS on behalf of the Teriflunomide Multiple Sclerosis Trial Group. Efficacy of oral teriflunomide in multiple sclerosis with relapses: Cognitive


outcomes from a Phase III trial (TEMSO). Amsterdam. ECTRIMS. October 2011.

231.232. Comi G, O’Connor P, Wolinksy J, Confavreux C, Kappos L, Olsson T, Benzerdjeb J, Benamor M, Truffinet P, Wang D, Miller A, Freedman MS on behalf of the Teriflunomide Multiple Sclerosis Trial Group. Extension of a Phase III trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: Safety outcomes with up to four years of follow-up. Amsterdam. ECTRIMS. October 2011.

232.233. Montalbán X, Hartung H-P, Edan G, Kappos L, Polman C, Freedman MS, Miller D, Barkhof F, Lanius V, Stolz C, Stemper B, Sandbrink R, Pohl C, Pleimes D. The use of disease-modifying therapy in the BENEFIT extension study. Amsterdam. ECTRIMS. October 2011.

233.234. Menon S, Shirani A, Zhao Y, Oger J, Traboulsee A, Freedman MS, Tremlett H. Characteristics of aggressive multiple sclerosis: Findings from British Columbia, Canada. Amsterdam. ECTRIMS. October 2011.

234.235. Freedman MS, Atkins HL, Bowman MJ, on behalf of the Canadian MS/BMT Study Group. Neurological recovery following treatment of aggressive multiple sclerosis with immunoablation and autologous stem cell transplantation. Amsterdam. ECTRIMS. October 2011.

235.236. Confavreux C, O’Connor P, Freedman MS, Benzerdjeb H, Wang D, Bar-Or A, for the Teriflunomide Multiple Sclerosis Trial Group. Long-term safety and tolerability of teriflunomide in multiple sclerosis: 9-year follow-up of a Phase II study. Amsterdam. ECTRIMS. October 2011.

236.237. Edan G, Kappos L, Montalbán X, Polman C, Freedman MS, Hartung H-P, Miller D, Barkhof F, Lanius V, Stolz C, Stemper B, Pohl C, Sandbrink R, Pleimes D. Long-term effect of early treatment with interferon-beta-1b after a first clinical even suggestive of multiple sclerosis: 8-year observational extension of the Phase 3 BENEFIT Trial. Amsterdam. ECTRIMS. October 2011.

237.238. Barkhof F, Nagtegaal G, Polman C, Freedman MS, Hartung H-P, Miller D, Montalbán X, Kappos L, Edan G, Pleimes D, Beckmann K, Pohl C, Stemper B, Sandbrink R. IFNB-1b therapy started at CIS reduces the evolution of persistent T1 hypointensities on brain MRI. Amsterdam. ECTRIMS. October 2011.

238.239. Costello F, Hodge W, Pan I, Burton J, Freedman MS, Stys P, Trufyn J, Kardon R for CORE: The Calgary Optic Neuritis Research Group. The impact of gender on retinal nerve fibre layer integrity after acute optic neuritis. Amsterdam. ECTRIMS. October 2011.

239.240. Freedman MS, Hartung H-P, Miller D, Montalbán X, Kappos L, Polman C, Edan G, Barkhof F, Petkau J, Beckmann K, Stemper B, Pohl C, Sandbrink R. Predictors of disease activity in CIS patients treated with IFNB-1b in the BENEFIT Study. Amsterdam. ECTRIMS. October 2011.

240.241. Kappos L, Hartung H-P, Freedman MS, Boyko A, Mikol D, Freudensprung U, Plitz T, for the ATAMS Study Group. ATAMS: A randomized trial of the B-cell-targeting agent atacicept in patients with relapsing multiple sclerosis. Amsterdam. ECTRIMS. October 2011.

241.242. Freedman MS, Polman CH, De Stefano N, Kappos L, Barkhof F, Uitdehaag BMJ, Hennessy B, Casset-Semanaz F, Rocak S, Stubinski B, Comi G. Efficacy of subcutaneous


interferon -1a in patients with a first demyelinating event: Subgroups of the REFLEX Trial. World Congress in Neurology. Marrakesh Morocco. November 2011.

242.243. Freedman MS, Comi G, De Stefano N, Kappos L, Barkhof F, Polman CH, Uitdehaag BMJ, Hennessy B, Lehr L, Stubinski B. Treatment of patients with a first clinical demyelinating event: Lessons from trials of interferon b and glatiramer acetate. World Congress in Neurology. Marrakesh Morocco. November 2011.

243.244. Walker LAS, Berard J, Bowman M, Atkins HL, Freedman MS. PASAT performance before and after immunoablative therapy and bone marrow transplant in individuals in MS. 40

th Meeting International Neuropsychological Society. Montréal QC. Feb 2012.

244.245. Berard J, Walker LAS, Bowman M, Atkins HL, Freedman MS. Cognitive fatigue in

individuals with multiple sclerosis undergoing immunoablative therapy and bone marrow transplant. 40

th Meeting International Neuropsychological Society. Montréal QC. Feb 2012.

245.246. Berard J, Walker LAS, Bharadia V, Bowman M, Lee H, Atkins HL, Freedman MS.

Neuroimaging correlates of cognitive change following immunoablative therapy and bone marrow transplant in MS: A pilot study. 40

th Meeting International Neuropsychological

Society. Montréal QC. Feb 2012.

246.247. Atkins H, Bowman M, Allan D, Bence-Bruckler I, Bredeson C, Faught C, Freedman MS, Halpenny M, Hamelin L, Lucas K, Martin L, McDiarmid S, Sabloff M, Tay J, Huebsch L, Canadian Blood Services (Ottawa, CA). Fifteen years of stem cell transplantation for autoimmune diseases at The Ottawa Hospital. 36

th Annual Meeting of the European Group

for Blood and Marrow Transplantation. Geneva Switzerland. April 2012.

247.248. Atkins H, Bowman M, Allan D, Anstee G, Bence-Bruckler I, Bredeson C, Faught C,

Freedman MS, Halpenny M, Hamelin L, Hodgins M, Lucas K, Martin L, McDiarmid S,

Mitchell Sabloff, Tay J(1), Huebsch L. Fifteen years of stem cell transplantation for

autoimmune diseases at The Ottawa Hospital. Canadian Blood and Marrow Transplant

Group Conference. Toronto ON. April 2012.

248.249. Darlington P, Ouamara N, Stonebridge I, Rozenberg A, Freedman MS, Antel J, Bar-Or

A. Fingolimod treatment in multiple sclerosis increases the ability of circulating γδ T cells to

regulate pro-inflammatory Th1 and Th17 T cell responses. AAN. Apr 25 2012.

249.250. Miller A, Lublin F, O'Connor P, Wolinsky J, Comi G, Kappos L, Freedman MS, Olsson

T, Dive-Pouletty C, Bego-Le-Bagousse G, Confavreux C. AAN. Apr 25 2012. S30:

Multiple Sclerosis: Clinical Interventions and Clinical Trials.

250.251. Freedman MS, O'Connor P, Wolinsky J, Confavreux C, Comi G, Kappos L, Olsson T,

Truffinet P, Dukovic D, Miller A. Teriflunomide increases the proportion of patients free

from disease activity in the TEMSO Phase III Study... AAN. Apr 25 2012. Poster

Discussion: Multiple Sclerosis: Clinical Trial Disease Activity Freedom.

251.252. Stuve O, Selmaj K, Lodz K, Li D, Hartung H-P, Hemmer B, Kappos L, Freedman MS,

Rieckmann P, Montalban X, Auberson LZ, Pohlmann H, Mercier F, Dahlke F, Wallstrom E.

BAF312, a selective sphingosine-1-phosphate receptor modulator improves MRI and clinical


outcomes in relapsing-remitting multiple sclerosis (RRMS). AAN. Apr 25 2012. Session

S30: Multiple Sclerosis: Clinical Interventions and Clinical Trials.

252.253. Edan G, Kappos L, Montalban X, Polman C, Freedman MS, Hartung H, Miller D,

Barkhof F, Lanius V, Stemper B, Pohl C, Sandbrink R, Pleimes D. Early initiation of

interferon beta-1b after a first clinical event suggestive of multiple sclerosis: Clinical

outcomes and use of disease-modifying therapy from the BENEFIT Extension Study. AAN.

Apr 25 2012. Poster Discussion Session: Multiple Sclerosis: Clinical Trial Disease Activity

Freedom.

253.254. Comi G, De Stefano N, Freedman MS, Barkhof F, Polman CH, Uitdehaag BMJ, Verdun di Cantogno E, Lehr L, Issard D, Haller S, Hennessy B, Kappos L. Efficacy of two dosing frequencies of subcutaneous interferon beta-1a on the risk of conversion from a first demyelinating event to multiple sclerosis: 3-year results of a phase III, double-blind multicentre trial (REFLEXION). ENS 22

nd Annual Meeting. Prague, Czech Republic. June

2012.

254.255. Vermersch P, Czlonkowska A, Grimaldi L. Confavreux C, Comi G, Kappos L, Olsson T, Jodl S, Bauer D, Truffinet P, Miller A, Wolinsky J, Freedman MS, O’Connor P, for the TENERE Trial Group. Evaluation of patient satisfaction from the TENERE study: A comparison of teriflunomide and subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis. ENS 22

nd Annual Meeting. Prague, Czech Republic. June 2012.

255.256. De Stefano N, Comi G, Kappos L, Freedman MS, Polman CH, Uitdehaag BMJ, Verdun

di Cantogno E, Lehr L, Issard D, Hennessy B, Barkhof F. Effect of two dosing frequencies of subcutaneous interferon beta 1-a on lesion volumes in patients with a first clinical demyelinating event suggestive of multiple sclerosis: Results of the phase III REFLEX study extension (REFLEXION). ENS 22

nd Annual Meeting. Prague, Czech Republic. June 2012.

256.257. Lublin F, Bowen J, Huddlestone J, Kremenchutzky M, Carpenter A, Corboy J, Freedman

MS, Krupp L, Paulo C, Hariri R, Fischkoff. A phase 1b, randomised, placebo-controlled, multiple-dose study of human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis. ECTRIMS. Lyon France. Oct 11 2012

257.258. Li DKB, Hemmer B, Stuve O, Hartung H-P, Freedman MS, Rieckmann P, Montalban X, Zhang-Auberson L, Pohlmann H, Wallstrom E, Selmaj K, Kappos L. Siponimod (BAF312) treatment leads to early MRI benefits in relapsing remitting multiple sclerosis patients: Results from a phase 2 study. Poster presentation. ECTRIMS. Lyon France. Oct 11 2012.

258.259. Freedman MS, Arnold DL, Cohen J, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj K, Weiner H, Miller T, Twyman CL, Vallee M, Margolin DH, Panzara M, Efficacy of alemtuzumab in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy (CARE-MS-II): subgroup analyses by previous DMT use. ECTRIMS. Lyon France. Oct 11 2012.

259.260. Barkhof G, Nagtegaal G, Wattjes MP, Polman CH, Hulst HE, Freedman MS, Hartung H-P, Miller DH, Montalban X, Kappos L, Edan G, Pleimes D, Beckmann K, Pohl C, Stemper B, Sandbrink R. Early therapy with IFNB-1b started at the first event suggestive of MS reduces the evolution of persistent T1 hypointensities on brain MRI. ECTRIMS. Lyon France. Oct 12 2012.


260.261. Polman CH, Cree B, Lubetzki C. Miller D, Lublin F, Weiner H, Hartung H-P, Wolinsky JS, Kappos L, Freedman MS, Montalban X, Kornyeyeva E, Pirozzi C. Holdbrook F. Trial design and baseline data of the INFORMS (fingolimod in patients with primary progressive multiple sclerosis) study. Poster presentation. ECTRIMS. Lyon France. Oct 12 2012.

261.262. Hartung H-P, Pigeolet E, Li D, Hemmer B, Kappos L, Freedman MS, Stüve O,

Rieckmann P, Montalban X, Ziemssen T, Zhang-Auberson L, Wallström E, Selmaj K. The selective sphingosine 1-phosphate receptor modulator siponimod (BAF312): magnetic resonance imaging lesion and lymphocyte relationship in a phase 2 study in relapsing-remitting multiple sclerosis. Poster presentation. ECTRIMS. Lyon France. Oct 12 2012.

262.263. Olsson T, Boster A, Fernandez O, Freedman MS, Pozzilli C, Bach D, Berkani O, Mueller M, Sidorenko T, Melanson M. Efficacy and safety of ponesimod, an oral, selective sphingosine 1-phosphate receptor-1 modulator, in patients with relapsing-remitting multiple sclerosis: results from a phase IIb, randomized, double-blind, placebo-controlled trial. Poster presentation. ECTRIMS. Lyon France. Oct 12 2012.

263.264. Fernandez O, Pozzilli C, Freedman MS, Olsson T, Melanson M, Bach D, Berkani O, Mueller M, Sidorenko T, Boster A. Pharmacodynamic effect, safety and tolerability of ponesimod, a selective sphingosine 1-phosphate receptor-1 modulator, in patients with relapsing-remitting multiple sclerosis. Poster presentation. ECTRIMS. Lyon France. Oct 12 2012.

264.265. Bar-Or A, Freedman MS, Kremenchutzky M, Menguy-Vacheron F, Bauer D, Jodl S, Truffinet P, Benamor M, O’Connor P. Effect of teriflunomide on immune responses to seasonal influenza vaccination in patients with relapsing multiple sclerosis: results from the TERIVA Study. Poster presentation. ECTRIMS. Lyon France. Oct 12 2012.

265.266. Walker LAS, Berard J, Bowman M, Atkins HL, Lee H, Freedman MS. Longitudinal change in PASAT performance following immunoablative therapy and haematopoietic stem cell transplant in MS. Poster presentation. ECTRIMS. Lyon France. Oct 12 2012.

266.267. Montalban X, Kappos L, Freedman MS, Hartung H-P, Edan G, Miller DH, Polman CH, Barkhof F, Stemper B, Herrmann J, Stolz C, Sandbrink R, Pohl D, Pleimes D. Application of the revised version of the 2010 McDonald diagnostic criteria: retrospective comparison using the BENEFIT clinical study dataset. Poster presentation. ECTRIMS. Lyon France. Oct 12 2012.

267.268. Ascherio A, Munger K, Simon C, Kappos L, Polman CH, Freedman MS, Hartung H-P, Miller DH, Montalban X, Edan G, Barkhof F, White R, Sandbrink R, Pohl C. Serum 25-hydroxyvitamin D concentrations among patients in BENEFIT predicts conversion to multiple sclerosis, MRI lesions and brain volume loss. Poster presentation. ECTRIMS. Lyon France. Oct 12 2012.

268.269. Barkhof F, Freedman MS, Comi G, Kappos L, Polman CH, Uitdehaag BMJ, Lehr L, Issard D, Haller S, Hennessy B, De Stefano N. Effect of two dosing frequencies of subcutaneous interferon-beta-1a on brain volume changes in patients with a first clinical demyelinating event: 36-month results of a phase III, double-blind, multicentre trial (REFLEX) and its extension (REFLEXION). Poster presentation. ECTRIMS. Lyon France. Oct 12 2012.

269.270. Comi G, Freedman MS, De Stefano N, Barkhof F, Polman CH, Uitdehaag BMJ, Lehr L, Issard D, Haller S, Bennessy B, Kappos L. Effect of two dosing frequencies of subcutaneous interferon-beta-1a on conversion to MS and MRI measures of disease in patients with a first


clinical demyelinating event: 3-year results of phase III, double-blind, multicentre trials (REFLEX/REFLEXION). Poster presentation. ECTRIMS. Lyon France. Oct 12 2012.

270.271. Freedman MS, Olsson T, Melanson M, Fernandez O, Boster A, Bach D, Berkani O,

Mueller M, Sidorenko T, Pozzilli C. Dose-dependent effect of ponesimod, an oral, selective sphingosine 1-phosphate receptor-1 modulator, on magnetic resonance imaging outcomes in patients with relapsing-remitting multiple sclerosis. Poster presentation. ECTRIMS. Lyon France. Oct 13 2012.

271.272. Long-term outcomes after autologous haematopoietic cell transplantation for multiple sclerosis: a joint study from the Center for International Blood and Marrow Research (CIBMTR) and the European Group for Blood and Marrow Transplantation (EBMT). Muraro P, Pasquini M, Atkins H, Bowen J, Farge D, Fassas A, Freedman MS, Georges G, Hamerschlak N, Havdrova E, Kozak T, Mancardi GL, Morais D, Nash R, Pavletic S, Ouyang J, Saiz A, Badoglio M, Zhong X, Sormani MP, Saccardi R. Oral presentation. EBMT 2013 (39

th Annual Meeting of the European Group for Blood & Marrow Transplantation). London

UK. April 7 2013.

272.273. Long-term efficacy, safety and tolerability of ponesimod in patients with relapsing–remitting multiple sclerosis. Freedman MS, Boster A, Fernandez O, Melanson M, Pozzilli C, D'Ambrosio D, Sidorenko T, Olsson T. Poster presentation. AAN. San Diego CA. Mar 18 2013.

273.274. Immune response to seasonal influenza vaccination in patients with relapsing multiple sclerosis treated with teriflunomide: The TERIVA study. O'Connor P, Bar-Or A, Freedman MS, Kremenchutzky M, Menguy-Vacheron F, Bauer D, Truffinet P, Benamor M. Poster presentation. AAN. San Diego CA. Mar 18 2013.

274.275. Frequency of infections during treatment with teriflunomide: Pooled data from three placebo-controlled teriflunomide studies. Singer B, Comi G, Milan, Miller A, Olsson T, Wolinsky J, Kappos L, Confavreux C, Freedman MS, Benzerdjeb H, Li H, Philippe Truffinet P, O'Connor P. Poster presentation. AAN. San Diego CA. Mar 18 2013.

275.276. Phase 2 BOLD extension study safety results for siponimod (BAF312) in patients with relapsing–remitting multiple sclerosis. Hartung H-P, Selmaj K, Li DKB, Hemmer B, Freedman MS, Stuve O, Rieckmann P, Montalban X, Ziemssen T, Zhang-Auberson L, Hunter B, Rochotte E, Wallstrom E, Kappos L, Basel. Poster presentation. AAN. San Diego CA. Mar 18, 2013.

276.277. Oral cladribine safety profile in patients with a first demyelinating event: Top line results from the Phase III ORACLE MS study. Leist T, Comi G, Cree B, Coyle P, Freedman MS, Hartung H, Vermersch P, Orejudos A, Lachenal N, Scaramozza M. Poster presentation. AAN. San Diego CA. Mar 18, 2013.

277.278. Contribution of CSF to the diagnosis of McDonald MS: Retrospective analysis in the BENEFIT study. Montalban X, Kappos L, Freedman MS, Hartung H, Edan G, Miller D, Polman C, Barkhof F, Stemper B, Herrmann J, Stolz C, Sandbrink R, Pohl C, Pleimes D. Poster presentation. AAN. San Diego CA. Mar19 2013.

278.279. Teriflunomide reduces relapse-related sequelae, hospitalizations and corticosteroid use: A post-hoc analysis of the phase 3 TOWER study. O'Connor P, Lublin F, Wolinsky J, Comi G, Confavreux C, Lyon, Freedman MS, Miller A, Olsson T, Dive-Pouletty C, Taniou C, Selzer M, Kappos L. Poster presentation. AAN. San Diego CA. Mar 21 2013.

http://www.abstracts2view.com/aan/view.php?nu=AAN13L_P01.156















279.280. Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing–remitting multiple sclerosis. Stuve O, Hartung H-P, Freedman MS, Li DKB, Hemmer B, Kappos L, Rieckmann P, Montalban X, Ziemssen T, Zhang-Auberson L, Hunter B, Rochotte E, Wallstrom E, Selmaj K. Poster presentation. AAN. San Diego CA. Mar 21, 2013.

280.281. Efficacy of alemtuzumab vs IFNB-1a in relapsing-remitting multiple sclerosis patients who experienced disease activity while on prior therapy (CARE-MS II): Subgroup analysis by previous disease modifying therapy (DMT) use. Freedman MS, Arnold D, Cohen J, Coles A, Confavreux C, Fox E, Hartung H, Havrdova E, Selmaj K, Weiner H, Miller T, Twyman C, Lake S, Margolin D, Panzara M, Compston A. Poster presentation. AAN. San Diego CA. Mar 21, 2013.

281.282. Oral cladribine delays time to conversion to clinically cefinite MS in patients with a first demyelinating event: Top line results from the phase III ORACLE MS study. Leist T, Comi G, Cree B, Coyle P, Freedman MS, Hartung H, Vermersch P, Orejudos A, Lachenal N, Scaramozza M. Poster presentation. AAN. San Diego CA. Mar 21 2013.

282.283. Study design and baseline characteristics of the INFORMS Study: Fingolimod in patients with primary progressive multiple sclerosis. Miller D, Cree B, Dalton C, Freedman MS, Hartung H, Kappos L, Lubetzki C, Lublin F, MacManus D, Montalban X, Weiner H, Wolinsky J, De Vera A, Kornyeyeva E, Li B, Pirozzi C, von Rosenstiel P, Polman C. Poster presentation. AAN. San Diego CA. Mar 21 2013.

283.284. Long term impact of early initiation of Interferon beta-1b after a first clinical event suggestive of multiple sclerosis: Additional relapse rate, EDSS, and MSSS analyses after 8 years. Edan G, Kappos L, Montalban X, Polman C, Freedman MS, Hartung H, Miller D, Barkhof F, Lanius V, Herrmann J, Stolz C, Stemper B, Pohl C, Sandbrink R, Pleimes D. Poster presentation. AAN. San Diego CA. Mar 21 2013.

284.285. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: Results from TOWER, a second, pivotal, phase 3 placebo-controlled study. Miller A, Kappos L, Comi G, Confavreux C, Freedman MS, Olsson T, Wolinsky J, Bagulho T, Delhay J-L, Zheng Y, Truffinet P, O'Connor P. Poster presentation. AAN. San Diego CA. Mar 19 2013.

285.286. Pre-defined subgroups analyses of TOWER, a placebo-controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Moses H, Freedman MS, Kappos L, Miller A, Olsson T, Wolinsky J, Confavreux C, Comi G, Bagulho T, Zheng Y, Truffinet P, O'Connor P. Poster presentation. AAN. San Diego CA. Mar 21 2013.

286.287. Confavreux C, Olsson TP, Comi G, Freedman MS, Miller A, Wolinsky JS, Kappos L, Delhay J-L, Li H, Truffinet P, O’Connor P. Teriflunomide hepatic safety results: pooled data from three placebo-controlled studies. ENS. June 10 2013. Barcelona Spain. Poster presentation.

287.288. Freedman MS, Confavreux C, Olsson T, Comi G, Miller A. Wolinsky J, Kappos L, Benzerjeb H, Dukovic D, Truffinet P, O’Connor P. Teriflunomide efficacy and safety analyses: Results from TEMSO and TOWER. Poster presentation. CMSC. May 2013. Orlando FL.

288.289. Arnaout A, Mahzart M, Freedman MS. Conservative management of hyperthyroidism arising from alemtuzumab treatment in MS. Poster presentation. CMSC. May 2013.













http://www.abstracts2view.com/aan/view.php?nu=AAN13L_S01.004





Orlando FL.

289.290. Ascherio, Munger K, Simon C, Kappos L, Polman CH, Freedman MS, Hartung H-P, Miller D, Montalban X, Edan G, Barkhof F, Sandbrink R, Kochert K, Pohl C. 25-hydroxyvitamin D and multiple sclerosis activity during therapy with interferon beta-1b. Poster presentation. CMSC. May 2013. Orlando FL.

290.291. Freedman MS, Kappos L, Edan G, Montalban X, Polman CH, Hartung H-P, Miller DH, Barkhof F, Lanius V, Hermann J, Stolz C, Stemper B, Pohl C, Sandbrink R, Pleimes D. Predictors of disease activity in patients with clinically isolated syndrome (CIS) treated with interferon beta 1b in the BENEFIT trial. ECTRIMS. Copenhagen Denmark. October 3 2013. Poster presentation.

291.292. Freedman MS, Ben-Amor A-F, Issard D, Casset-Semanaz F. Assessing a tool to predict disease activity in patients with multiple sclerosis: A post-hoc analysis of clinical trial data on patients treated with subcutaneous interferon beta-1a. ECTRIMS. Copenhagen Denmark. October 3 2013. Poster presentation.

292.293. Kappos L, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Truffinet P, Cavalier S, Delhay JL, Dukovic D, O’Connor P. Pooled efficacy data from two phase 3 placebo-controlled trials of oral, once-daily teriflunomide. ECTRIMS. Copenhagen Denmark. October 3 2013. Poster presentation.

293.294. Vollmer T, Radue E, Vermersch P, Von Rosenstiel P, Putzki N, Meinel M, Sfikas N, Merschhemke M, Freedman MS. Clinical and magnetic resonancy imaging (MRI) disease activity after fingolimod discontinuation. ECTRIMS. Copenhagen Denmark. October 3 2013. Poster presentation.|

294.295. Freedman MS, Atkins H, Bowman M on behalf of the Canadian MS/BMT Study Group. Long-term outcome of the Canadian multiple sclerosis BMT Study: Efficacy and safety of treating aggressive multiple sclerosis with immunoablation and autologous stem cell transplantation. ECTRIMS. Copenhagen Denmark. October 3 2013. Poster presentation.

295.296. Freedman MS, Wolinsky J, Comi G, Kappos L, Olsson T, Miller A, Benamor M, Dukovic D, Liang J, Truffinet P, O’Connor P. Long-term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. ECTRIMS. Copenhagen Denmark. October 3 2013. Poster presentation.

296.297. Leist T, Freedman MS, Kappos L, Olsson T, Miller A, Wolinsky J, O’Connor P, Benamor M, Delhay J, Truffinet P, Dukovic D, Li J, Comi G. Pooled safety data from three placebo-controlled teriflunomide studies. ECTRIMS. Copenhagen Denmark. October 3 2013. Poster presentation.

297.298. Ascherio A, Munger K, White R, Kochert K, Simon C, Polman C, Freedman MS, Hartung H-P, Miller DH, Montalban X, Edan G, Barkhof F, Pleimes D, Sandbrink R, Kappos L, Pohl C. Vitamin D as a predictor of multiple sclerosis activity and progression. ECTRIMS. Copenhagen Denmark. October 3 2013. Platform presentation.

298.299. Miller A, wolinsky J, Kappos L, Comi G, Freedman MS, Olsson T, Rugina A, Bauer D, Delhay J, Wamil B, Truffinet P, O’Connor P. TOPIC main outcomes: efficacy and safety of once-daily oral teriflunomide in patients with clinically isolated syndrome. ECTRIMS. Copenhagen Denmark. October 3 2013. Platform presentation.


299.300. Torres C, Lum C, Chakraborty S, Hogan MJ, Nguyen T, Bussiere M, Freedman MS. Extracranial venous abnormalities: A pathological finding in multiple sclerosis or a normal anatomical variant? ECTRIMS. Copenhagen Denmark. October 4 2013. Poster presentation.

300.301. Mäurer M, Lublin F, Comi G, Freedman MS, Kappos L, Miller A, Olsson T, Wolinsky J, Dive-Pouletty C, Bozzi S, O’Connor P. Impact of severe relapses on disability, fatigue and health-related quality of life outcomes: a pooled dataset of the phase 3 TEMSO and TOWER studies. ECTRIMS. Copenhagen Denmark. October 4 2013. Poster presentation.

301.302. Garg S, Tam R, Li D, Roy-Hewitson C, Zhao Y, Freedman MS, Traboulsee A. Cortical atrophy in SPMS and its assosication with cognitive impairment and whole brain over two years. ECTRIMS. Copenhagen Denmark. October 4 2013. Poster presentation.

302.303. MacMillan EL, Tam R, Zhao Y, Vavasour IM, Li DKB, Oger J, Freedman MS, Kolind SH, Traboulsee AL. Progressive MS shows significant decreases in brain glutamate and glutamine over 2 years. ECTRIMS. Copenhagen Denmark. October 42013. Poster presentation.

303.304. Pozzilli C, Fernández Ó, Olsson T, Freedman MS, Melanson M, Boster A, Radue E-W, Hennessy B, Rames A, D’Ambrosio D. Maintenance of efficacy, safety and tolerability of ponesimod in patients with relapsing remitting multiple sclerosis: phase II extension study. ECTRIMS. Copenhagen Denmark. October 4 2013. Poster presentation.

304.305. Munger KL, Kochert K, Simon C, Kappos L, Polman C, Freedman MS, Hartung H-P, Miller DH, Montalban X, Edan G, Barkhof F, Sandbrink R, Ascherio A, Pohl C. Molecular dissection of the role of vitamin D in determining multiple sclerosis activity. ECTRIMS. Copenhagen Denmark. October 4 2013. Poster presentation.

305.306. Mikol D, Freedman MS, Goldman MD, Hartung H-P, Havrdova E, Jeffery D, Kappor R, Miller A, Sellebjerg F, Lee S, Chen D, Cadavid D, Ticho B. ASCEND study of natalizumab efficacy on reducing disability in patients with secondary progressive multiple sclerosis: baseline demographics and disease characteristics. ECTRIMS. Copenhagen Denmark. October 4 2013. Poster presentation.

306.307. Macdonell R, Lublin F, Comi G, Freedman MS, Kappos L, Mäurer M, Miller A, Olsson TP, Wolinsky JS, Bozzi S, Dive-Pouletty C, O’Connor P. Teriflunomide reduces relapse-related sequelae, severe relapses, hospitalisations and corticosteroid use: pooled data from the phase 3 TEMSO and TOWER studies. ECTRIMS. Copenhagen Denmark. October 4 2013. Poster presentation.

307.308. Kang H, Tam R, Traboulsee A, Zhao U, Riddehough A, Freedman MS. Corpus callosum atrophy in a large SPMS cohort and its correlation with PASAT as a cognitive marker. Parallel Session 13. ECTRIMS. Copenhagen Denmark. October 5 2013. Platform presentation.

308.309. Freedman MS, Macdonell R, Maurer M, Dukovic D, Truffinet P, Bozzi S, Dive-Pouletty C, Comi G. Teriflunomide demonstrates consistent clinical efficacy across two phase 3 studies: Results from TEMSO and TOWER. European CHARCOT Foundation. Nov 2013. Poster presentation.

309.310. Walker LAS, Berard JA, Bowman M, Freedman MS, Atkins HL. Cognitive correlates of health-related quality of life in MS patients undergoing immunoablative therapy and autologous hematopoietic stem cell transplantation (IA-HSCT). Annual Meeting of the


International Neuropsychological Society. Waikoloa HI. Feb 2014. Poster presentation.

310.311. Atif S, Walker LAS, Berard JA, Rees LM, Freedman MS. Relationship between MSNQ and objective cognition in early relapsing-remitting multiple sclerosis: Self and informant ratings. Annual Meeting of the International Neuropsychological Society. Waikoloa HI. Feb 2014. Poster presentation.

311.312. Osman L, Berard JA, Rees LM, Cousineau D, Freedman MS, MacLean H, Walker LAS. Group differences and test-retest reliability of a working memory measure in multiple sclerosis and controls: A preliminary analysis. Rotman Institute Conference. Toronto ON. March 10-11 2014. Poster presentation.

312.313. Freedman MS. Application of immune tolerance approaches to the treatment of MS. 9th

International Congress on Autoimmunity. Nice, France. March 28, 2014.

313.314. Schippling S, Pleimes D, Gilles Edan G, Montalban X, Freedman MS, Hartung H,

Miller

D, Barkhof F,

Radu E-W,

Hermann J, Pohl C,

Sandbrink S,

Martin R. MRI phenotypes as

predictors of clinical outcomes in patients with CIS in the BENEFIT population. Poster Session I: MS and CNS inflammatory Disease: Clinically Isolated Syndromes. AAN. Apr 28 2014.

314.315. Metz LM, Traboulsee A,

Li D, Duquette P,

Yeung M,

Kremenchutzky M,

Vorobeychik G,

Freedman MS, Bhan V,

Blevins G,

Marriott J,

Grand'Maison F,

Lee L,

Thibault M,

Eliasziw

M, Wee Yong V,

Cerchiaro G,

Wiebe S,

Cheng Y,

Zhao G,

Greenfield J,

Topor M,

Riddehough A. Randomized trial of minocycline for clinically isolated syndrome and early single relapse multiple sclerosis: Study design, participant characteristics, and recruitment challenges. Poster Session I: MS and CNS inflammatory Disease: Clinically Isolated Syndromes. AAN. Apr 28 2014.

315.316. Sormani MP, Barkhof F, Kappos L,

Edan G,

Freedman MS,

Montalban X,

Hartung H,

7

Miller D, Hermann J,

Lanius V,

Beckmann K,

Sandbrink R,

Pohl C,

Pleimes D. Predicting

response to interferon beta-1b therapy in patients with clinically isolated syndrome. Poster Session I: MS and CNS inflammatory Disease: Clinically Isolated Syndromes. AAN. Apr 28 2014.

316.317. Singer B, Comi G,

Miller A,

Freedman MS,

Benamor M,

Truffinet P. Teriflunomide

treatment is not associated with increased risk of infections: Pooled data from the Teriflunomide Development Program. Poster Session II: MS and CNS Inflammatory Disease: Treatment Safety. AAN. Apr 29 2014.

317.318. Leist T, Freedman MS,

Benamor M,

Truffinet P,

Dukovic D,

Comi G. Pooled safety data

from four placebo-controlled teriflunomide studies. Poster Session II: MS and CNS Inflammatory Disease: Treatment Safety. AAN. Apr 29 2014.

318.319. Freedman MS, Wolinsky J,

Comi G,

Kappos L,

Olsson T,

Miller A,

Benamor M,

Dukovic D, Liang J,

Truffinet P,

O'Connor P. Safety and efficacy of teriflunomide for up to 9

years in relapsing forms of multiple sclerosis: Update of the TEMSO Extension Trial. Poster Session III: MS and CNS Inflammatory Disease: Clinical Trials Outcomes. AAN. Apr 29 2014.

319.320. Kappos L, Stuve O,

Hartung H,

Freedman MS,

Li D,

Hemmer B,

Rieckmann P,

Montalban X, Ziemssen T,

Hunter B,

Arnould S,

Wallstrom E,

Selmaj K. Safety and efficacy

of siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis: Results from dose-blinded extension phase of BOLD Study. Poster Session III: MS and CNS


Inflammatory Disease: Clinical Trials Outcomes. AAN. Apr 29 2014.

320.321. Olsson T, Comi G,

Freedman MS,

Miller A,

Wolinsky J,

Truffinet P,

Cavalier S,

Dukovic

D, O'Connor P, Kappos L. Patients free of clinical MS activity in TEMSO and TOWER:

pooled analyses of two phase 3 placebo-controlled trials. Poster Session III: MS and CNS Inflammatory Disease: Clinical Trials Outcomes. AAN. Apr 29 2014.

321.322. Freedman MS, Ben-Amor A-F,

Aycardi E,

Issard D,

Casset-Semanaz F. Assessing a

scoring system to predict disease activity in patients with multiple sclerosis: Post hoc analyses of data from clinical trials of subcutaneous interferon Beta-1a. Poster Session III: MS and CNS Inflammatory Disease: Clinical Trials Outcomes. AAN. Apr 29 2014.

322.323. Virender Bhan V, Lapierre Y,

Freedman MS,

Duquette P,

Selchen D,

Migounov V,

Walt

L, Zhang A . Anti-JC virus antibody prevalence in canadian MS patients. Poster Session IV:

MS and CNS Inflammatory Disease: Biomarkers. AAN. Apr 30 2014.

323.324. Edan G, Kappos L, Montalban X,

Freedman MS,

Hartung H,

Miller D,

Barkhof F,

Hermann J, Lanius V,

Pohl C,

Sandbrink R,

Pleimes D. Patient-reported quality of life in the

BENEFIT trial. Poster Session IV: MS and CNS Inflammatory Disease: Biomarkers. AAN. Apr 30 2014.

324.325. Ascherio A, Munger K,

White R,

Kochert K,

Claire Simon KC,

Freedman MS,

Hartung

H, Miller D,

Montalban X,

Edan,

Barkhof F,

Pleimes D,

Sandbrink R,

Kappos L, Pohl C.

Vitamin D as predictor of multiple sclerosis activity and progression in patients with CIS treated early with interferon beta-1b. ePoster Session: MS and CNS Inflammatory Disease II. AAN. Apr 30 2014.

325.326. Freedman MS, Wolinsky JS, Giancarlo C, Kappos L, Miller A, Olsson T, Liang J, Dukovic D, Benamor M, Truffinet P, O’Connor P, for the TERACLES Study Group. Safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis treated with interferon-beta. CONy. Berlin Germany. May 2014.

326.327. Miller AE, Wolinsky JS, Freedman MS, Bauer D, Benamor M, Truffinet P, O’Connor, for the TOPIC Study Group. TOPIC: Efficacy and safety of once-daily oral teriflunomide in patients with early stage MS. CONy. Berlin Germany. May 2014.

327.328. Chan A, Freedman MS, Truffinet P, Dukovic D, Kappos L. Patients with high disease activity in TEMSO and TOWER: Pooled analyses of two phase 3 placebo-controlled trials. CONy. Berlin Germany. May 2014.

328.329. Freedman MS, Dukovic D, Benamor M, Truffinet P, Kappos L. Consistent treatment effect of teriflunomide in subgroups based on pre-trial therapy: Pooled analyses of TEMSO and TOWER. Poster presentation. CMSC. May 30 2014.

329.330. Freedman MS, O’Connor P, Duquette P, Schecter R. High continuation rate, good disease control after switching from natalizumab to fingolimod. Poster presentation. CMSC. May 30 2014.

330.331. Ascherio A, Munger K, White RA, Kochert K, Simon KC, Polman CH, Freedman MS, Hartung H-P, Miller DH, Montalban X, Edan G, Barkhof F, Pleimes D, Radu EW, Sandbrink R, Kappos L, Pohl C. Vitamin D deficiency as an early predictor of long-term disease activity in patients starting interferon beta-1b at clinically isolated syndrome. Poster presentation. CMSC. May 30 2014.


331.332. Atkins HL, Bowman M, Allan D, Arnold D, Bar-Or A, Bence-Buckler I, Bredeson C, Hamelin L, Huebsch L, McDiarmid S, Sabloff M, Sheppard D, Tay J, Walker L, Freedman MS. Recovery of functional disabilities in multiple sclerosis patients following hematopoietic stem cell transplant suggests regional difference in repair capacity of the central nervous system. 12

th Annual Meeting International Society for Stem Cell Research.

Vancouver BC. June 2014.

332.333. Freedman MS, Burton J, Schecter R. Real-life patient adherence and follow-up monitoring with fingolimod. CNSF. June 5 2014. Banff AB.

333.334. Freedman MS, Montalban X, Miller A, Dive-Pouletty, Leist P. Assessing the comparative outcomes from teriflunomide and dimethyl fumarate studies in relapsing MS: use of “number needed to treat” analysis. ISPOR Submitted June 2014

334.335. Walker LAS, Osman L, Berard J, Rees L, Cousineau D, MacLean H, Freedman MS. Brief International Cognitive Assessment for MS (BICAMS): Preliminary findings from the Canadian validation study. A/ECTRIMS Sept 11 2014. Poster presentation. Boston MA.

335.336. Walker LAS, Berard J, Berrigan L, Rees L, Freedman MS. CTIP performance in early relapsing-remitting MS: Group differences and potential confounds. A/ECTRIMS Sept 11 2014. Poster presentation. Boston MA.

336.337. Freedman MS. Assessing a predictive score for disease activity in secondary progressive multiple sclerosis: post-hoc analysis of data from the SPECTRIMS study. A/ECTRIMS Sept 12 2014. Poster presentation. Boston MA.

337.338. Freedman MS. Assessing a predictive score for long-term disability progression in relapsing-remitting multiple sclerosis: 7/8-year follow-up in the PRISMS study. A/ECTRIMS Sept 12 2014. Poster presentation. Boston MA.

338.339. Osman L, Berard J, Rees L, Cousineau D, Freedman MS, MacLean H, Walker LAS. Subjective and objective measures of cognition in MS: A preliminary ahnalysis of correlations and test-retest reliability. Poster presentation. A/ECTRIMS Sept 12 2014. Boston MA.

339.340. Black J, Freedman MS. Inflammation and neurodegneration. Platform presentation . A/ECTRIMS Sept 12 2014. Boston MA.

340.341. Berard J, Rees L, Freedman MS, Walker LAS. A longitudinal evaluation of cognitive fatigue in MS using the PASAT. Poster presentation. A/ECTRIMS Sept 11 2014. Boston MA.

341.342. Sellebjerg FT, Miller A, Freedman MS, Kapoor R, Hartung H-P, Havrodova E, Jeffrey D. Correlations between patient-reported ambulatory function (MSWS-12) and objective disability measurements in SPMS: Analysis of ASCEND baseline data. Poster presentation. A/ECTRIMS Boston MA. Sept 12 2014.

342.343. Freedman MS, Dukovic D, Benamor M, Truffinet P, Kappos L. Evaluating the effect of teriflunomide in subgroups defined by prior treatment: pooled analyses of phase 3 TEMSO and TOWER studies. Poster presentation. A/ECTRIMS Boston MA Sept 2014.

343.344. Kappos L, Radue E-W, Freedman MS, Cree B, Sormani MP, Sfikas N, Francis G, Tomic D, Piani Meier D, De Stefano N. Inclusion of brain volume loss in a revised measure of multiple sclerosis disease-activity freedom: the effect of fingolimod. Poster presentation.


A/ECTRIMS Sept 2014. Boston MA

344.345. Putzki N, Clifford DB, Bischof D, Moore A, Weinshenker BG, Freedman MS. Characteristics of PML cases in multiple sclerosis patients switching to fingolimod from natalizumab. Platform presentation. A/ECTRIMS Sept 2014. Boston MA

345.346. Kappos L, Edan G, Freedman MS, Montalban X, Miller DH, Hartung H-P, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrik R, Suarez G, Wicklein E-M. Clinical outcomes in patients with CIS treated with interferon beta-1b: 11-year follow-up of BENEFIT. Poster presentation. A/ECTRIMS Sept 2014. Boston MA

346.347. Comi G, Freedman MS, Kappos L, Miller AE, Olsson TP, Wolinsky JS, Benamor M, Dukovic D, Truffinet P, O’Connor PW. Effect of teriflunomide on lymphocyte and neutrophil counts: pooled analyses from four placebo-controlled studies. Poster presentation. A/ECTRIMS Sept 2014. Boston MA

347.348. Leist TP, Freedman MS, Kappos L, Olsson TP, Miller AE, Wolinsky JS, O’Connor PW, Benamor M, Truffinet P, Dukovic D, Comi G. Pooled safety analyses from the teriflunomide clinical development program. Poster presentation. A/ECTRIMS Sept 2014. Boston MA

348.349. De Stefano N, Sprenger T, Freedman MS, Cree B, Sormani MP, Haring DA, Francis G, Piani Meier D, Tomic D, Kappos L. Including threshold rates of brain volume loss in the definition of disease-activity-free in multiple sclerosis using fingolimod phase 3 data. Poster presentation. A/ECTRIMS Sept 2014. Boston MA

349.350. Munger K, Kochert K, Fitzgerald K, Arnason B, Barkhof F, Comi G, Cook S, Edan G,Filippi M, Freedman MS, Goodin D, Hartung H-P, Jeffery D, Kappos L, Miller D, Montalban X, O’Connor P, Hemmer B, Mueller-Myhsok C, Muhlau M, Suarez G, Sandbrink R, Ascherio A, Pohl C. Genetic modification of 25(OH)D levels in MS. Poster presentation. A/ECTRIMS Sept 2014. Boston MA

350.351. Black JD, Freedman MS. Neuro-axonal damage in MS may be mediated by interaction of innate immunity and anti-axonal antibodies. Platform presentation. A/ECTRIMS Sept 2014. Boston MA

351.352. Freedman MS The new landscape of MS centres organization. 16th

MS Nurse international workshop Sept 9 2014 A/ECTRIMS Boston MA

352.353. Freedman MS . MS Academia Multiple sclerosis advanced course: Current disease modifying drugs: evaluating the evidence. Sept 9 2014. A/ECTRIMS Boston MA

353.354. Vermersch P, Thangavelu K, Benamor M, Truffinet P, Freedman MS. Effect of teriflunomide across patient subgroups based on prior treatment: pooled analyses of the phase 3 Temson and Tower studies. CONy. Budapest, Hungary. March 27 2015.

354.355. Thomas P. Leist, Mark Freedman,

Aaron E. Miller,

Catherine Dive-Pouletty,

Xavier

Montalban . Assessing Comparative Outcomes from Teriflunomide and Dimethyl Fumarate

Studies in Relapsing MS: Use of “Number Needed to Treat” Analysis. AAN. Washington, DC. April 21 2105.

355.356. Kathryn Fitzgerald, Kassandra Munger,

Mark Freedman,

Hans Hartung,

David Miller,

Xavier Montalban, Gilles Edan,

Frederik Barkhof,

Rupert Sandbrink,

Ludwig Kappos,

Gustavo Suarez, Christoph Pohl,

Alberto Ascherio

.Vitamin D as a Predictor of Functional


Deficits in Multiple Sclerosis. AAN. Washington, DC. April 22 2015.

356.357. Juanzhi Fang, Patricia K. Coyle, Ali Hassan, Choon Cha, Fernando Dangond,

Anthony

T. Reder, Mark S. Freedman. No Evidence of Disease Activity in Patients with Relapsing

MS Treated with Interferon Beta-1a SC tiw versus Interferon Beta-1a IM qw: Subgroup Analyses of the EVIDENCE Study. AAN Washington, DC April 23 2015.

357.358. Mark Freedman, Giancarlo Comi,

Nicola De Stefano,

Frederik Barkhof,

Bernard

Uitdehaag, Ludwig Kappos,

Tanya Fischer,

Liang Chen

. Effect of Two Dosing Frequencies

of Subcutaneous Interferon (scIFN) β-1a on Conversion to Multiple Sclerosis (MS) in Patients with a First Clinical Demyelinating Event (FCDE): 5-year Results of Phase III, Double-blind, Multicenter Trials (REFLEX/REFLEXION). AAN. Washington, DC. April 23 2015.

358.359. Mark Freedman, Giancarlo Comi, Nicola De Stefano, Frederik Barkhof, Bernard

Uitdehaag, Ludwig Kappos, Tanya Fischer, Liang Chen .Safety and Immunogenicity of Two Dosing Frequencies of Subcutaneous Interferon (scIFN) β-1a in Patients with a First Clinical Demyelinating Event (FCDE): 5-year Results of Phase III, Double-blind, Multicenter Trials (REFLEX/REFLEXION) AAN. Washington, DC. April 23 2015.

359.360. Richard Macdonell, Martin Stangel,

Matthias Mäurer,

Deborah Dukovic,

Philippe

Truffinet, Sylvie Bozzi, Catherine Dive-Pouletty, Mark S. Freedman

.Teriflunomide

Shows Consistent Clinical Efficacy on Severe Relapses across Two Phase 3 Trials in Patients with Relapsing forms of Multiple Sclerosis, TEMSO and TOWER. AAN. Washington, DC. April 23 2015.

360.361. Gilles Edan, Mark Freedman,

Xavier Montalban,

David Miller,

Hans Hartung,

Bernhard

Hemmer, Edward Fox,

Frederik Barkhof,

Sven Schippling,

Andrea Schulze,

Dirk Pleimes,

Christoph Pohl, Rupert Sandbrink,

Gustavo Suarez,

Eva-Maria Wicklein,

Ludwig Kappos

Long-term Impact of Early MS Treatment with Interferon Beta-1b (IFNB-1b): Clinical, MRI, Employment, and Patient-Reported Outcomes (PROs) at the 11-Year Follow-up of BENEFIT (BENEFIT 11). AAN. Washington, DC. April 23 2015.

361.362. Daniel Mikol, Jeff A. Cohen,

Mark Freedman,

Myla Goldman,

Hans-Peter Hartung,

Eva

Havrdova, Douglas Jeffery,

Raj Kapoor,

Aaron Miller,

Finn Sellebjerg,

Deborah Kinch,

Sophia Lee, Diego Cadavid

. Rationale for EDSS-Plus, the Primary Composite Endpoint of

Disability Progression in the ASCEND Phase 3 Study of Natalizumab for Secondary Progressive Multiple Sclerosis: A Post Hoc Analysis of IMPACT Study Data. AAN. Washington, DC. April 23 2015.

362.363. Marcelo Kremenchutzky, Mark S. Freedman,

Amit Bar-Or,

Deborah Dukovic,

Myriam

Benamor, Philippe Truffinet,

Paul W. O'Connor

. 12-Year Clinical Efficacy and Safety Data

for Teriflunomide: Results from a Phase 2 Extension Study. AAN. Washington, DC. April 23 2015.

363.364. Frederik Barkhof, Giancarlo Comi,

Mark S. Freedman,

Bernard Uitdehaag,

Tanya

Fischer, Liang Chen,

Ludwig Kappos,

Nicola De Stefano

Effect of Two Dosing Frequencies

of Subcutaneous Interferon (scIFN) β-1a on MRI Lesion and Brain Volume Changes in Patients with a First Clinical Demyelinating Event (FCDE): 5-year Results of Phase III REFLEX Study Extension (REFLEXION). AAN. Washington, DC. April 23 2015.

364.365. Anthony T. Reder, Mark S. Freedman,

Juanzhi Fang,

Ali Hassan,

Choon Cha,

Fernando

Dangond, Patricia K. Coyle

.Early Effects of Interferon Beta-1a SC tiw Versus Interferon

Beta-1a IM qw on MRI Outcomes in Patients with Relapsing MS in the EVIDENCE Study.


AAN. Washington, DC. April 23 2015.

365.366. Thomas P. Leist, Mark S. Freedman,

Ludwig Kappos,

Tomas P. Olsson,

Aaron E.

Miller, Jerry S. Wolinsky,

Paul W. O'Connor,

Myriam Benamor,

Philippe Truffinet,

Deborah

Dukovic, Giancarlo Comi

. Pooled Safety Analyses from Teriflunomide Clinical Studies.

AAN. Washington, DC. April 23 2015.

366.367. Raj Kapoor, Douglas L. Arnold,

Aaron Miller,

Mark S. Freedman,

Myla D. Goldman,

Hans-Peter Hartung, Eva Havrdova,

Douglas Jeffery,

Finn Sellebjerg,

Carmen Castrillo-

Viguera, Yun Chen,

Diego Cadavid,

Daniel Mikol

. Gray Matter Volume Correlates with

Information Processing as Measured by the Symbol Digit Modalities Test (SDMT) but Not with Physical Disability as Measured by the Expanded Disability Status Scale (EDSS) in Patients with Secondary Progressive Multiple Sclerosis (SPMS): Analysis of Baseline Correlations from the ASCEND Natalizumab Study. AAN. Washington, DC. April 23 2015.

367.368. MS Freedman, Xavier Montalban, Aaron E Miller, Catherine Dive-Pouletty, Thomas P Leist. Number Needed to Treat” Analysis to Assess the Comparative Outcomes From Teriflunomide and Dimethyl Fumarate Studies in Relapsing Multiple Sclerosis. ISPOR. Philadelphia, PA. May 20 2015.

368.369. Richard Macdonell, Martin Stangel,

Matthias Mäurer,

Deborah Dukovic,

Philippe

Truffinet, Sylvie Bozzi, Catherine Dive-Pouletty, Mark S. Freedman

.Teriflunomide

Shows Consistent Clinical Efficacy on Severe Relapses across Two Phase 3 Trials in Patients with Relapsing forms of Multiple Sclerosis, TEMSO and TOWER: 2 phase 3 trials. ISPOR. Philadelphia, PA. May 20 2015.

369.370. L Kappos, EW Radue, T Sprnger, E Havrdova, MS Freedman, B.A.C. Cree, MP Sormani, N Sfikas, N Bergvall, D Piani Meier, D Tomic, N de Stefano. Effect of fingolimod on the revised, more comprehensive measure of no evidence of disease activity and worsening (NEDA-4) at 12 and 24 months. EAN. Berlin, Germany. June 2015.

370.371. MS Freedman, Xavier Montalban, Aaron E Miller, Catherine Dive-Pouletty, Thomas P Leist. Number Needed to Treat” Analysis to Assess the Comparative Outcomes From Teriflunomide and Dimethyl Fumarate Studies in Relapsing Multiple Sclerosis. EAN. Berlin, Germany. June 2015.

371.372. G Edan, MS Freedman, X Montalban, H-P Hartung, B Hemer, EJ Fox, F Barkhof, S Schippling, IK Penner, FW Foley, A Schulze, D Pleimes, C Pohl, R Sandbrink, G Suarez, EM Wickleink, L Kappos for the BENEFIT Study Group. Impact of early treatment of MS with interferon beta-1b: Patient-reported outcomes at the 11-year follow-up of BENEFIT (BENEFIT 11). EAN. Berlin, Germany. June 2015.

372.373. Martin Marziniak, MS Freedman, Myriam Benamor, Philippe Truffinet, Karthinathan Thangavelu, Thomas P Leist. Teriflunomide: Pooled Hepatic Safety Outcomes From Placebo Controlled Studies and Long-term Extensions. EAN. Berlin, Germany. June 2015.

Date post:	12-Feb-2019
Category:	Documents
Upload:	doanxuyen
View:	241 times
Download:	0 times

AME MARK STEVEN FREEDMAN - ECTRIMS Congress · Mark Steven FREEDMAN 3 PROFESSIONAL TRAINING:...

Documents